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Met, the receptor of Hepatocyte Growth Factor, is a receptor tyrosine kinase 
(RTK) overexpressed or mutated in cancer. RTKs have been increasingly 
recognised to signal post-endocytosis, possibly leading to unique 
consequences on cellular outcome due to the spatial and temporal activation 
of downstream signalling pathways. The objectives of my study were to 
investigate the role of Met “endosomal signalling” in cancer progression. 
 
I found, using four human breast cell lines, that the requirement of Met 
endocytosis for Met signalling as well as Met trafficking significantly vary with 
the cells’ aggressiveness, suggesting Met resides longer on endosomes in 
invasive cells. Furthermore Met endosomal localisation increases with the 
progression of breast cancer of human samples. Our study suggests that the 
endosomal location of Met is important in breast cancer progression.  
 
I used a model of Wt and two Met oncogenic mutants, M1268T and D1246N, 
expressed in NIH3T3 fibroblasts. I determined some mechanisms regulating 
the constitutive endocytosis and defect in degradation of the mutants. I 
established that targeting these mechanisms could be used to reduce Met 
mutants’ tumourigenicity. Thus impairing c-Cbl or Grb2 expression and/or 
binding to Met mutant or restoring Met mutant degradation through inhibiting 
the chaperone protein HSP90, greatly reduced the transforming capacities of 
the mutants in vitro and in vivo, including the D1246N that I show to be 
resistant to small molecule Met inhibitors.  
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I demonstrated that Met activation leads to Met and β1-integrin co-trafficking. 
Once on endosomes, β1-integrin is necessary to sustain Met-dependent 
ERK1/2 phosphorylation, cell migration and in vivo metastasis as well as Met 
dependent anchorage-independent growth and tumorigenesis in vivo. 
Importantly this role of β1-integrin is matrix-adhesion independent and 
suggests the existence of a novel mode of integrin signalling; “an endosomal 
inside-in signalling”.  
 
Thus, inhibition of Met endosomal signalling may provide a potential 
therapeutic option in preventing the development and progression of Met 
driven cancers as well as overcoming drug resistance. 
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I-Receptor Tyrosine Kinases 
 
Receptor tyrosine kinases (RTKs) comprise a family of cell surface receptors 
possessing a domain with intrinsic enzymatic activity allowing the transfer of 
a phosphate from ATP to the hydroxyl groups of tyrosine1. Through the 
transfer of phosphates, signals can be passed on, via the receptor, to other 
proteins with tyrosine kinase activity1; thereby allowing RTKs to be effective 
signalling molecules. 
 
There are 58 various different RTKs, which are separated into 20 subfamilies 
depending on their structure2. All RTKs contain an extracellular, often 
glycosylated, ligand-binding domain; a transmembrane domain, consisting of 
a single helix; a juxtamembrane domain; a catalytic domain and a C-terminal 
tail. The majority of RTKs are made up of a single polypeptide chain though 
















Figure 1: Receptor tyrosine kinases  
 
The 20 subfamilies of RTKs are separated according to their structure. 
All RTKs have an extracellular ligand binding domain, a transmembrane 
domain, a juxtamembrane domain, a catalytic domain and a C-terminal tail. 
 
Based on Blume-Jensen. P & Hunter. T., Nature 20012and Lemmon. MA. & Schlessinger. J., 
Cell 20103. 




II-The RTK Met and its ligand HGF 
 
1) Met 
Met belongs to a small subfamily of receptor tyrosine kinases containing Met, 
Ron and avian Sea4, 5 Met was first discovered as the TPR-MET oncogenic 
fusion protein in 1984 by Cooper et al.6, 7. A human osteogenic sarcoma cell 
line was treated with the carcinogenic compound N-Methyl-N-nitro-N-
nitrosoguanidine, causing the chromosomal translocation of the TPR locus 
(Transocated Promoter Region) from chromosome 1 just in front of the Met 
gene6, 7. The result was the constitutively active TPR-MET oncogene.  The 
carcinogenic compound that led to its discovery originally gave Met its name 
although it was later further named after its role in metastasis8, 9. A few years 
later Met was discovered to belong to the family of RTKs10. It is a proto-
oncogene and is found expressed on the surface of epithelial and endothelial 
cells, where it binds specifically to its ligand, hepatocyte growth factor (HGF).  
 
a- Gene 
The Met gene is found on the long arm of chromosome 7 at band 7q3111 
(NCB1). It is greater than 120kb in length and contains 21 exons, divided up 
by 20 introns12. It shares many similarities with the Insulin receptor gene, 
which is reflected in a close homology of 44% between the two proteins12. 
Alternative splicing produces three isoforms of Met. The most abundant form 
of Met lacks 18 amino acids in the extracellular part of the receptor compared 
to a minor form of Met which, although it is able to undergo 
autophosphorylation, is unable to be cleaved proteolytically into the α and β 
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subunits 12, 13.  and it is unknown therefore whether or not it acts as a 
functional receptor in vivo12. Another isoform, Metsm, lacks 47 amino acids in 
the juxtamembrane domain that are important for Protein Kinase C 
phosphorylation, which is involved in downregulation of the receptor12. 
  
b-Structure 
Met initially exists as an inactive precursor, consisting of a 170KDa single 
chain that undergoes proteolytic cleavage at a furin position to create the 
190kDa mature form of Met5, 14. The mature form consists of an heterodimer 
of an α and a β chain that are linked via disulphide bonds14. The 45KDa α 
chain is extracellular, while the 145KDa β chain is both extracellular and 
intracellular since it crosses the plasma membrane. The receptor has a 
domain structure, with the extracellular part of the receptor containing a 
Sema domain, a Met Related Sequence, that is rich in cysteines, a region 
with numerous repeats containing many glycine and proline residues and 
four immunoglobulin-like regions8, 15. The extracellular region of the β chain, 
together with the α chain, forms the binding site for HGF14, 16. The 
intracellular part of the receptor contains a C-terminal region, a tyrosine 












Figure 2: The structure of the Met receptor tyrosine kinase16 
Met consists of an α and a β chain that are linked via disulphide bonds. The 
extracellular domain is made up of the α chain and part of the β chain, which 
forms the HGF binding site. The transmembrane domain crosses the plasma 
membrane, while the juxtamembrane domain contains the Ser975 and 
Y1003 residues that are involved in the negative regulation of Met. The 
kinase domain contains the Y1234 and Y1235 phosphorylation sites 
necessary for Met activation. Within the C-terminal region is a multi-substrate 
docking site containing the Y1349 and Y1356 phosphorylation sites required 
for downstream signalling. 
 
Based on Trusolino. L. & Comoglio. P.M Nature Reviews Cancer 2002.16 
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2) Hepatocyte Growth Factor (HGF) 
 
HGF is the only known ligand for Met17 It is produced by mesenchymal cells, 
in close proximity to the epithelial/endothelial cells containing the Met 
receptor, as HGF has a restricted ability for diffusion, due to its high affinity 
for binding to heparin-sulphate proteoglycans18. HGF was first discovered in 
1987 as both ‘Scatter Factor’ by Stoker et al.19 and ‘Hepatocyte Growth 
Factor’ by Nakamura et al.20. Only a few years later, once HGF was cloned21, 
did it become clear that these were in fact the same molecule22-24. 
 
a-Gene 
The HGF gene is found on chromosome 7 at chromosomal bands 7q11.2-
2125, spanning approximately 70kb and consisting of 18 exons and 17 
introns25. Alternative splicing leads to the production of three isoforms of 
HGF, including the full length form and two truncated forms: NK1 and NK2 
(“N terminal Kringle”, see below). Both of these truncated isoforms bind Met 
with high affinity but while the NK1 form can still initiate activation of Met 




HGF is part of the plasminogen family of proteins, however it has no 
proteolytic activity16. Like Met, HGF also has a domain structure, made up of 
an amino-terminal domain, four kringle domains and a serine proteinase 
homology domain14, 15. Initially, HGF is produced as a 92KDa single chain in 
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an inactive precursor form and this is then cleaved by serine proteinases that 
are often overexpressed in the tumour stroma27 including hepsin, matripase, 
urokinase plasminogen activator (uPA), tissue-type plasminogen activator 
(tPA), coagulation factor X11 and the related molecule HGF activator 
(HGFA)8, 28-30. Inhibitors, including HGF activator inhibitor 1 and 2, can 
counteract the action of the HGF activating serine proteases8. The cleavage 
of HGF causes the formation of a bioactive heterodimer, consisting of a 
69KDa α (the amino-terminal, with a hairpin loop, and four kringle domains) 
and a 34KDa β chain (the serine proteinase homology domain) that are 
linked via disulphide bonds14, 15, 20. The amino terminal domain and the 
kringle 1 domain form the binding site for the Met receptor14. It has been 






















Figure 3: The structure of Hepatocyte Growth Factor16  
HGF is produced as a single chain inactive precursor. Cleavage by serine 
proteases at a site between an arginine (R) and a valine (V), produces the 
mature form consisting of an α and β chain linked by disulphide bonds. HGF 
has a domain structure.  The 69KDa α chain consists of an amino-terminal 
domain, within which is a single peptide (SP) and a hairpin loop (HL), and 
four kringle domains (K1-4). The 34KDa β chain contains a serine proteinase 
homology domain. 
 






III- Met signalling 
 
1) Met activation 
Binding of HGF to the Met receptor leads to the stable dimerisation of two 
molecules of Met. This enables transautophosphorylation of the tyrosine 
kinase domain at tyrosine residues Y1234 and Y123515, followed by 
transphosphorylation of the two tyrosine residues Y1349 and Y135614, 15 in 
the C-terminal region (Figure 2)27. This forms a multisubstrate docking site, 
which is unique to members of the Met subfamily32 and essential for Met 
signalling. It enables Met to bind to multiple substrates and activate a variety 
of signalling pathways either through direct interaction with signalling 
molecules or through adaptors27, 32. This site is unique to Met as most RTKs 
have several tyrosines located in their intracellular domain each of which is 
responsible for binding to a specific signalling molecule. 
 
2) Adaptors 
There are two major adaptor molecules that are essential for Met signalling; 
Grb2 (Growth Factor Receptor Bound Protein 2) and Gab1 (Grb2 Associated 
Binder 1). Gab1 binds to activated Met on either Y1349 or Y1356 through its 
specific ‘Met binding site’ consisting of 13 amino acids, leading to a strong 
interaction between Met and Gab133. Gab1 contains multiple tyrosine sites 
that, when phosphorylated, mediate the additional binding of proteins 
including Phosphatidylinositol 3-kinase (PI3K), CT10 Regulator of Kinase 
(CRK), Phospholipase Cγ (PLCγ), SH2-domain-containing protein tyrosine 
phosphatase 2 (Shp2) and p120 Ras-GTPase-activating protein (p120-Ras-
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GAP)27, 33. Gab1 can also bind to Met indirectly through the adaptor Grb234, 
35, which binds to Met at Y1356/3534, through an SH2 binding site36. Thus 
two molecules of Gab1 can bind, one directly and one indirectly, to Met 
simultaneously. It is worth noting that the docking site of a single Met 
molecule can only bind one substrate at a time, although in a Met dimer 
Gab1 can bind to one Met monomer at Y1349 and Grb2 at Y1356 on the 
other monomer simultaneously14. 
 
 
3) Signalling pathways 
Various signalling molecules are recruited to activated Met either directly or 
through the adaptor proteins I have just described. Src, SH2-domain 
containing (SHC), CRK-like protein (CRKL), PI3K, Signal transducer and 
activator of transcription 3 (Stat3), PLC-γ, and Shp2 are all capable of binding 
to Met directly through their SH2 domain, with PI3K, PLC-γ, and Shp2 
binding to Met through Y135627, 36.  
In endothelial cells, activation of Shp2 via Gab1 has been shown to be 
important for branching morphogenesis and activation of the MAPK 
pathway33, while activation of SOS (Son of Sevenless) through Grb2 leads to 
the activation of Ras27, 37, which will lead consequently to activation of both 
the MAPK and PI3K pathways as well as activation of Rac1 and FAK, both of 
which are important regulators of migration and tubulogenesis38. Activation of 
phosphatidylinositol 3-kinase (PI3K), by either direct binding to Met or 
through Ras or Gab1, will lead to the activation of AKT which is involved in 
cell survival, cell-cycle progression, cell growth and cell metabolism27, 39. 
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Upregulation of the MAPK pathway leads to the activation of ERK1/2, which 
is involved in cell proliferation, survival, differentiation, apoptosis, motility and 
metabolism27, 40. The transcription factor STAT3 plays an important role in 
Met-dependent, anchorage-independent growth and tumourigenesis41, while 
the NF-κB transcription factors are also activated in response to Met 
activation27. Met signalling also has been linked to the JNK (c-Jun N-terminal 
kinase) through Gab1-Crk42(Figure 3). Thus Met can activate a wide variety 
of signalling pathways and have multiple effects on cell function. 
 
 
4) Negative regulation of Met 
Due to the wide variety of cellular processes that are initiated following Met 
signalling, it is important that it is tightly controlled.  
Down-regulation of Met signalling can be controlled by its degradation (see 
part IV-5).  
Alternatively, in the juxtamembrane region there is a serine residue, serine 
985, which gets phosphorylated by either PKC (Protein Kinase C) or Ca2+-
dependent kinases when intracellular calcium levels increase upon Met 
activation43. The phosphorylation of this site reduces the tyrosine kinase 
activity of Met44, acting as a negative feedback loop to help prevent 










Figure 4: Signalling pathways initiated by Met signalling 
Activation of Met upon HGF binding leads to the activation of multiple 
signalling moecules either through their direct binding to Met or by indirect 
binding though the adaptors Gab1 and Grb2. This leads to the activation of 
many signalling pathways that, in turn, induce the various cellular processes 
outlined above. 
 




5) Biological functions 
The signalling pathways initiated by Met activation mediate the survival, 
motility and proliferation of cells. When responding cells are endothelial cells 
this leads to angiogenesis and 3D tubule formation, which is necessary for 
the development of many organs14, 45. In vitro, HGF stimulates the scattering 
and invasion of cells as well as the creation of ‘branched tubules’14. 
 
Expression of both Met and HGF are necessary during foetal development. 
Mice lacking either Met or HGF expression die in utero46-48. Met signalling 
controls the proliferation and survival of placental trophoblasts48. It is also 
involved in liver development46 and in promoting the release and migration of 
the progenitor cells that form various muscle groups47.  
 
In adults, expression of HGF and Met also often is increased in injured 
tissues14. Plasma levels of HGF are increased following liver49 and heart 
injury50 and Met expression in keratinocytes has been shown to be required 
for wound healing51. Furthermore, Met signalling is also involved in 
angiogenesis. Met is expressed on endothelial cells and HGF has been 
demonstrated to induce endothelial cell proliferation and migration in vitro as 
well as angiogenesis in vivo52, 53. Recombinant HGF treatment can increase 
VEGF (Vascular endothelial growth factor) production in keratinocytes as 
well as in cancer cells54, 55. The Met inhibitor PHA-665752 has been shown to 
reduce angiogenesis by both reducing VEGF production and by increasing 
production of thrombospondin-1, an angiogenesis inhibitor56.  
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Angiogenesis is one of the six hallmarks of cancer originally proposed by 
Douglas Hanahan and Robert Weinberg in 200057. These hallmarks are 
biological characteristics acquired by tumour cells during cancer formation; 
sustaining proliferative signalling, resisting cell death, evading growth 
suppressors, enabling replicative immortality, activating invasion and 
metastasis and finally inducing angiogenesis57. Met has been shown to be 
involved in many of these processes8. Interestingly, loss of pericytes, which 
are cells that surround and provide structural support to blood vessels, in 
breast cancer associated blood vessels, has been associated with an 
increase in hypoxia and increased Met activation and expression, which in 
turn correlates with reduced overall patient survival58. Deregulated Met 
signalling has also been shown to play a large role in cancer formation and 
progression through the activation of the many cellular processes it can 












IV- Met endocytic trafficking 
 
1) RTK endocytosis 
Following receptor activation and dimerisation, RTKs undergo endocytosis in 
order that they can ultimately be degraded. There are various means of 
endocytosis, of which the most well characterised is the clathrin dependent 
pathway59. Alternative pathways include macropinocytosis and the lipid-raft 
dependent pathway, a subset of which is termed the caveolin pathway59, 60. 
RTKs mostly internalise by the clathrin or the caveolin pathway. 
 
Clathrin dependent endocytosis relies on many adaptor proteins, the majority 
of which bind clathrin, the plasma membrane, the cargo as well as other 
adaptors with each playing a role in the formation of clathrin-coated pits61. 
These include the multimeric adaptor protein AP-260, 61 and the monomeric 
adaptors (clathrin-associated sorting proteins (CLASPs)) including 
CALM/AP180, Epsin1, Eps15, Dab2 and Hip161. Together these complexes 
allow the formation of the clathrin coat in a pit-like structure around the cargo 
within the plasma membrane. Once formed, the GTPase dynamin, 
assembles and encircles itself around the top of the pits, allowing the clathrin 
coated vesicle (CCV) to break away60, 61 (Figure 4). 
 
2) Met endocytosis 
Studies in HeLa cells have shown that internalisation of Met occurs via 
clathrin and dynamin mediated endocytosis, since knock-down of clathrin or 
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presence of a dominant negative version of dynamin prevents Met 
endocytosis62, 63.  
In order to initiate internalisation of the Met receptor, the E3 ubiquitin ligase 
c-Cbl (Casitas B-lineage Lymphoma) is required, which has two functions. 
Firstly, the ubiquitin ligase activity of c-Cbl is required when c-Cbl binds 
indirectly to Met via the SH3 domain of Grb2, which binds to Met at the 
phosphorylated Y1356 site64-66. In addition to the role of c-Cbl as a ubiquitin 
ligase it also acts as scaffold protein that is required for Met endocytosis. C-
Cbl links Met to endophilins via the adaptor CIN85 (Cbl-interacting protein of 
85 kDa)67. Endophilins are involved in invagination of the plasma 
membrane68, which is one of the first steps in the initiation of clathrin 
dependent endocytosis. The direct binding of c-Cbl to Met and its ubiquitin 
ligase activity are also required for Met degradation and will be discussed in 
a later section. Clathrin adaptors regulating Met endocytosis are largely 


















Figure 5: Clathrin mediated internalisation  
Clathrin mediated endocytosis of cell surface receptors requires adaptor 
proteins, such as AP-2, epsin and Eps15, which bind to clathrin, the plasma 
membrane and the cargo. This leads to the formation of clathrin-coated pits 
around the cargo, which forms a clathrin-coated vesicle that eventually 
breaks away from the plasma membrane through the GTPase Dynamin. 
 






3) RTK trafficking 
Once the clathrin coated vesicles have formed, clathrin is removed from the 
vesicles and the vesicles fuse with early endosomes in a process involving 
the GTPase Rab571. The Rab5 effector EEA1(Early endosome antigen 1) is 
required for endosome docking and membrane fusion and as a consequence 
EEA1 is used as a marker of early endosomes72. SNARES (Soluble N-
ethylmaleimide-sensitive factor attachment protein receptor) are present on 
vesicle membranes; they form tetrahelical complexes with each other 
resulting in membrane fusion71.  
 
Once in the early endosomal compartment, the vesicles can be sorted for 
degradation or they can be recycled back to the plasma membrane with their 
cargo, allowing RTKs to be stimulated by their ligand once again. This 
‘sorting’ is controlled by Rab GTPases. Rab4 directs vesicles to a fast 
recycling route, whereas Rab8 and Rab11 direct them to a slow recycling 
route71, 73. Rab7 sorts vesicles to lysosomes for degradation 71, 73 (Figure 6).  
Hrs (hepatocyte-growth-factor-regulated tyrosine kinase Substrate) is located 
on early endosomes74, 75 and is involved in directing receptors to the MVB 
pathway for degradation75, 76. Hrs has been shown to sort ubiquitinated 
proteins into clathrin-coated microdomains of early endosomes through its 
ability to bind ubiquitin, phosphatidylinositol (3)-phosphate (an endosomal 
lipid) and clathrin75-77. Furthermore, Hrs is found in a complex with another 
ubiquitin binding protein STAM (Signal Transducing Adaptor Molecule), 
which together form the ESCRT-0 (Endosomal Sorting Complex Required for 
Transport-0) complex. ESCRT-0 is required for the recruitment of ESCRT-I, 
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which in turn recruits ESCRT-II and accordingly ESCRT-III and the 
consequent guidance of cargo into multivesicular bodies (MVB’s) prior to 
lysosomal degradation78-80. 
 
It has been shown that different methods of internalisation can target RTKs 
for different fates. Sigismund et al. demonstrated that the dose of EGF was 
able to determine the route of internalisation and the consequent fate of 
EGFR81. A low dose of EGF leads to EGFR being internalised by clathrin-
mediated endocytosis after which the majority of it is sorted for recycling 
back to the plasma membrane. Meanwhile a high dose of EGF causes EGFR 
to be internalised by a clathrin independent mechanism after which it is 
targeted for degradation81.  Therefore, it is possible for the route of trafficking 
to be determined by the route of internalisation, and for the route of 



















Figure 6: RTK trafficking 
RTKs mostly internalise by the clathrin or the caveolin pathway. Once 
vesicles have been internalised they fuse with early endosomes in a process 
involving the GTPase Rab571, from where they are sorted by other 
RabGTPases. Rab4 directs vesicles to a fast recycling route, whereas Rab8 
and Rab11 direct them to a slow recycling route71, 73. Rab7 together with 
ESCRT complexes, directs vesicles to the MVB prior to trafficking to 
lysosomes for degradation 71, 73 
 




4) Met trafficking 
Met trafficking from an early endosomal compartment to a perinuclear 
compartment is operated along microtubules and promoted by Protein 
Kinase C- α (PKC α)62, 82 (Figure 8). The non-receptor tyrosine phosphatase 
PTP1B has been shown to associate with Met and to be an important 
phosphatase in controlling Met phosphorylation upon HGF stimulation83. 
However it also has an important function in regulating vesicle fusion and 
hence in allowing Met to reach a perinuclear location84. This is believed to be 
due to the role of PTP1B in dephosphorylating N-ethylalemide-sensitive 
factor (NSF), which is involved in breaking up the SNARE complex and 
allowing additional vesicle fusion events84.  
 
Recently, Abella et al. demonstrated that dorsal ruffles, which are apical 
membrane protrusions, form following HGF treatment and act as a signalling 
microdomain for the Met receptor in MDCK epithelial cells85. Following HGF 
treatment, Met is transcytosed in Rab4 positive endosomes from the 
endosome to Gab1 positive dorsal ruffles on the apical surface of cells. In 
this microdomain Met remains active and furthermore phospho-Gab1 and 
phospho-ERK 1/2 are also found to be present, suggesting that dorsal ruffles 
provide a location for Met to signal to its downstream partners85. From here, 
Met is internalised into Rab5 positive compartments, traffics to Hrs positive 
compartments in a perinuclear location and then gets degraded (Figure 7)85. 
 
Met recycling has been reported through a specific interaction with Golgi-
localised gamma ear-containing Arf-binding protein 3(GGA3) within Rab4 
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positive endosomes and this interaction is aided by Arf6 and Crk86. The 
resultant increased recycling of Met leads to a decrease in Met degradation, 
causing a less sustained ERK phosphorylation and reduced migration upon 
HGF stimulation86.  
 
5) Met degradation and stability 
RTKs usually are targeted for degradation by ubiquitination. Once RTKs 
reach late endosomes they can enter the multivesicular body, which will fuse 
with lysosomes leading to their degradation.  
 
a) Met degradation 
The trafficking of Met to a perinuclear location is not required for its 
degradation82. The actual mechanism by which Met is degraded is unclear, 
since Met degradation has been shown to occur both by proteosomal82 and 
lysosomal mechanisms63, 87. 
Phosphorylation of the tyrosine site Y1003 in the juxtamembrane of Met 
enables direct binding of c-Cbl. Although this interaction between Y1003 and 
c-Cbl is not required for Met endocytosis, it is required for ubiquitination of 
Met by c-Cbl and the consequent targeting of Met for degradation through 
the phosphorylation of Hrs 82, 88 89. In fact, the fusion of a monoubiquitin to a 
ubiquitination deficient Met-Y1003F mutant, that does not directly bind c-Cbl, 
is able to restore normal Met degradation89.  
Additionally, LRIG1 (Leucine-rich repeats and immunoglobulin-like domains 
1) can interact with Met in HEK-293T cells and destabilise Met in an HGF 




Figure 7: Met internalisation, trafficking and degradation 
Met is internalised by clathrin dependent endocytosis upon HGF stimulation. 
c-Cbl is required for Met endocytosis by binding to Met via Grb2, leading to 
Met ubiquitination, or by acting as a scaffold between Met and CIN85-
endophilin leading to membrane curvature. Met is recruited to the 
EEA1/Rab5/Rab4 positive early endosome where it remains phosphorylated. 
Binding of c-Cbl to Y1003 of Met, leads to Met ubiquitination and to the 
phosphorylation of Hrs, which leads to Met sorting for degradation. Some 
Met may recycle either to the plasma membrane through interaction with 
GGA3 or to Gab1 positive dorsal ruffles. From the early endosome, Met 
traffics to the Lamp1/Rab7 positive perinuclear endosome, where it is 
progressively targeted for degradation. LRIG1 may also interact with Met, 





b) Protection against degradation by HSP90 
HSP90 (Heat-shock protein 90) is a molecular chaperone that has been 
demonstrated to stabilise Met and protect it from degradation91. I shall later 
outline in detail the role of HSP90 in cancer and in Met degradation, but I 
shall first describe HSP90 structure and function. 
 
• HSP90 
HSP90 is an evolutionarily conserved molecular chaperone that prevents 
misfolding, stabilises or ensures the correct activation of over 200 different 
proteins within cells92, 93. The chaperone Heat Shock Protein 70 (HSP70) is 
involved in recruiting the client protein to HSP90 with the help of co-
chaperones. HSP90 is an ubiquitously expressed protein found mostly in the 
cytoplasm, which makes up between 1-2% of the total protein within a cell, 
however its expression increases under cellular stress and in cancer94. 
HSP90 often appears to be associated with mutated proteins involved in 
oncogenesis, possibly due to the high expression levels of the mutated 
protein but also due to their unstable conformations94. Mutated proteins 
found to be associated with HSP90 include v-src and p5394. It is possible for 
HSP90 to translocate to the nucleus or be secreted into the extracellular 
matrix where it has been shown to be involved in the maturation of MMP-2, 
which plays a role in tumour cell invasion94, 95.  
 
• HSP90 Structure 
There are two cytosolic isoforms of HSP90; HSP90α and HSP90β (HSP86 
and HSP84 respectively in mice)96. HSP90α is inducible, while HSP90β is 
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expressed constitutively94, 97. It is the HSP90α isoform that has been found to 
be upregulated in various tumours94 and furthermore has been associated 
with a poor prognosis98.  
 
HSP90 is usually found as a constitutive homodimer, with dimerisation 
occurring at the carboxy-terminal end97. Each HSP90 monomer has three 
domains; an amino-terminal domain, which contains an ATP-binding site, a 
middle domain, which is involved in controlling ATP hydrolysis, and a C-
terminal domain, where the dimerisation between two HSP90 monomers 
occurs92.  
 
• HSP90 Chaperone Cycle 
HSP90 participates in a dynamic ATP-controlled chaperone cycle. As shown 
in Figure 8, upon ATP binding the homodimer undertakes a more closed 
conformation, with the N-termini of the monomers associating with each 
other and part of the N-terminus closing over the ATP-binding pocket. 
Structural studies are still on-going and for the moment, although it is not 
clear exactly where the client proteins bind, several studies have suggested 
that they may bind in the middle domain94, 99-101 . 
 
Phosphorylation of HSP90 can occur at multiple tyrosine, serine and 
threonine sites and can have contradictory effects on HSP90 chaperone 
activity93. For example decreased phosphorylation of HSP90 at Ser226 and 
Ser255 increases the interaction between HSP90 and its client Apoptotic 
peptidase activating factor 1 (APAF1) in a subset of leukaemias93, 102. 
  54 
Meanwhile, the HSP90 client WEE1, which is involved in cell cycle 
progression, phosphorylates HSP90 at Y38 which increases the ability of 
HSP90 to chaperone cancer related proteins, including HER2, while 
simultaneously decreasing the binding ability of HSP90 inhibitors93, 103. 
 
• HSP90 Co-chaperones 
There are at least 20 known co-chaperones that can either positively or 
negatively regulate HSP90 function in many different ways. They can be 
involved in the specific recruitment of client proteins to HSP90, the 
prevention or reduction in HSP90 ATP activity, control of the chaperone cycle 
or by engaging other chaperone molecules92. 
 
The co-chaperone Hop/STIP1 (HSP70/HSP90 Organising Protein) binds to 
the C-terminus of HSP90 and the C-terminus of HSP70 assembling an active 
complex, where the client protein is transferred from HSP70 to HSP90100, 104, 
105. Alternatively, the co-chaperone CHIP (Carboxyl terminus of HSP70 
Interacting Protein), an E3 ubiquitin ligase, is involved in ubiquitinating 
HSP70 clients and targeting them for degradation by the proteosome106. 
Often client proteins increase their assocation with CHIP when HSP90 












Figure 8: HSP90 Chaperone Cycle 
ATP binds an HSP90 homodimer, causing a conformational change in the 
molecule, such that the N-termini of the monomers closely associate with 
each other. Co-chaperones can also play a role in altering the chaperone 
cycle, for example by changing ATP activity. 
 




Other co-chaperones include CDC37 (cell-division-cycle 37 homologue), 
which is responsible for bringing kinases such as AKT108 to the HSP90 
complex, where it binds HSP90’s N-terminus94, 109 and the co-chaperone 
AHA1 (activator of HSP90 ATPase homologue 1), which increases the rate 
of ATP hydrolysis by HSP90 through encouraging the middle domain to 
associate with the N-terminus of HSP9094. Meanwhile, the co-chaperone p23 
keeps HSP90 in the ATP hydrolysis state, promoting and maintaining 
HSP90’s interaction with client proteins92, 110-112.  
 
• HSP90 in Cancer 
In recent years, much work has focused on understanding the role of HSP90 
in cancer cells, where it can protect a wide range of oncogenic proteins from 
being misfolded or degraded93 (see Part 2). As a consequence there are a 
large number of pharmaceutical HSP90 inhibitors that have been produced 
and are undergoing, or are about to undergo, clinical trials in patients with 
advanced solid tumours including prostate, pancreatic, gastric and non-small 
cell lung cancer. HSP90 inhibitors are also being tested in haematological 
malignancies including in multiple myeloma patients for whom a few Phase 3 
trials have recently been completed, but results are, as yet, unknown 
(http://www.clinicalstrials.gov). 
 
1 – Inhibitors of HSP90 
• Inhibitors which bind to the N-terminal ATP-binding pocket 
The first pharmaceutical product that was discovered to have potential in 
inhibiting the action of HSP90 was the antibiotic Geldanamycin discovered in 
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1970113, 114. Since then, there have been several derivatives produced which 
have an improved toxicity profile and a higher specific affinity for HSP90. 
 
A derivative of Geldanamycin, 17-allylamino-17-demethoxy-geldanamycin 
(17-AAG)(also known as KOS-953 or Tanespimycin), has similar activity to 
Geldanamycin but with lower toxicity issues115 and became the first HSP90 
inhibitor to enter clinical trials. It showed positive clinical benefits in several 
oncology trials including Her2 (Human Epidermal Growth Factor Receptor 2) 
driven breast cancer, however it had a high liver toxicity93, 114. Another 
geldanamycin derivative 17-dimethylaminoethylamino-17-
demethocygeldanamycin (17-DMAG) had improved pharmacokinetics, 
however development appears to have stopped due to its high toxicity 
profile93, 116.  
 
Since, the discovery of these first HSP90 inhibitors, many more synthetic 
inhibitors have been developed or are currently under development by 
various pharmaceutical companies based on the structure of HSP90 using X-
ray crystallography114, 116. The more recently produced inhibitors include 
STA-9090, the structure of which is not yet available, and the small molecule 
inhibitor SNX-5422, a prodrug that converts to SNX-2112, which have both 
shown promising results so far114, 116.   
 
• Inhibitors which alter HSP90’s interaction with its co-chaperones 
Novobiacin, a coumarin antibiotic, binds to HSP90 in its C-terminal domain 
and reduces its interactions with HSP70 and the co-chaperones p23 and 
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cdc3794, 117-119. While Novobiocin itself has a low affinity for HSP90, several 
derivatives have been produced that appear to have good anti-proliferative 
effects on several cancer cell lines93 120-122.  
 
The range of HSP90 inhibitors available demonstrates that HSP90 is a 
promising target in many cancers. There are currently 77 recruiting, ongoing 
or recently completed clinical trials (http://www.clinicalstrials.gov). 
 
2 – HSP90 in cancer 
• The role of HSP90 in cancer cells 
HSP90, acts by helping cells respond to environmental stress. Cancer cells 
are continually under stress due to various factors including restricted 
nutrient and oxygen supply, genetic instability and assault by the host’s 
immune system114.  By protecting so many cellular proteins during such 
stress, HSP90 allows cancer cells to survive and proliferate causing some 
cancer cells to become dependent on HSP90114, 123. Importantly, HSP90 in 
tumour cells (and tumour tissue) has been found to be more highly 
associated with the co-chaperones p23 and Hop than HSP90 from normal 
cells92, 124. In addition HSP90 has also been found to have a higher ATPase 
activity in tumour cells92, 124.  
 
• Inhibition of HSP90 in cancer cells 
Many clients of HSP90 inhibition are known oncogenes and HSP90 inhibition 
provides an alternative way to disrupt oncogene activity, particularly if such 
proteins are overexpressed or mutated, with the additional benefit that 
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multiple oncogenes can be inhibited simultaneously. A study by Kamal et al. 
demonstrated that 17-AAG binds to HSP90 from cancer cells with 100 fold 
greater affinity than HSP90 from normal cells124. 
 
As already mentioned, Her2 driven breast cancer has proven to be an 
HSP90 sensitive target in multiple studies, including in clinical trials125-127. 
Additionally, HSP90 inhibition has also been shown to be effective at 
inhibiting proliferation and inducing apoptosis in gastrointestinal stromal 
cancer cells (GIST) that were dependent on the Kit receptor tyrosine kinase, 
irrelevant of whether they were sensitive or insensitive to Imatinib (small 
molecule inhibitor of Bcr-Abl, Kit and PDGFRA)128.  
 
HSP90 inhibitors therefore seem to be highly effective in cancers driven by 
RTK overexpression; however studies have also shown them to effectively 
degrade mutant RTKs. Non-small cell lung cancer cells expressing the EGFR 
T790M mutant, that leads to resistance to the EGFR inhibitors Gefitinib and 
Erlotinib, remain sensitive to HSP90 inhibition129. Furthermore, a 
constitutively activated oncogenic mutant of the Ron receptor, Ron M1254T, 
was found to avoid c-cbl mediated downregulation but was more strongly 
associated with HSP90, HSP70 and CHIP than the WT receptor130. Moreover 
this mutant was more sensitive to treatment with the HSP90 inhibitors 
Geldanamycin or 17-AAG, partly due to a quicker dissociation of the HSP90-




• Inhibition of HSP90 co-chaperones in cancer cells 
The expression of the chaperone HSP70 is often increased following 
treatment with HSP90 inhibitors, which may be one reason that HSP90 
inhibitors have proved to be not as effective as first hoped in clinical trials131. 
Interestingly, inhibition of both HSP70 and HSP72 (the inducible isoform of 
HSP70) simultaneously, leads to degradation of HSP90 client proteins and 
apoptosis in a range of tumour cells, without affecting normal cells131.  
 
Some work has also been done on inhibition of HSP90 co-chaperones. For 
example, RNAi silencing of cdc37 has been shown to lead to degradation of 
HSP90 client proteins, specifically kinases and further sensitisation to HSP90 
inhibitors without induction of a heat shock response that can occur upon 
inhibition of HSP90132, 133. 
 
3 – Met and HSP90 
HSP90 has been shown to protect Met from degradation91, particularly when 
it is acting as an oncogene. Consequently, Geldanamycins can induce Met 
downregulation and inhibit HGF induced migration and invasion of 
leiomyosarcoma or glioblastoma cell lines91, 134. Importantly, HSP90 inhibition 
has been demonstrated to provide long lasting Met inhibition. The Met 
amplified cell lines H1993 (non-small cell lung cancer) and MKN45 (gastric 
carcinoma), initially are sensitive to a Met small molecule inhibitor, however 
they quickly (after 48 hours) activate downstream signalling molecules via 
alternative mechanisms. Nevertheless, HSP90 inhibition in these cells 
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provides inhibition of both Met, and its downstream signalling molecules over 
a more extended period of time (up to 96 hours)135.  
 
The efficacy of HSP90 inhibition to downregulate Met has been confirmed 
with the recently produced HSP90 inhibitor; SNX-2112136. It has been shown 
to down-regulate Met and many other kinases effectively in Met-amplified cell 
lines; EBC1 (non-small cell lung cancer), GTL-16 and MKN-45 (gastric 
cancer) as well as a GTL-16 cell line made resistant to the small molecule 
Met inhibitor PHA-665752136. Furthermore, a decrease in tumour growth was 
observed in vivo when mice were treated with SNX-5422, the pro-drug of 
SNX-2112136.  
 
The data that I will present in my thesis are derived from investigation of the 
role of HSP90 inhibition in two naturally occurring Met mutations, one of 
which is naturally resistant to small molecule Met inhibitors. 
 
c) Met Cleavage and Shedding. 
Alternative methods of Met degradation, which occur in a ligand independent 
manner, are Met cleavage and Met shedding66. Met cleavage has been 
described to occur during apoptosis as a way to prevent potential survival 
signals66. Cleavage is carried out by caspases that cleave Met into a 100kDa 
membrane-bound fragment and a 40kDa C-terminal fragment containing the 
tyrosine domain, thereby making Met unable to undergo ligand-dependent 
activation66. 
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Met shedding takes place to reduce accumulation of mature Met levels under 
basal conditions, independent of ligand stimulation, and it occurs through a 
process known as Presenilin-regulated intramembrane proteolyis (PS-RIP)27, 
66. Initially Met Cleavage occurs by MMPs (Matrix Matalloproteinases), 
involving ADAM10 (A disintegrin and matalloproteinase domain containing 
protein), leads to the shedding of an N-terminal fragment (NTF), leaving 
behind a membrane bound C-terminal fragment (CTF)66, 137-139. This C-
terminal fragment can either be directly degraded by the lysosome140 or, 
consequently, can undergo cleavage by the γ-secretase complex (the 
catalytic subunit of which is Presenilin) to produce a C-terminal fragment that 
can traffic to the lysosome and a membrane-bound intracellular domain (ICD) 
that undergoes proteosomal degradation27, 66, 137. The expression of Trk-Met, 
lacking the juxtamembrane region, shown to be required for appropriate 
metalloproteinase cleavage of Met, led to a large increase in cell migration in 
MDCK cells137. The formation of Met fragments is increased following 
treatment of cells with the human Met antibody DN30137. Thus, Met cleavage 









V- Met endosomal signalling 
 
1) The “Signalling endosome” concept 
Despite the role of endocytosis in receptor degradation, receptors are still 
able to signal from endosomes141. It currently is becoming clear that this 
“endosomal signalling” of RTKs is important for regulation of cell functions 
since it provides temporal and spatial regulation of the signalling pathways, 
as well as enabling the direct transfer of signalling complexes to their 
intended target141.  
 
2) Endosomal signalling of receptors 
Much of the current work on “endosomal signalling” has been carried out on 
EGFR, which was in fact the first RTK found to be present in endosomes with 
signalling partners142. The landmark study that founded the concept 
“endosomal signalling” was published in 1996 and showed that the Nerve 
Growth Factor (NGF) receptor can be found activated in endosomes together 
with its ligand143. This field has expanded rapidly since these first studies and 
has focused on trying to uncover the role of receptor localisation on cell 
signalling and function. 
 
EGFR has been found to be able to initiate and stimulate signalling pathways 
from endosomes, including activation of Rac, ERK1/2 and AKT in BT20 
breast cancer cells144. However, SHC and PLC-γ do not require endocytosis 
for their full activation and in fact are hyperphosphorylated if EGFR is 
maintained at the plasma membrane145. In endocytosis-defective cells, EGF 
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dependent cell proliferation is increased145, while cell survival and apoptosis 
are decreased144. This suggests that different signalling pathways and 
consequently cell functions are initiated from different locations within a cell. 
Other RTKs have also been investigated. The same authors as above found 
that in the same way as EGFR, PDGFR is also capable of initiating signalling 
from endosomal compartments146. Endocytosis of the insulin receptor has 
been shown to be required for full SHC and ERK1/2 activation147. An 
association between Vascular Endothelial Growth Factor Receptor 2 
(VEGFR-2) with Vascular Endothelial Cadherin (VEC) inhibits VEGFR-2 
endocytosis which, in turn, prevents cell proliferation148.  
 
Importantly, Jékely et al. demonstrated that RTK endocytosis is important for 
directional cell migration towards ligands during Drosophila development, 
making it the first study to suggest a link between endosomal signalling of 
RTKs and cell migration149.This finding was further developed by Assaker et 
al., who showed in Drosophila that fully functional trafficking between the 
plasma membrane and endosomes, involving both Rab5 and Rab11, was 
required to keep RTKs active at the leading edge of migrating border cells 
and consequently for directional cell migration150. 
 
As previously mentioned for EGFR, it is possible that a receptor can take 
various different internalisation routes, which can lead to different receptor 
fates81. TGF-β receptor has also been shown to internalise both through 
caveolin and clathrin dependent mechanisms151. Interestingly, clathrin-
mediated internalisation into EEA1/SARA (Smad anchor for receptor 
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internalisation) -positive endosomes leads to continued signalling of TGF-β 
through Smad-2, while internalisation through cavelolin lipid rafts into 
caveolin-positive endosomes leads to receptor degradation151.  
 
Endosomal signalling has also been shown to occur from other non-tyrosine 
kinase receptors, including G-protein coupled receptors (GPCRs). For 
example, the inhibition of β2-adrenergic receptor endocytosis leads to a 
reduction in MAPK activation, while Shc and Raf activation are unaffected141, 
152. Furthermore, Endo180, a collagen receptor, provides another example of 
a non-RTK that signals from endosomes. Endo180 mainly resides in 
endosomes due to its constant recruitment to clathrin-coated pits leading to 
its constitutive internalisation and recycling back to the cell surface153. In 
doing so, Endo180 brings collagen into endosomes, allowing collagen to be 
degraded and this accounts for remodelling of the extracellular matrix154. 
However, aside from this function of Endo180, it also has an important role in 
the activation of Rho, ROCK, Cdc42 and Rac during cell migration155, 156. 
Importantly, Endo180 needs to internalise and be present on endosomes for 








Figure 9: Trafficking and “endosomal signalling” of Met 
Met is internalised by clathrin mediated endocytosis and traffics from early 
endosomes to a perinuclear compartment along microtubules. This traffic is 
promoted by PKCα activity. While in endosomes Met can continue to signal 
and is required for the full activation of ERK1/2 and STAT362, 157. 
 
Based on Kermorgant S et al. Embo J, 200462 
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3) Met endosomal signalling 
Studies on the endosomal signalling of the Met receptor are just beginning to 
surface. Palamidessi et al. showed that clathrin-dependent endocytosis upon 
HGF (or Rab5 overexpression) is required for the activation of Rac158. 
Endosomes bring together Rac with its GEF, Tiam1, leading to its 
activation158. Once activated, Rac relocates to the plasma membrane where 
it carries out its role in actin remodelling and consequent cell migration158. 
However, in this study no link to Met localisation was made. Activation of Met 
leads to the downstream activation of a wide variety of signalling pathways 
and therefore some control over the spatial and temporal activation of the 
signalling molecules is necessary. Kermorgant et al. have demonstrated that 
Met undergoes “endosomal signalling”62, 82, 157. These studies show that 
endocytosis is required for full activation of the MAPK pathway and STAT3 
upon HGF stimulation62, 157. Full activation of ERK 1/2 and resulting induction 
of wound healing upon Met activation depends on Met internalisation and 
trafficking to early endosomal compartments, but does not require Met 
trafficking to perinuclear endosomes62. Whereas, Met internalisation and 
trafficking to a perinuclear compartment is required for sustained STAT3 
activation and nuclear accumulation, which is consequently required for HGF 
induced wound healing (Figure 9)157.  
 
Recently, our lab has shown that a constitutively active Met mutant has 
altered trafficking, which through increased endosomal signalling leads to 
increases tumourigenicity159. My contribution to this work is detailed in the 
Results section, but briefly this was the first study to make a direct link 
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between endosomal signalling of Met and tumourigenesis. As well as this 
initial “proof of principle” study I have also investigated this concept in a 
variety of other cancer cell models.  
 
4) Mechanisms of endosomal signalling 
Not much is known about how signalling complexes assemble on 
endosomes. One possibility is the recruitment of specific adaptors. 
Endosomes act as signalling platforms bringing together various components 
for signal generation. One such ‘scaffolding molecule’ is Appl1, a Rab5 
effector molecule, found in endosomes, known as APPL endosomes160, 
which later mature into EEA1 positive early endosomes161. Appl1 associates 
both with AKT and transmembrane receptors162. Its localisation on 
endosomes is required for full activation of the Akt pathway and cell survival 
during zebrafish development, making it the first study to investigate 
endosomal signalling in vivo162. MP1 (MEK1 partner) is another scaffold 
protein localised to late endosomes by the adaptor protein p14, where it 
binds to MEK1, activates ERK1/2 and controls EGF dependent 
proliferation163. As I mentioned earlier, endosomes have been shown to act 
as a scaffold for Rac to assemble with and be activated by its GEF Tiam1 
upon HGF stimulation158, however this study did not investigate Met 
localisation. Recent work from our lab has found that the presence of Met, 
together with PI3K and a specific Rac GEF, on perinuclear late endosomes is 
required for sustained Rac activation upon HGF in breast cancer cells 
(Menard et al. Paper in revision).  
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As well as acting as a scaffolding platform, endosomes also provide the 
acidic pH required for many signalling pathways73, while also providing 
protection from phosphatases157. 
 
VI- Met in Cancer 
 
In addition to the increased expression of Met in injured tissue, increased 
expression of Met / HGF occurs in many cancers and higher levels of Met 
expression often correlate with a poor prognosis14. This can occur through 
paracrine (HGF is released from the surrounding stroma) and autocrine 
(HGF is released from the tumour cells themselves) activation of the Met 
receptor15. Alternatively, if the receptor is overexpressed or there is an 
activating point mutation, Met can become activated without the need for 
ligand binding14, 15. The presence of HGF can initiate Met transcription15 and, 
furthermore, some oncogenes, for example RAS, can bring about the 
transcription of Met and consequently lead to its overexpression164. 
 
Activating mutations of Met have been found in many cancers including 
ovarian, gastric, liver, kidney and head and neck cancer14. Thus, Met may 







1) Met in breast cancer  
a) Breast cancer 
Breast cancer is the leading cause of cancer-associated deaths in females in 
the Western world, despite huge advances in breast cancer detection and 
treatment165. Premalignant lesions begin with ductal hyperplasia which 
progress to carcinoma in situ and finally to invasive disease165. There are two 
main types of lesions; lobular lesions and ductal lesions, the latter of which is 
the most common166. These can progress to lobular carcinoma in situ (LCIS) 
or ductal carcinoma in situ (DCIS) respectively166. Here, cells have 
proliferated filling the ductal/lobular space but the myoepithelial and 
basement membrane layers remain intact165. Once this is broken, invasive 
carcinoma is present, either invasive lobular carcinoma (ILC) or invasive 
ductal carcinoma (IDC)165, 166 and metastasis can occur (Figure 10). There is 
no guarantee that carcinoma in situ will progress to invasive breast cancer 
and determining which patients with in situ disease will develop frank 
carcinoma is one of the problems currently facing breast cancer treatment165, 
166. 
Gene expression studies have shown that there are 5 major types of breast 
carcinoma according to their molecular make-up; normal breast-like, 
HER2(ErbB2)-positive, basal-like and oestrogen receptor (ER) positive, 
which can be subdivided into 2 groups; luminal A (highest levels of ER 
expression) and luminal B (lower ER expression)167. The other three 
subtypes are ER negative167. The luminal A subtype has the best prognosis, 
while the HER2(ErbB2)-positive and basal subtypes have the least 







Figure 10: Breast cancer disease progression 
A normal duct is surrounded by a layer of epithelial cells, enclosed by a layer 
of myoepithelial cells, which lie on the basement membrane. Atypical ductal 
hyperplasia is the result of proliferation of the epithelial cells, if this 
proliferation distends the intraductal space then ductal carcinoma in situ is 
present. This is often accompanied by a high level of stromal infiltrate and 
some of the myoepithelial/basement membrane layer may have started to 
break. Invasive ductal carcinoma is diagnosed if the epithelial cells have 
invaded through the myoepithelial/basement membrane layer. 
 







Basal-like breast cancers are often “triple negative”: oestrogen receptor, 
HER-2 and progesterone-receptor negative169. Furthermore, individuals with 
BRCA1 mutations tend to develop basal-like breast carcinoma and this tends 
to occur at a younger than average age. There is therefore a desperate need 
for new treatment targets to be found for this type of breast cancer12. Basal-
like breast cancer cells express cytokeratins 5, 14 or 17 as well as p53, c-kit, 
EGFR and p63169. CD44 has also been found to have increased expression 
in basal breast cancer cell lines and primary breast cancer tissue samples 
due to amplification of 11p13, which contains 19 genes including CD44170. 
However silencing of CD44 did not reduce cell survival or proliferation and so 
it is not believed to be the amplicon driver but rather associated with 11p13 
amplification170. The collagen receptor Endo180 has been shown to be 
significantly correlated with basal breast cancer and significantly associated 
with shorter disease-free survival in a cohort of 880 invasive breast 
cancers171. 
 
b) Met in Breast Cancer 
It is thought that Met is overexpressed in 20-30% of breast cancers172-174. A 
recent study has suggested that Met may be a marker for the basal breast 
cancer phenotype175. Met therefore may provide a valuable target for breast 
cancer therapy176. 
 
• In Vitro Studies 
HGF has been shown to be produced by adipocytes in the breast stroma and 
to encourage the growth of a murine mammary carcinoma by the paracrine 
  73 
activation of Met177. Met expression itself has been shown to be upregulated 
in various breast cancer cell lines178 and its expression has been associated 
with angiogenic and lymphangiogenic factors in DCIS179. In vitro models of 
DCIS, using the two cell lines MCF10.DCIS and SUM102, have been used to 
demonstrate that HGF can promote the invasion of these cells by increasing 
their ability to degrade collagen type IV and the expression and secretion of 
uPA and uPAR 180.  
 
Expression of Met may also be associated with drug resistance. Her2 
positive breast cancer cells, which also express high levels of Met, have 
been reported to have reduced sensitivity to Trastuzumab (or Herceptin), an 
antibody against Her2, currently used in the clinic. Additionally HER2+ cells 
following Trastuzumab therapy appear to upregulate their Met expression. 
Combining Trastuzumab treatment with Met inhibition may benefit Her2 
positive patients by sensitising the HER2+ cells to Trastuzumab181. 
 
• In Vivo Studies 
A transgenic mouse model, where oncogenic Met was expressed in the 
mammary glands, led to the development of a range of mammary tumours 
with similarities to basal breast cancers182. Furthermore, studies have shown 
that 73% of mice with loss of BRCA1 and Trp53 had high expression of 
Met183, which may correspond to the basal breast cancer phenotype. 
In vivo nude mouse models of MDA-MB-231 xenografts injected with HGF or 
MRC-5 fibroblasts (which secrete high levels of HGF), were shown to have 
reduced growth including reduced angiogenesis following treatment with the 
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HGF antagonist NK4184, thus demonstrating that inhibition of Met signalling in 
models of basal breast cancer may be an effective therapy. 
 
• Clinical Studies 
Several studies have been performed on clinical samples obtained from 
breast cancer patients and they indicate that Met may play a role in breast 
cancer progression. Overexpression of Met in 40 cases of primary breast 
cancer was found to be correlated significantly with the risk of progression of 
the disease and metastasis, reducing the disease free survival from 53 
months (low Met expression) to 8 months176. In a study by Garcia et al. 270 
out of 283 patients with invasive ductal carcinoma who died or had 
metastatic disease were positive for Met expression by immunostaining, 
while only 50 out of 633 patients who were alive or had no metastatic 
disease were positive175. Furthermore, the poor prognosis of individuals with 
overexpression of Met is independent of expression of Her2/neu176. 
Ghousssoub et al. studied 91 tissue samples from patients with invasive 
ductal breast carcinoma using immunofluorescence174. Strong expression of 
Met was found in 22% of these samples174. These patients had significantly 
reduced survival rates, from 89% 5-year survival in Met negative patients to 
52% in Met positive patients174. This was found to be an independent 
prognostic factor that was as good as or better than, other prognostic factors 






Therefore Met appears to be important for the formation and progression of 
breast cancer, as well as in the development of resistance to other TKIs 
(Tyrosine kinase inhibitors). Furthermore, it may be a particularly good target 
for the basal breast cancer sub-group. However, the studies mentioned 
above have only investigated Met expression and signalling. What about Met 
trafficking and endosomal signalling in such tumour cells? 
  
c) Aberrant receptor trafficking in breast cancer 
• Non-RTKs 
A few studies have described altered receptor trafficking in breast cancer. 
The collagen receptor Endo180, has been shown to be upregulated in basal 
breast cancer as I mentioned previously. However, importantly, the 
internalisation of this constitutively recycling receptor is required for its role in 
increased tumour growth observed in mice154. The G protein associated 
receptor PAR-1 has been shown to have dysregulated trafficking by slow 
internalisation and recycling, that prevents it being sorted to lysosomes for 
degradation, leading to its persistent signalling185. 
 
• Modification of endocytic regulators 
The first endocytic protein demonstrated to be involved in tumourigenesis 
was Hip1. Rao et al. showed that Hip1 expression was significantly higher in 
breast cancer tissue compared to normal breast tissue and this correlated 
with high EGFR expression. This correlated to increased EGFR expression 
in Hip1 overexpressing NIH3T3 cells in vitro as well as increased tumour 
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formation in vivo186. Since this study, other endocytic proteins have been 
found to be dysregulated in cancer. Analysis of microarray expression 
profiles of 737 primary invasive breast cancer cases identified two amplicons 
at 17q12 and 8p11-12 that occurred in tumours187. The 8p11-12 amplicon 
occurred in 17% of breast cancer cases analysed and the Rab-coupling 
protein (RCP) gene, involved in recycling, was found to be the gene most 
significantly associated with metastasis which was located in this region187. 
Overexpression of RCP led to the normal human mammary MCF-10A cells 
acquiring tumourigenic properties with increased activation of Ras and 
ERK1/2187. This is most likely due to changes in the trafficking of receptors, 
particularly recycling187, 188.  The small GTPase Rab25, which also is involved 
in vesicle recycling of membrane receptors, including α5β1-integrin in 
epithelial cells189, has been shown to have increased expression in advanced 
breast and ovarian cancers190. The expression of Rab25 is associated with 
increased cell proliferation and survival in vitro as well as decreased overall 
patient survival190. Nevertheless, these studies on Hip1, RCP and Rab25 
only suggest that receptor trafficking is modified. Hip1, RCP and Rab25 are 
all endocytic regulators that control the trafficking of many cell receptors 
including RTKs and so there could be numerous effects as a consequence of 
their modified expression.   
 
• RTKs 
In terms of aberrant trafficking of RTKs in breast cancer, very little has been 
published. The EGFRvIII mutant, found in many cancers including breast 
cancer191, 192, lacks part of its extracellular domain and is unable to undergo 
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proper phosphorylation of its c-Cbl binding site (Y1045)193; thus, leading to a 
defect in ubiquitination, internalisation and degradation of the receptor193. 
Moreover, Rab11a, has been shown to be overexpressed in DCIS and to 
induce proliferation and increased MAPK signalling in MCF10A cells upon 
EGF stimulation, through recycling of EGFR194. 
 
• Summary 
The studies on activated receptors, such as the EGFRvIII mutant and PAR-1 
receptors, demonstrate persistent signalling due to a prolonged lifespan.  
They have decreased degradation through decreased internalisation or 
increased recycling. Therefore, so far nothing has been shown 
demonstrating a difference in RTK internalisation and trafficking towards 
endosomes or a direct role for endosomal signalling in breast cancer 
progression. Furthermore, there is no report of dysregulated trafficking or 
endosomal signalling of Met in breast cancer to our knowledge. 
 
2) Met mutations in cancer 
a) RTK mutations in cancer 
Several RTK mutations have been discovered in cancer. They lead to RTKs 
being constitutively active and can confer drug resistance. For example, 
EGFR mutations in the kinase domain (exons 18-21) have been found in 
10% of non-small cell lung cancers, mostly occuring in adenocarcinomas, 
which result in increased EGFR activation195. These mutations usually are 
sensitive to TKIs; however some mutations, such as the T790M mutation or 
insertion mutations in exon 20, lead to resistance to EGFR inhibitors195. 
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The RTKs Kit and Ret contain a highly conserved kinase domain with Met 
and interestingly, mutations have been identified which correspond to the 
Met mutations I have been investigating. The constitutively activating M918T 
mutation located in the kinase domain of Ret is homologous to the M1268T 
Met mutation I will describe later, and has been found to be the cause of 
most cases of multiple endocrine neoplasia type 2B196, 197. Meanwhile, the 
constitutively activating D816Y/V in the kinase domain of Kit is homologous 
to the D1246N Met mutation, which I will also describe later, and has been 
found to occur in mastocytosis198, 199. 
 
The studies mentioned above are believed to indicate that Met mutations 
may be oncogenic due to their constitutive kinase activity. A few studies have 
described RTK mutants that have been found to have altered trafficking. The 
EGFR L858R and L816Q mutations in the activation loop of EGFR that were 
discovered in NSCLC lead to a defect in degradation due to an association 
with HSP90 and therefore are sensitive to treatment with HSP90 inhibitors200. 
The EGFRvIII mutant lacks part of its extracellular domain and is unable to 
undergo proper phosphorylation of its c-Cbl binding site (Y1045)193; thus, 
leading to a defect in ubiquitination, internalisation and degradation of the 
receptor193. 
Nevertheless, prior to the work carried out in our lab, no RTK mutations have 
been discovered that lead to altered trafficking corresponding to increased 




b) Met Mutations in Cancer 
• Identification of Met Mutations in Cancer 
Mutations in Met have been identified in a variety of human cancers, 
including papillary renal-cell carcinoma, childhood hepatocellular cancer, 
gastric cancer and lymph node metastasis of head and neck squamous-cell 
carcinoma16. Recently, a somatic intronic mutation was discovered in lung 
cancer, leading to an alternative spliced Met transcript and consequent 
deletion of exon 14, encoding for the juxtamembrane domain201.  
 
Schmidt et al. discovered the first Met mutations in 1997 when they found 
germline and sporadic missense mutations in the tyrosine kinase domain in 
cases of papillary renal carcinoma202. In order to investigate whether these 
mutations could influence cancer progression, Jeffers et al. expressed them 
in NIH3T3 cells, which lack Met expression and which were selected for their 
low HGF production203. The mutations, which included M1268T, D1246H, 
Y1248H, Y1248C, V1238I, V1206L and M1149T, were found to constitutively 
activate Met, with M1268T the most strongly activated203. All of the mutants 
formed tumours in athymic nude mice more rapidly than those with wild type 
Met, with the M1268T mutants being the most tumourigenic both in vitro and 
in vivo203.  
 
• Mechanism of increased tumourigenicity of Met mutants 
Recent work from our lab by Carine Joffre has advanced the understanding 
of the mechanisms of the increased tumourigenicity of the Met mutants. As 
mentioned briefly previously, it was found that while the mutants, M1269T 
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and D1246N, were more highly phosphorylated than the wild type Met 
stimulated with HGF, it was not only their constitutively high activation that 
was the cause of their high tumourigenicity.  
 
The mutants were found to be constitutively internalised and recycled back to 
the membrane and to have a defect in degradation (Figure 11). The result of 
this is the accumulation of the Met mutants on endosomes, where they 
continue to signal. There was found to be a requirement for endocytosis for 
Rac1 activation, suggesting that Rac1 is activated on endosomes by Met 
mutants. Blocking the endocytosis of the Met mutants was able to reduce cell 
migration and anchorage independent growth as well as tumour growth and 
in vivo metastasis of cells expressing these variants. Furthermore, blocking 
Met endocytosis had no effect on Met phosphorylation, thus the reduction in 
tumourigenesis observed by the alteration of mutant Met trafficking was 
independent of Met activation159. This demonstrates that the tumourigenicity 
of this Met mutant requires both constitutive Met activation and its 
accumulation on endosomes. Therefore inhibiting either of these 














Figure 11: Model of Wt Met and oncogenic mutant Met signalling 
Taken from Joffre C et al., Nat. Cell Biol., 2011159
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VII- Targeting Met in cancer  
 
1) Types of Met Signalling Inhibitors 
Since Met signalling is involved in multiple human cancers, various inhibitors 
have been produced that target either Met or its ligand HGF. There are 
currently no Met inhibitors used as a first line treatment for cancer in the 
clinic. There are however many clinical trials, currently running, to evaluate 
their therapeutic potential. 
 
a) ‘Decoy’ HGF  
A truncated form of HGF, ‘NK4’ (N-terminal Kringle 4), was developed by 
Date et al.204. By binding to Met, it inhibits HGF-Met binding204. It has been 
shown to have anti-tumourigenic, anti-metastatic as well as anti-angiogenic 
effects in various human cancer models205. 
 
b) HGF antibodies 
Amgen has produced quite a few monoclonal anti-HGF antibodies206. 
AMG102 is the best characterised and has proven to reduce tumour growth 
in vitro and in vivo working in synergy with Temozolomide or Docetaxel 
chemotherapeutic agents207. It is currently undergoing many Phase I and II 
clinical trials both as a monotherapy and in combination with chemotherapy 
in the treatment of various cancers including glioma, prostate cancer, 




c) ‘Decoy’ Met 
Michieli et al. developed a soluble Met protein that matched the extracellular 
region of Met, thus lacking a kinase domain and the ability to signal208. 
Furthermore, the ‘Met decoy’ binds to both HGF and full size Met with high 
affinity, thus inhibiting signalling through both ligand binding and receptor 
dimerisation208. 
 
d) Met antibodies 
The OA-5D5 monoclonal anti-Met antibody (also called METMab or 
Onartuzumab) was developed by Genentech and showed high efficacy in 
vitro and in vivo in U87MG glioma cells, which contain an HGF/Met autocrine 
loop, by inhibiting HGF-Met binding8, 209. It has shown very positive results in 
combination with the EGFR inhibitor Erlotinib in the treatment of non-small 
cell lung cancer (NSCLC) and has recently entered a Phase II trial in the 
treatment of triple negative breast cancer8. 
 
e) Non-ATP- Competitive Small Molecule Met Inhibitors 
ARQ197, produced by ArQule, has been shown to inhibit Met over a panel of 
230 kinases210. It inhibits the phosphorylation of Met and its downstream 
targets in a variety of cancer cell lines, where Met was either activated upon 
HGF stimulation or independently of HGF210, 211, although it more favourably 
inhibits the inactive form of Met212. It does so by preventing ATP binding, but 
through a novel non-competitive method8 It binds the ATP-binding cleft and 
an unique hydrophobic pocket8, 212. ARQ197 binding makes the ATP binding 
site non-polar and unsuitable for ATP binding, but it also stabilises Met in its 
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inactive conformation212.  ARQ197 has produced promising results in phase 
II clinical trials treating NSCLC patients together with erlotinib and, as a 
result, ARQ197 combined with erlotinib has recently moved into phase III 
clinical trials8. 
 
f) ATP- Competitive Small Molecule Inhibitors 
• Met inhibitors 
This class of inhibitors act by competing with ATP for the activation of Met. 
K252a was the first to be described in the 1990’s and it is an analogue of 
Staurosporine45, 213. Despite not being aimed specifically at Met it was found 
to efficiently inhibit Met activation of wild type and, particularly, mutant 
(M1268T) Met activity45, 214.  More recently, more specific Met inhibitors, 
unrelated to K252a, have been developed. The first to be developed, SU-
11274 and PHA-665752, are structurally related, both containing an indolin-
2-core45 (Figure 12).  
 
SU11274 was developed in 2003 by Sugen (now Pfizer)215. It was found to 
be 50-fold more active to Met than a panel of other kinases with an IC50 
against Met activity of 20nM216. In vitro assays demonstrated that SU11274 
inhibits Met phosphorylation as well as downstream signalling and cell 
viability217. 
 
PHA-665752 was developed around the same time as SU11274 also by 
Sugen (now Pfizer)218. PHA-665752 inhibited Met activity with an IC50 of 9nM 
and was also found to be 50-fold more sensitive against Met than a panel of 
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other tyrosine kinases218. In vitro assays demonstrated that PHA-665752 
inhibits Met phosphorylation as well as downstream signalling218, 219 and in 
doing so inhibited cell proliferation, survival, migration and invasion218. 
Furthermore, in vivo assays with PHA-665752 led to a reduction in either 
tumour volume or growth in the Met dependent cell lines GTL-16 (express 
high levels of constitutively active Met) and S114 (NIH3T3 cells that have 
been engineered to express high levels of HGF together with Met)218. It also 
led to a reduction in the growth of small cell lung56 cancer (NCI-H69) and 
non-small cell lung cancer (NCI-H441) xenografts, which express high levels 
of Met220, 221, through inhibition of both tumour cell growth and 
angiogenesis56. Finally, tumours containing Met amplification have been 
shown to be especially sensitive to PHA-66572222 as well as those containing 
the oncogenic TPR-MET form of Met219. Development of resistance to PHA-
665752 has been described in vitro and in vivo in Met dependent GTL-16 
cells by activation of HER family members or amplification of KRAS and Met 
itself223, 224. 
However, the major problem with both SU-11274 and PHA-665752 is that 






Figure 12: Small Molecule Met Inhibitors 
The structure of SU-11274, PHA-665752, PF-02341066 and PF-421709 
developed by Pfizer. The structurally related SU11274 and PHA-665752 
have a common indolin-2-core. The more recently developed PF-02341066 
and PF-4217903 are based on the 3-benzyloxy-2-aminopyridine chemical 
series and triazolopyrazine chemical series respectively.  
 
Adapted from Wang X et al, Mol. Cancer Ther., 2003215, Christensen et al, Cancer Res., 
2003218, Zou HY et al, Cancer Res., 2007225, and Timofeevski et al., Biochem, 2009226.
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PF-2341066 is an orally available compound developed in 2007 by Pfizer. 
The development of this novel Met inhibitor was based on the crystal 
structure of Met with PHA-665752 bound in the kinase domain227 and 
belongs to the 3-benzyloxy-2-aminopyridine chemical series226. It is a much 
more potent and specific inhibitor of Met activity than SU11274 and PHA-
665752, with 100 fold selectivity for Met over 90% of the 120 kinases 
tested225. However, PF-2341066 inhibits the activation of both Met and ALK 
(Anaplastic Lymphoma Kinase) and their downstream signalling pathways in 
a dose dependent manner. In vivo studies showed that treatment with PF-
2341066 inhibited tumour growth of both Met (GTL-16) and HGF (U87MG) 
dependent tumours as well as causing regression of some tumours, including 
non-small cell lung cancer (NCI-H441)225. The mechanisms for this inhibition 
were found to be through a decrease in proliferation and an increase in 
apoptosis of the tumour cells as well as a decrease in angiogenesis225.  
 
PF-4217903 is another more recent orally available compound from Pfizer, 
belonging to the triazolopyrazine chemical series. It potently inhibits Met 
activation and was found to be greater than 1000 fold selective compared to 
a panel of 208 other kinases226. Its potency against wild type Met is similar to 
PF-2341066 and it has demonstrated increased activity against several Met 
mutants226.  
 
Although here I have outlined those small molecule Met inhibitors relevant to 
my study, there are a variety of additional inhibitors that have been produced 
by multiple pharmaceutical companies recently. I have summarised the 
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variety of Met inhibitors that have entered clinical trials in Table 1. 
Some are broader inhibitors targeting Met and other RTKs such as VEGFR. 
This approach of targeting multiple kinases can be very effective. An 
example of this is XL184 (cabozantinib), which targets many RTKs including 
MET, VEGFR2, and RET. In a phase I trial of patients with metastatic or 
unresectable medullary thyroid cancer, 49% had tumours that underwent 
shrinkage and 41% had stable disease for a minimum of 6 months. These 



















et inhibitors in clinical trials 
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VIII- Integrins and RTKs 
 
Integrins are a family of transmembrane receptors that form heterodimers 
from an α and a β subunit. In mammalian cells there are 18 different α 
subunits that can bind non-covalently to one of 8 β subunits, the 
combinations of the two subunits form 24 different integrins (Figure 13)228.  
 
The β1 subunit is ubiquitously expressed and is the β-subunit of most ECM 
binding integrins as it forms the largest subgroup as it can associate with 12 
α partners229. It has roles in foetal development, cell migration, differentiation, 
haematopoiesis, assembly of the ECM and tumourigenesis230. 
 
Integrins directly link the cell cytoskeleton to various components of the 
extracellular matrix (ECM), consisting of collagens, laminins and proteins 
containing the RGD (Arginine-Glycine-Aspartic acid) motif (including 
fibronectin and vitronectin)228, 231. They therefore play a major role in cell 
adhesion and also in cell migration by supplying the necessary traction but 
as well through remodelling of the ECM via relocalisation and activation of 
various proteases, including MMP2, MMP9 and uPAR, at the migrating edge 












Figure 13: Integrin heterodimers found in adherent cells 
This diagram outlines all the integrin heterodimers that can occur in adherent 
cells and to which ligands in the extracellular matrix they bind.  
 








1) Integrin activation 
Integrins have several possible conformations, often discussed in terms of 
integrin activation, which affect their ligand-binding affinity234. There are high-
affinity, intermediate-affinity and low-affinity conformations and within a cell a 
dynamic equilibrium between the conformational states of the integrin 
population is present231. Once this equilibrium shifts towards an increase in 
the high-affinity conformation then this is characterised as integrin 
activation231. The proportion of integrins in active and inactive conformations 
varies depending on cell type and cell behaviour. For example, a higher 
proportion of integrins are in the inactive conformation in circulating platelets 
but integrin activation occurs upon platelet activation, while a higher 
proportion of integrins are in the active conformation in adherent epithelial 
cells but will cycle between inactive and active states during cell migration231. 
 The low-affinity (inactive) conformation of integrins has a bent shape 
(Figure 14), the intermediate-affinity conformation has an extended shape 
while the high affinity (active) conformation has an extended shape and is 
bound to its ligand, although it is possible for the low-affinity form to also be 
ligand bound235. This change in conformation is thought to occur with a 
separation of the cytoplasmic tails of the alpha and beta subunits. 
Integrin activation can occur either through extracellular events, including 










Figure 14: Integrin activation and signalling 
The low-affinity (inactive) conformation of integrins has a bent shape, while 
the high affinity (active) conformation has an extended shape and is bound to 
its ligand. “Outside-in signalling” occurs when ligand binding of an integrin 
heterodimer leads to tyrosine phosphorylation of two motifs in the 
cytoplasmic tail, which can lead to the phosphorylation of intracellular 
molecules such as FAK . “Inside-out signalling” occurs through the binding of 
the intracellular cytoskeletal protein Talin, which increase ligand affinity 
through altering the integrin conformation. 
 





2) Integrin Signalling 
In fact, integrins are known to play a role in cell signalling. Although they 
themselves lack kinase activity, their binding to molecules in the ECM leads 
to the recruitment and activation of various intracellular signalling molecules 
at sites called focal adhesions232.  
 
a) “Outside-In Signalling” 
There are two regions of the β-integrin subunit cytoplasmic tail that are 
involved in integrin signalling; the membrane-proximal NPxY motif and the 
membrane distal NxxY motif231. Tyrosine phosphorylation of these regions 
occurs after ligand binding or through interaction with RTKs as described in 
Part 4 and leads to altered binding affinity of interactors such as Talin and 
Tensin231. The majority of integrins are able to activate Focal Adhesion 
Kinase (FAK) at Y397 through the cytoplasmic domain of the β  subunit236. 
This leads to formation of a FAK-Src complex, which consequently 
phosphorylates the scaffolding molecules p130Cas and paxillin232, 233, 236. 
This can lead to the downstream activation of AKT/PKB, MAPK/ERK as well 
as Rac233, all of which are known to contribute to cell migration. Moreover, 
recruitment of talin, paxillin, vinculin, tensin and α-actinin to focal adhesions 
provides a link to the actin cytoskeleton232.  
 
b) “Inside-Out Signalling” 
Furthermore, integrins can signal in a bidirectional manner as changes in the 
cytoskeleton, are able to alter the ligand-binding affinity of integrins, termed 
“inside-out signalling”228, 231. This occurs through the binding of the 
  95 
intracellular protein Talin, a cytoskeletal protein that is linked to the actin 
cytoskeleton, to the cytoplasmic domain of the β integrin subunit235, 237, 238. In 
doing so, it is thought that Talin disrupts an electrostatic interaction between 
the α and β cytoplamic tails, altering the conformation of the integrin and 
increasing its ligand affinity235, 238. Another group of β integrin subunit binding 
proteins that have been found to be involved are the Kindlins, which bind to a 
more distal region of the β integrin cytoplasmic tail compared to Talin, and 
can help regulate integrin activation together with Talin235, 238. 
 
3) Integrin trafficking  
Fibonectin-binding integrins were the first integrins shown to undergo 
endocytosis and recycling in CHO fibroblasts in a study published in 1989 by 
Bretscher et al.239. It has recently become clear that integrin trafficking is an 
important process enabling the formation and dismantling of focal adhesions, 
ECM remodelling and the redistribution of integrins in the plasma 
membrane231, 240. These functions consequently allow cellular adherence and 
migration. Integrin internalisation can occur via clathrin-dependent and –
independent mechanisms231, 240. Some integrins use a specific pathway, 
while others can use several that can sometimes depend on the activation 
state of the integrin231, 240.  
 
Arjonen et al. recently showed in cancer cells that the active and inactive 
forms of β1-integrin follow different trafficking pathways241. Both the active 
and inactive forms of β1-integrin internalise via clathrin and dynamin 
dependent mechanisms. However the active form has a faster overall rate of 
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internalisation and traffics to a Rab7 positive compartment with its ligand, 
while the inactive form undergoes a slower internalisation and is quickly 
recycled back to the Arf6 positive protrusions of the plasma membrane in a 
Rab4 and F-actin dependent manner241. The consequence is that a greater 
proportion of β1-integrin in the active conformation is present in the 
cytoplasm with the majority of inactive β1-integrin at the plasma 
membrane241 
In recent years it has emerged that integrins can undergo altered trafficking 
in cancer cells. As I have previously mentioned, the GTPase Rab25 has 
been associated with tumour progression. In fact, Rab25 can directly 
associate with β1-integrin and supports α5β1 integrin dependent invasion 
through fibronectin by maintaining a population of recycling α5β1 integrin at 
pseudopodial tips189.  
 
4) Integrin-RTK cross-talk 
There are various ways in which RTKs and integrins have been shown to 
crosstalk. They can associate together at the plasma membrane upon 
integrin binding to the ECM or they can crosstalk via converging downstream 
signalling molecules242. 
 
a) Cross-talk in RTK-integrin Signalling 
• RTK influence on integrin signalling 
The “classical” model of cross-talk between RTKs and integrins occurs when 
growth factors stimulate integrin activation243. Stimulation of cells with growth 
factors such as EGF can lead to the disassembly of focal adhesions244, 
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which are locations of integrin based ECM attachment to the actin 
cytoskeleton involving many molecules232. Furthermore activation of RTKs by 
their growth factors can also alter integrin expression levels243. 
 
 
• Integrin influence on RTK Signalling 
The fact that integrins can influence RTK signalling has been much less 
studied and is a relatively new concept. Most of the studies in this area have 
focused on the adhesion dependent activation of RTKs. It has been shown 
that integrins are capable of activating RTKs through binding to the 
extracellular matrix (Figure 15), independently of their ligand. For example 
ligand binding of β1 or αv integrins leads to a transient EGFR 
phosphorylation in ECV304 endothelial cells245. Furthermore, adhesion leads 
to an increase in the number of EGFR molecules on the cell surface and, 
importantly, EGFR and β1 have been found to form a complex at the plasma 
membrane245, 246. The cytoplasmic domain of β1 as well as c-Src and 
p130Cas are required for this integrin mediated EGFR phosphorylation, while 
p125 FAK has been found not to be required246. 
 
The studies just mentioned are all dependent on cell adhesion. Interestingly, 
a study by Guo et al. showed that β4-integrin is required for ErbB2 
dependent mammary tumourigenesis in vivo, independent of α6β4-integrin 
ligand binding 247. ErbB2 was found to associate with the signalling domain of 
β4-integrin and induce β4-integrin phosphorylation through Src-family 
kinases 247. Furthermore, β4-integrin was found to be required for Src-family 
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kinases induction of ErbB2 phosphoryaltion, so β4-integrin and ErbB2 require 
each other for full signalling capability247. The β4-integrin signalling domain 
was found to increase c-Jun activation, through JNK nuclear translocation as 
well as Stat3 activation; events which promote hyperproliferation and cell 
junction disruption respectively247. 
 
b) Cross-talk in RTK-Integrin Trafficking 
The fact that RTKs and integrins can regulate each other’s trafficking is a 
relatively new concept, but it is particularly relevant given the importance of 
the trafficking of both molecules in cancer cells. 
 
• RTK influence on integrin trafficking 
A few studies have demonstrated that RTK activation can regulate integrin 
trafficking248. For example, stimulation of HeLa cells with foetal calf serum or 
EGF leads to the recycling of internalised β1-integrin in a Rab11 and Arf6 
dependent manner248, 249. Moreover, activation of VEGFR1 has been 
demonstrated to transport αvβ3 to the plasma membrane from early 
endosomes in a Rab4 dependent manner250. This was shown to be important 
for ECM remodelling and in vitro capillary branching250. In a similar manner, 
stimulation of NIH3T3 cells with PDGF is required for the recycling of αvβ3 to 
the leading edge of cells and is consequently important for cell migration251. 
 
• Integrin influence on RTK trafficking 
Alternatively, integrins also have a role to play in RTK trafficking. A study by 
Caswell et al showed that inhibition of αvβ3 in cancer cells brings about 
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increased recycling of α5β1 and EGFR, which is dependent on RCP, leading 
to increased EGFR signalling and cell migration252. Interestingly, inhibition of 
αvβ3-integrin using Cilengitide, has also been shown to promote Rab4-driven 
recycling of VEGFR and β3-integrin, protecting VEGFR from degradation240, 
253. These results might help to explain why Cilengitide has not had the 
hoped for effect in blocking angiogenesis in cancer patients in clinical 
trials.253 The concentration required to inhibit angiogenesis and tumour 
growth is high, once the plasma concentration falls to 0.2-20nM it becomes 
tumour-promoting253. 
 
• Co-trafficking between RTKs and integrins 
Indirect cross-talk between RTKs and integrins has also been described 
through co-trafficking along a similar pathway in cells containing mutant p53. 
The tumour suppressor protein p53 acts by inducing cell death following cell 
stress or damage and mutations in the p53 gene lead to a loss of protein 
function in approximately 50% of cancers254. However recent evidence has 
emerged that mutant p53 can have added pro-tumourigenic roles in addition 
to the loss of tumour suppressor functions. Muller et al. demonstrated that 
the presence of mutant p53 leads to an increased recycling of both α5β1 and 
EGFR, in an RCP dependent manner255. 
 
5) Integrin-Met cross-talk 
Numerous studies have reported integrin-Met cross-talk, however few 
describe mechanisms for how the cross-talk occurs, with none investigating 
where the cross-talk occurs. 
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 a) Cross-talk in Met-integrin signalling 
• The influence of Met on integrin signalling 
HGF can increase α2-integrin expression in adherent MDCK cells256. HGF 
has also been shown to activate αvβ3 integrin in normal thyroid cells (HTU-5) 
promoting cell attachment and spreading257. These studies demonstrate that 
Met activation can play a role in integrin signalling in an anchorage 
dependent manner.  
 
Importantly, Met has been shown to associate specifically with α6β4 (not with 
EGFR or Ron) independently of both Met and integrin ligand binding258. In 
fact, this study by Trusolino et al. published in 2001 was the first to suggest 
that integrins could have a role in cell functions that was independent of 
ligand binding. They demonstrated that the activation of Met leads to the 
phosphorylation of the cytoplasmic tail of the β4 integrin subunit258 which is 
required to sustain Met dependent anchorage independent growth, protection 
from apoptosis and in vivo metastasis258. These biological functions require 
the phosphorylated β4 to bind to Shc, which can then activate the MAPK 
pathway and may also activate PI3K258. Therefore in this situation the β4-
integrin is acting as a signalling scaffold molecule to enhance Met signalling 
rather than as an adhesion receptor. Furthermore, phosphorylation of β4 
integrin  on Tyr1257, 1440 and 1494 following Met activation leads to the 
binding of β4 integrin to Shp2, with Tyr 1440 being necessary259. This leads 
to activation of Src, which phosphorylates Gab1 on the residues involved in 
Grb2 binding259. Both Shp2 and Src are required for anchorage independent 
growth. 
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• The influence of integrins on Met signalling 
Cellular adherence was originally shown to induce Met phosphorylation in 
tumour cells by Wang et al.260. More recently Mitra et al have reported that 
binding of α5β1-integrin to fibronectin initiates a direct association between 
α5-integrin and Met, leading to HGF independent Met phosphorylation and a 
consequent association between Met and Src in ovarian cancer cells261.  
However, unlike the study by Trusolino et al., these studies were shown to be 
all dependent on cell adhesion. 
 
b) Cross-talk in Met-Integrin Trafficking 
• Co-trafficking between Met and integrins 
In a similar way to EGFR, mutant p53 also increases Met signalling as well 
as Met dependent cell migration and invasion. This is due to increased 
recycling of both Met and α5β1, both of which were found to interact with 
RCP262. However, this study did not show whether Met and α5β1 recycle and 
co-localise together or separately.  
 
c) Summary 
So far no studies have yet shown that Met can directly alter integrin 
trafficking or vice versa. It is not known whether the ubiquitously expressed 
β1-integrin could promote Met signalling as α6β4 integrin does. Furthermore, 
the location of Met-integrin cross-talk and whether cross-talk could occur on 





Figure 15: Integrin – RTK crosstalk. 
Ligand binding of integrins can induce phosphorylation of RTKs. Additionally 
ligand binding of RTKs can lead to phosphorylation of the β1-integrin 
cytoplasmic tail, which can then act as a signalling scaffold for RTK 
signalling.  
 
Based on Guo W et al, Nat Rev Mol Cell Biol, 2004233 
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6) Targeting integrins in cancer 
Many integrins have been found to be overexpressed in a variety of human 
tumours; the expression of α4β1, α5β1, α6β4, αvβ3, αvβ5 and αvβ6 have all 
been associated with tumour progression, while α2β1 may behave in an 
opposite way as a tumour suppressor232. As a consequence of this, the 
pharmaceutical industry is trying to target these  cell surface receptors. 
Cilengitide, developed by Merck KGaA, is an αv inhibitor which is showing 
positive results against glioblastoma in clinical trials and is consequently 
undergoing a Phase III trial232. Alternatively, integrin expression in tumours 
could potentially be used for tumour imaging or to enable specific drug 
delivery232. 
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AIMS OF THE PROJECT 
 
The objectives of my thesis were to investigate the potential role of Met 
signalling, trafficking and endosomal signalling in cell transformation, 
migration and in the development and progression of cancer to metastatic 
competence using several different models. 
 
Through overexpression, Met is thought to play a role in breast cancer 
progression175, 176, however precise mechanisms are unknown. In particular, 
Met trafficking and potential endosomal signalling in breast cells has not 
been documented. 
My first aim, therefore was, to investigate mechanisms of Met signalling in 
breast cancer progression using basal breast cancer cell lines, ranging from 
a normal to a pre-invasive and finally to a highly aggressive phenotype, 
expressing endogenous WT Met (MCF10A, MCF-10ADCIS.com, MDA-MB-
468 and MDA-MB-231). I compared Met signalling and subsequent migration 
of these cells, Met trafficking and the potential role of Met endosomal 
signalling in the stimulation of their migration. I extended this study to 
investigate Met expression and localisation in a series of normal, ductal 
carcinoma in situ (DCIS) and invasive ductal carcinoma breast tissue 
samples. 
 
Met also can play a role in cancer progression through activating mutations 
in the kinase domain that have been identified in various human cancers202. 
Through transferring these mutations into cell models, it was shown that they 
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lead to Met constitutive activation and cell transformation in vitro and in 
vivo203. The high activation status of these Met mutants has been assumed 
to be the cause of their oncogenicity. However, the trafficking / endosomal 
signalling and the potential link with the oncogenicity of such mutants had, 
until now, not been investigated.  
Working alongside Dr. Carine Joffre, who has found that these mutants 
present an increased internalisation and recycling and a defect in 
degradation, my second aim was therefore to investigate the signalling, 
particularly the endosomal signalling, of two oncogenic Met mutants, M1268T 
and D1246N, previously identified in renal cell papillary carcinoma. We used, 
as a model, NIH3T3 cells expressing Met Wt or mutants. My personal 
contribution included firstly testing the sensitivity of various small molecule 
Met inhibitors on these Met mutants. Secondly, I investigated the 
mechanisms of Met endocytosis of the Met mutants’ and I attempted to 
restore the mutants degradation using HSP90 inhibition. My aim was then to 
observe the consequences of both inhibiting Met endocytosis and restoring 
Met degradation on Met dependent cell transformation both in vitro and in 
vivo.  
It is known that Met undergoes cross-talk with integrins in both anchorage 
dependent and independent conditions258, 260, 261. However, whether β1 
integrin specifically could promote Met signalling has still to be discovered. 
Furthermore, the localisation of Met-integrin cross-talk or whether one 
molecule can directly influence the trafficking of the other is not yet fully 
known. 
 My final aim was, therefore, to investigate initially the role of β1-integrin in 
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Met signalling and cell function in two cell models and furthermore to examine 
the location of this cross-talk. The first is a cell model consisting of the β1-
integrin null GD25 cells, the GD25- β1A (containing β1-integrin) cells and 
GD25-YYFF (containing β1-integrin with mutations in two crucial tyrosines in 
the NXXY motif of the β1 cytoplasmic tail) cells. The second cell model 
consists of HEK-293 cells containing a tetracycline inducible constitutively 
activated Met-GFP, which induces a loss of cellular adherence and growth of 
the cells in suspension. This therefore provides us with the opportunity to 
observe the role of β1-integrin in Met signalling in unanchored cellls. Finally I 
investigated whether β1-integrin was required for Met dependent 
tumourigenesis in vivo using the previously described Wt and M1268T Met 






MATERIALS AND METHODS 
 
1) Cell Lines and Cell culture 
 
All cell lines were certified by STR (Short Tandem Repeats) DNA profiling, 
which was performed by the Barts and The London Genome Centre in May 
2011. 
 
The MDA-MB-231 and MDA-MB-468 cell lines (ATCC) were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM, PAA) containing 1% L-
glutamine and 10% foetal bovine serum (FBS). The MCF-10ADCIS.com cell 
line (obtained from Dr. Steve Santner) was cultured in 1:1 DMEM: Ham’s F12 
(PAA) containing 1% L-glutamine and 5% horse serum (HS). The MCF10A 
cell line (ATCC) was cultured in 1:1 DMEM: Ham’s F12 (PAA) containing 1% 
L-glutamine and 5% foetal bovine serum (FBS), supplemented with EGF 
(20ng/ml) (Peprotech), Hydrocortisone (0.5mg/ml) (Sigma Aldrich) and 
human Insulin (10µg/ml) (Sigma Aldrich).  MRC-5 fibroblasts were obtained 
from the ATCC and maintained in Minimum essential medium (MEM, PAA) 
containing 10% FBS.  
 
NIH-3T3 mouse fibroblast cells were obtained from the ATCC and cultured in 
DMEM containing 10% donor calf serum (DCS, Gibco Life Technologies). 
NIH-3T3 mouse fibroblast cells stably transfected with either wild type murine 
Met, or the mutated versions of murine Met M1268T and D1246N were a gift 
from Prof. G. Vande Woude203. They were cultured in DMEM containing 10% 
  108 
donor calf serum (DCS, Gibco Life Technologies)159, 203. NIH-3T3 mouse 
fibroblast cells stably transfected with either human Wt Met or the mutated 
versions of Met M1268T and M1268T/N1358H were cultured in DMEM 
containing 10% donor calf serum (DCS, Gibco Life Technologies) and 
800µg/ml G418 (Sigma Aldrich). 
 
The β1-integrin-deficient GD25 cell line (GD25), GD25 cells expressing wild-
type β1A (β1A) or mutant β1A (β1A-YYFF)263 were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) containing 10% foetal bovine serum (FBS) 
(Sigma Aldrich), and 2 mM l-glutamine, with the addition of puromycin (5 
µg/ml)(Sigma Aldrich) for the β1A and β1A-YYFF cells.  
 
T-REx™-293 cell line stably transfected with Met-GFP (“Met-GFP cells”) were 
maintained in DMEM containing 10% FBS Penicillin/Streptomycin and 5 mg/ml 
Blasticidin (Invitrogen Life Technologies) with the addition of 400 µg/ml of 
Zeocin (Invitrogen Life Technologies). Expression of Met-GFP was induced by 
treating the stable cell line with indicated doses of tetracycline for indicated 
times (for most experiments, 0.1 µg/ml for 16 hours).  
 
All cells were cultured in an humidified atmosphere of 8% CO2 at 37oC and 






2) Patients and tissue samples 
 
TMA 
Tissue microarrays (TMAs) were constructed by Dr. James Hulit and Dr. 
Colan Ho-Yen from 153 cases of invasive breast cancer, 47 cases of in-situ 
breast cancer (DCIS) and 5 cases of normal breast tissue in triplicate (3 x 
0.6mm cores) from each formalin fixed, paraffin embedded tumour block 
obtained from the Barts Cancer Institute tissue bank, kindly provided by 
Professor Louise Jones. TMA sections were cut at a thickness of 4µm and 




a) Antibodies  
Antibodies for Western blotting: 
25H2 anti-Met (1/1000), rabbit polyclonal phospho-p44/42 MAP kinase (Thr 
202/Tyr 204)(1/1000), rabbit polyclonal phospho-Met (Tyr 1349)(1/1000), 
phospho-Met (Tyr 1234-1235)(1/1000), Gab1 (Tyr 307)(1/1000) and 
phospho-AKT (Ser 473)(1/1000) from Cell Signaling; mouse monoclonal anti-
α-tubulin (1/5000) from Sigma Aldrich; rabbit polyclonal anti-human Met 
intracellular domain (CVD13) from Invitrogen Life Technologies); rb2 
(1/1000), c-Cbl 
(1/1000), HSC-70 (1/2000), and Met (B2) (1/200) from Santa Cruz 
Technologies; Clathrin heavy chain(1/1000) and HSP90 \(1/1000) from BD; 
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HSP90α (1/1000) from Abcam; HSP90β (1/1000) from BIOMOL 
International; 
mouse monoclonal anti-GFP from CR-UK and rat monoclonal anti-mouse 
anti- β1-integrin, clone MB1.2 (MAB1997) from Millipore. 
Secondary anti-goat, anti-rat, anti-mouse and anti-rabbit IgG horseradish 
peroxidase(HRP)-coupled antibodies (1/1000) were obtained from 
Amersham. 
 
Antibodies for immunofluorescence: 
Goat polyclonal anti-early endosome antigen 1 (EEA1) (1/100) from Santa 
Cruz Technologies; phospho-tyrosine (4G10) (1/100) from Upstate, anti-
human Met from R&D (1/100); mouse anti-human Met (1/100) from 
Novacastra; rat monoclonal anti-mouse anti- β1-integrin, clone MB1.2 
(MAB1997) from Millipore; rat monoclonal anti- β1-integrin in active 
conformation, clone 9EG7 from BD Biosciences; mouse monoclonal anti-
human anti- β1-integrin, clone DF7 from Biomol International and rat 
polyclonal anti- β1-integrin (AIIB2) from the Developmental Studies 
Hybridoma Bank. 
Alexa 488 labelled donkey anti-goat or anti-mouse IgG secondary antibodies 
(1/500) were obtained from Molecular Probes. Cy3-labelled and Cy5 labelled 
donkey anti-mouse or anti-rabbit IgG secondary antibodies (1/1000) were 





Antibodies for flow cytometry: 
Anti-human Met (1/50) was obtaind from R&D. Alexa-488 donkey anti-goat 
IgG (1/250) from Molecular Probes was used as a secondary antibody. 
 
b) Inhibitors and growth factors 
The Met inhibitor SU11274, the VEGFR inhibitor SU1498 and the EGFR 
inhibitor AG490 were obtained from Calbiochem and were used at 2µM, 2µM 
and 50µM respectively. PHA-665752 and PF-2341066 were kindly given to us 
by Dr. Christensen (Pfizer, La Jolla) and were used at 100nM and 200nM 
respectively. Dynasore, the FGFR inhibitor PD17074 and cycloheximide were 
purchased from Sigma Aldrich and used at 80mM, 25nM and 50µg/ml 
respectively. In experiments where Dynasore treatment was required, it was 
necessary for all cells to be starved in 0% serum for 24 hours. Dynole 34-2 
was used at 50µM and provided as a gift by P.J. Robinson (Children's Medical 
Research Institute Australia). The VEGFR antibody DC101 was a kind gift 
from Dan Hicklin, ImClone Systems, Inc. and was used at 1.25µg/ml. 17-AAG 
obtained from Calbiochem was used at 100nM/150nM/200nM as indicated. 
Alexa-546-conjugated phalloidin (used at 1/250) and Cy3-conjugated 
transferrin (used at 1/500) were purchased from Molecular Probes. 
Tetracycline was used at 0.1 µg/ml for the indicated times (16 hours for most 
experiments) and was obtained from Sigma Aldrich. Mounting media 
containing DAPI was obtained from BD Pharmaceutics. Purified human 
recombinant HGF (R&D Systems) was used at 50ng/ml unless otherwise 




hWt Met construct 
The human Met Wt construct has a V5/histidine tag and is within the 
pRK5neo plasmid obtained from Dr. M. Kong-Beltran (Genentech, San 
Fransico)201. hM1268T and hM1268T/N1358H were produced using the 
Quick Change II XL mutagenesis kit (Stratagene) by Dr. Véronique Calleja 
and checked by full sequencing by Dr. Ludovic Menard. 
 
d) RNAi and shRNA 
Below are the sequences of RNAi/shRNA used. The AllStars Neg. Control 
siRNA (20 nmol) (no sequence provided) was obtained from Qiagen. 
Lentiviral transfection of shCHC was performed by Carine Joffre. 
 











































Chain RNAi Dharmacon 1 CAACUUAGCUGGUGCUGAA 
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   2 UAGAGGAGCUUAUCAACUA 
c-Cbl RNAi Dharmacon 1 GAUCUGACCUGCAAUGAUU 
1 UGAAUGAGCUGGUAGAUUA 




















RNAi Dharmacon 3 GCACAGAUCCCAAGUUUCA 
β1-integrin 
RNAi Qiagen - AAGAAGGCTCGAGAGTCCTAT 
 
 
4) Western Blot Analysis 
 
Stimulation experiments 
Breast cancer cell lines and GD25 cells were plated in 6 well plates at 2.5x105 
cells/well for 24 hours and then starved in serum-free medium for 24 hours. 
NIH3T3 cells were plated in 6-well plates at 105 cells/well for 24 hours. 
However, when Met degradation was being investigated, NIH3T3 cells were 
plated in 6-well plates at 4x104 cells/well for 48 hours. Cells were treated with 
17-AAG (at the indicated dose) 16 hours prior to the experiment and 
cycloheximide (1/100) 2 hours prior to the experiment.  
On the day of the experiment, where required cells were pre-treated with 
inhibitors for 30 minutes and then stimulated in serum-free medium with 50 
ng/ml of HGF for the times indicated. 
  114 
Cell lysis 
Cells were put on ice, washed with cold PBS and incubated in RIPA lysis 
buffer (Upstate) containing 1mM sodium orthovanadate (Sigma Aldrich), 
1mM sodium fluoride (Sigma Aldrich), and protease inhibitor cocktail (1/100, 
Calbiochem) for 10 minutes. Cells were then harvested and placed on a 
rotating wheel for 20 minutes,at 4oC, after which the lysates were centrifuged 
at 13000g for 10 minutes at 4oC. The pellet was discarded and the Bio-Rad 
Dc Protein Assay Kit was used as described by the manufacturer (Bio-Rad 
Laboratories) to determine the protein concentration of each sample. 
 
Western blot 
An equal amount of protein (as determined by the Bio-Rad Dc Protein Assay 
Kit) was diluted in 4x sample buffer (Invitrogen Life Technologies) containing 
DTT (Dithiothreitol), except when Western blotting under non-reducing 
conditions (anti-mouse anti- β1-integrin MAB1997), in which case sample 
buffer was used without DTT. The proteins were separated by sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). Samples 
were loaded into pre-cast gels (4-12% Bis-Tris Gel, Invitrogen Life 
Technologies) and run for 1.5 hours at 150 V. Rainbow Molecular Weight 
Marker (GE Amersham) was loaded into one lane to monitor the 
electrophoresis progress. Proteins were then transferred to Hybond 
nitrocellulose membranes (Schleider & Schuell) using a wet transfer system 
at 35 V over 3 hours. Membranes were incubated with TBS containing 3% 
BSA (Sigma Aldrich) and 0.1% Tween (Sigma Aldrich) for 20 minutes, 
Membranes were then incubated with the indicated antibodies diluted in TBS 
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containing 3% BSA and 0.1% Tween for a minimum of 5 hours at 4oC. 
Following three 10 minute washes with TBS containing 0.1% Tween (TBST), 
Membranes were incubated with horseradish peroxidase-linked secondary 
antibodies in TBS containing 3% BSA and 0.1% Tween for 1 hour at room 
temperature. Following three 10 minute washes with TBST, Enhanced 
Chemoluminescence reagents (Amersham Biosciences) were used to 
visualise the protein. Chemiluminescence films (Amersham Biosciences) 
were exposed and developed.  
 
Densitometry 
Protein levels were quantified using ImageJ software. All values were 
normalised to the loading control tubulin or HSC70 or alternatively total 
protein levels when measuring phosphorylated proteins. 
 
5) Flow Cytometry 
 
Met internalisation assay 
Cells were plated in 24 well plates at 5 x 104 for 24 hours prior to being 
stimulated in serum free medium with HGF (100ng/ml) for the indicated 
times. Cells were immediately placed on ice at the end of the HGF 
stimulation to prevent further Met internalisation and were kept on ice for the 
duration of the experiment. Cells were incubated with cold acid wash medium 
(DMEM and HCL + 1% BSA) for 7 minutes, followed by two washes in cold 
FACS buffer (PBS +2% SVF). Cells were then incubated at 4oC with goat 
anti-Met antibody (R&D systems), diluted in FACS buffer, for 45 minutes. 
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Two controls were used: no primary antibody or a Goat IgG isotype primary 
antibody. Cells were washed three times in cold FACS buffer and incubated 
with anti-goat-Alexa-488 secondary antibody for 30 minutes. After which, the 
cells were washed three times in cold FACS buffer and detached using 
EDTA diluted in cold FACS buffer at a concentration of 5mM (300µl/well). 




Immunofluorescence on cells 
Cells were plated in 24 well plates onto 13mm glass coverslips. Breast cell 
lines were plated at 5x104. NIH3T3 cells were plated at 2x104 onto coverslips 
coated with 0.01% poly-l-lysine (Sigma Aldrich).  GD25 and HEK293 cells 
were plated at 5x104 onto coverslips coated with 0.01% poly-L-lysine (Sigma 
Aldrich). After 24 hours, or 48 hours if 24 hours of starvation or 16 hours of 
tetracycline treatment was required, cells were pre-treated with inhibitors 
where required and stimulated with HGF (50ng/ml) or HGF labelled with 
alexa-555 (50ng/ml)(HGF*) at indicated time points, and fixed in 4% 
paraformaldehyde for 10 minutes. Free aldehydes were quenched in NH4Cl 
50mM for 10 minutes. Aspecific sites were blocked and the cells 
permeabilised in PBS containing 2% BSA and 0.1% Triton x 100 for 15 
minutes. Cells were then incubated the primary antibody (dilution 1:100) in 
PBS-2% BSA for 30 minutes. Cells were washed 3 times in PBS prior to 
incubation in the secondary antibody (dilution 1:500) in PBS-2% BSA for 30 
minutes. After three washes in PBS and one wash in dH2O, coverslips were 
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mounted on glass slides with Prolong Gold antifade reagent (Invitrogen), 
which contains DAPI. When the 9EG7 antibody was used, 5mM EGTA 
(Ethylene glycol tetraacetic acid) and 2mM MgCl2 were added to the PBS. 
 
Immunofluorescence on the paraffin embedded sections 
Following de-waxing in xylene and rehydration in decreasing concentrations 
of ethanol, sections underwent antigen retrieval in citrate buffer heated in the 
microwave for 20 minutes. Aspecific sites were blocked in PBS containing 
0.5% BSA and 0.5% donkey serum for 30 minutes. The sections were then 
permeabilised in 0.1% Triton. Sections were stained with a mouse anti-
human Met (1/100,Novacastra) and rabbit EEA1 (1/100) antibodies 
overnight, which were then detected using secondary antibodies (1/500) 
labelled with the appropriate fluorohrome, incubated for 2 hours. Sections 
were rehydrated and then mounted with Prolong Gold antifade reagent 
(Invitrogen Life Technologies). 
 
Confocal microscopy 
A confocal laser scanning microscope LSM510 (Carl Zeiss) with a 63x oil 
immersion objective, was used to analyse the coverslips. Alexa 488 was 
excited with the 488-nm line of an argon laser, Cy3 was excited with a 543-
nm HeNe laser and Cy5 was excited with a 633-nm HeNe laser. Each image 
represents a single section 0.7µM thick. 
Quantification of cells lacking stress fibres and cells with Rac at the plasma 
membrane were carried out on a minimum of 100 cells per condition per 
experiment. 
  118 
7) Cell Transfection  
 
Amaxa Nucleofactor technology transfection 
Both DNA and RNAi transfection of NIH3T3 cells were performed using an 
electroporation method using Amaxa Nucleofactor technology following 
the manufacturer’s instructions (Lonza). The nucleofection kit used was R 
using nucleofection program U-30. Cells were transfected when 70% 
confluent and plated for experiments directly following transfection. Cells 
were harvested or subjected to experimental procedures 72 hours after 
transfection unless otherwise stated. 
 
Lentiviral transduction 
Transductions to obtain a stable knockdown of protein expression were 
carried out using MISSIONTRC Lentiviral Transduction Particles (Sigma 
Aldrich) in a category II containment laboratory. 3000 cells were plated per 
well of a 96-well plate and 24 hours later lentiviral particles were added to the 
cells (which were no more than 70% confluent) in fresh media at a multiplicity 
of infection (MOI) 5 and 10. The following day, the medium was removed, the 
cells were washed gently, to remove viral particles, and fresh medium was 
added containing the selection agent puromycin (at 2µg/ml, the concentration 
previously determined to induce cell death in NIH3T3 cells over 3-5 days). 
Once resistant cells had expanded sufficiently, Western blots were 




8) Cell Proliferation Assay 
 
GD25 cells were plated in 24 well plates at 104 cells/well on day 0 and 
incubated in complete medium with or without HGF (10ng/ml). Two wells of 
cells were trypsinised and counted (twice per well) using a fast read 
haemocytometer after 24 (day 1), 72 (day 3) and 144 hours (day 6). 
 
9) Wound Healing Assay 
 
Cells were plated in 6 well plates at 2.5 x 105 for 24 hours and then incubated 
in serum-free medium for 24 hours. Prior to induction of the wound, cells 
were pre-treated with DMSO, SU11274 or Dynasore for 30 minutes. After 
which cells were scraped away (wounded) using a standard 100µl Gilson 
pipette tip, washed with serum-free medium and incubated with or without 
HGF. Pictures were taken of the wounds at time 0 and 17-24 hours later (as 
indicated). Quantification of the extent of wound closure was performed by 
measuring the wound area at 24 hours compared to 0 hours, using Adobe 
Photoshop.  
 
10) Transwell Migration Assay 
 
NiH3T3 cells were starved in DMEM containing 1% DCS 24 hours prior to 
the assay. 
Transwells (Corning) were removed from the plates and the underside of 
each membrane (containing 8µM pores) was coated with fibronectin (Sigma 
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Aldrich), diluted in PBS 1:100. After 30 minutes, the fibronectin was removed 
and the membranes were left to dry for 1 hour at room temperature. 600µl of 
complete medium was placed into the lower chamber below the membrane. 
HGF (50ng/ml) was added to this lower chamber where required. 2x104 cells 
were suspended in serum free medium and put into each Transwell, above 
the membrane. Where inhibitors were used, cells were pretreated for 30 
minutes and incubated with the inhibitor. NIH3T3, human breast cancer cell 
lines and GD25 cells were left for 2, 4 or 6 hours respectively. Media was 
then removed from each transwell and cells on top of the membrane were 
removed with cotton buds. Cells were fixed in 4% paraformaldehyde for 10 
minutes, washed in PBS and the nuclei were then stained with haematoxylin 
for 20 minutes. After washing in PBS, the membranes were removed using a 
scalpel and mounted onto glass slides using an aqueous mounting medium 
(Aquatex, VWR). Cells in ten random fields were counted per membrane at a 
magnification of 20x using a Zeiss Axiophot microscope. 
 
11) Biotin Internalisation Assay 
In this experiment there are three conditions:  
Total surface: Surface of cells undergo biotinylation but this is not cleaved, 
allowing the total amount of Met on the cell surface to be analysed.  
‘0’ minutes: Surface of cells undergo biotinylation and biotin cleavage, 
allowing the efficiency of the cleavage to be assessed. 
‘15’ minutes: Surface of cells undergo biotinylation, surface proteins are then 
allowed to internalise for 15 minutes at 37 oC and then biotin is cleaved from 
remaining proteins on the cell surface. 
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Plated cells were treated with cycloheximide 12 hours prior to the assay to 
inhibit protein synthesis.  
Cells were placed on ice and washed twice with cold PBS, they were then 
incubated with cold Biotin (0.2mg/ml) on a rotator for 45 minutes at 4oC. 
Following one wash with cold PBS the plates for which internailisation was to 
be measured had warm medium added and they were placed in the 
incubator at 37 oC for 15 minutes. The Total surface and ‘0’ timepoints 
remained on ice during this time at 4 oC. Following this, the cells were 
washed twice with PBS and the biotin was cleaved from the cell surface of 
the 0 and 15 minutes plates, using 8 ml freshly prepared 180mM MesNa cold 
reagent (Cat 63705, Sigma Aldrich), on a moving platform for 20 minutes at 4 
oC. The residual MesNa was then quenched by adding 1.6 ml freshly 
prepared 180mM Iodoacetamide (Cat i1149, Sigma Aldrich) to each plate 
and leaving them on the moving platform for a further 10 minutes at 4oC. 
Following two washes with PBS, the cells were then lysed in RIPA buffer. 
Meanwhile, 100ul of streptavidin-coated beads (Cat 16-126, Upstate) per 
sample were washed. Equal amounts of protein in an equal amount of lysis 
buffer were then added to the beads and they were incubated together on a 
rotating wheel at 4oC for 2 hours. Samples were then centrifuged and the 
beads were washed 3 times with lysis buffer at 4 oC, after which 25µl of warm 
sample buffer was added to the beads. After 10 minutes at 95 oC the 
samples were analysed by Western blot analysis.  
The percentage of internalised Met was calculated using the following 
formula: 
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Internalised Met = [(Met level after incubation at 37 oC)-(Met level at 0 
minutes)]/(total surface Met x 100). 
 
12) Soft Agar Assay 
 
0.3% agarose (type IX-A, Sigma Aldrich)(in PBS) was mixed with 5ml 
complete media per condition, which was subsequently filtered through a 
0.22µm filter (Millex, Millipore) and kept in a water bath at 37°C until 
needed. Cells were passed through a 21g syringe, to ensure single cell 
suspension, and then counted. 500 cells were placed into the bottom of each 
tube, on top of which 5ml of the media mixed with 0.3% agarose was then 
poured gently. The cells were gently resuspended throughout the medium-
agar mixture and the tubes were left to solidify on ice for approximately 20 
minutes. 1ml of complete medium was placed on top of the gels prior to them 
being placed at 37 oC and this medium was changed every 2 days.  
When inhibitors were used, they were added, once colonies began to form 
(Day 5 for NIH3T3 cells expressing various forms of Met), to the 1ml medium 
placed on top of the gels and this was changed every day. The concentration 
of the inhibitors was calculated so as to apply for the total volume. In 
experiments with GD25 cells HGF (14 ng/ml) was added or not daily as soon 
as colonies were observable by eye (day 8). When the experiment was due 
to be stopped (day 9 for NIH3T3 cells, day 6 when transfected with siRNA, 
and day 13 for GD25 cells), the medium on top was removed and the gels 
were poured into wells of a 12 well plate. Photos were then taken of whole 
wells using a Zeiss, Stemi SV11 microscope. Analysis took place by both 
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counting the number of colonies and measuring the area of the colonies 




To make the organotypic gels a mixture of 3.5 parts collagen (Collagen 1 rat 
tail, VWR International), 3.5 parts Matrigel (BD Matrigel Basement 
Membrane Matrix, VWR International), 1 part 10x DMEM (CR-UK Media 
Services), 1 part FBS and 1 part MEM containing MRC-5 fibroblasts (5 x 105 
cells per gel), was made on ice. 1ml of the combined mixture was then added 
to each well of a 24 well plate for as many gels as required and placed at 37 
oC for 1 hour to solidify. 1ml of MEM containing 10% FBS was placed on top 
of each gel and they were left at 37 oC overnight. The following day the 
media was removed from the tops of the gels and 5 x 105 of either MDA-MB-
231 or MCF-10ADCIS.com cells suspended in 1ml of their normal complete 
media, were plated onto the top of each gel. The gels were then left 
overnight at 37 oC. On the same day sterile nylon sheets approximately 2cm2 
(one for each gel) were coated with a mixture of 7 parts collagen, 1 part 10x 
DMEM, 1 part FBS and 1 part MEM + 10% FBS at a neutral pH. The sheets 
were left at 37 oC  for 30 minutes, after which a 1% glutaraldehyde solution 
(in PBS)(Sigma Aldrich) was added to the sheets and left at 4°C for 1 hour. 
Following 3 washes with PBSA and once in serum containing media the 
sheets were left in MEM + 10% FCS overnight at 4°C. The following day, one 
steel grid was placed into each well of a 6 well plate and a gel coated nylon 
sheet was placed on top (with collagen side facing upwards). Media were 
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removed from the top of each gel and the gels were then gently removed 
from the 24 well plate using a sterile spatula and placed onto each of the 
nylon sheets. 4.85ml of complete media (for the appropriate epithelial cells) 
were placed into each well so that it reached the under surface of the grid. 
Any inhibitors used were placed in the gels, with the epithelial cells and in the 
media placed beneath each gel. Media were replaced every 2 days and the 
gels were harvested after 14 days of culture. The gels were fixed in 4% 
paraformaldehyde for 24 hours and then stored in 70% ethanol, prior to being 
paraffin embedded. Sections of 8µm were cut for analysis. Haematoxylin 
eosin staining was performed and pictures taken on a Zeiss Axiophot 
microscope. ImageJ software was used to calculate the Invasion Index as 
developed by Nystrom et al.264:  
Invasive Index:   
Number of invading particles in the gel X total area of invading particles X 
average depth of invading particles 
 
14) In vivo tumourigenicity assays 
 
4-6 week old female athymic nude mice (CD1 Nu/Nu, Charles River UK) 
were used in accordance with United Kingdom Coordination Committee on 
Cancer Research guidelines and Home Office regulations. 
 
Tumour growth assay 
A 5 x 106/ml suspension of cells in PBS was prepared and 5 x 105 cells were 
injected (100µl of solution) subcutaneously into the right flank of nude mice 
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by Prof. Ian Hart. Tumours were measured daily using callipers and volumes 
were calculated using the following formula: 
length x width2 x (π/6) 
Once tumours reached 50mm3, 100µl of DMSO (control) or the relevant 
reagent was painted onto the skin over the top of the tumour and the 
surrounding skin. Once tumours reached 1cm in length, mice were killed 
humanely and the tumours were dissected. Part of each tumour was fixed in 
formal saline to be embedded in paraffin and part was snap-frozen for 
analysis by Western blotting. 
 
Lung colonisation assay 
A 5 x 106/ml suspension of cells in PBS was prepared and 5 x 105 cells were 
injected (100µl of solution) into the tail vein of nude mice by Prof. Ian Hart. 
After 21 days, mice were killed and the lungs were weighed and fixed in 
formal saline for 24 hours after which they were stored in 70% ethanol. 
Lungs were cut and embedded in paraffin, from which 4µM sections were cut 
and stained with haematoxylin/eosin. Analysis and image acquisition was 
undertaken using a Zeiss Axiophot microscope. 
 
15) Statistical Analysis 
 
Student’s t-Test was performed, following a two-tailed distribution, paired 
when comparing the same cell line and un-paired when comparing different 
cell lines. Met expression in tissue samples was analysed using a Chi-square 
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RESULTS CHAPTER I  
Met endosomal signalling correlates with breast cancer 
progression   
 
1) Met is phosphorylated by HGF to a similar level in MCF10ADCIS.com 
and MDA-MB-468 cells 
To investigate the role of Met and the mechanism of Met signalling in the 
progression of breast cancer, two breast cancer cell lines with different 
invasive phenotypes were studied: MCF10ADCIS.com and MDA-MB-468. 
The MCF10ADCIS.com cell line is a model of DCIS (ductal carcinoma in situ) 
adapted from the normal mammary gland cell line MCF-10A265. MDA-MB-
468 cells represent a more aggressive model of breast cancer with the ability 
to form lymph node metastases in nude mice266. Both of the cell lines used 
are representative of the basal breast cancer subtype267, 268,. Furthermore, 
we found these cell lines have similar Met expression levels (Figure 1A), 
making investigating differences in Met signalling dynamics more 
straightforward. 
 
Stimulation with recombinant HGF for 15 minutes led to a similar level of Met 
phosphorylation (Y1349 in the docking site) in each cell line (around 5 fold 
increase versus basal level, p<0.05) and this signal was sustained over a two 
hour period (Figure 1B and C). The activation of Met was shown to be 
specific as it was inhibited in the presence of 2µM SU11274, a specific small 
molecule Met inhibitor (Figure 1B). Additionally, I investigated the 
downstream signalling of Met in these cells. HGF stimulation led to a  
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significant activation of ERK1/2 and AKT in the MDA-MB-468 cells (Figure 
1D) (see Figure 6B for quantifications). However, no significant activation 
of these pathways could be detected in the MCF10ADCIS.com cells. This 
probably is because they already are highly phosphorylated in basal 
conditions (despite serum deprivation conditions for 24h). 
I then went on investigating the influence of Met signalling in cellular 
functions. 
 
2) HGF stimulates wound healing and chemotactic migration of 
MCF10ADCIS.com and MDA-MB-468 cells 
The addition of HGF led to a significant increase in the level of wound 
healing in both cell lines (2.2 and 2.6 fold versus no HGF in 
MCF10ADCIS.com and MDA-MB-468 respectively, p<0.05) (Figure 2). 
Treatment with SU11274 had no effect on the levels of basal wound healing 
and, following stimulation with HGF, the level of wound closure was reduced 
in both cell lines to that observed in the control with no HGF stimulation, 
indicating that the wound healing observed upon HGF stimulation is 
specifically a result of Met signalling. 
 
In Transwell migration assays both the MCF10ADCIS.com and the MDA-MB-
468 cells had a significant fold increase (1.8 fold and 1.6 fold respectively, 
p<0.05) in the number of cells migrating through the Transwell membranes 
upon 4 hours of HGF stimulation compared to the unstimulated control 
(Figure 3).  
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Thus, HGF triggers wound healing and cell migration of both cell lines. 
 
3) Following HGF stimulation, Met is internalised and traffics to early 
endosomes, where it remains activated  
Previous studies in our lab have reported the importance of Met localisation 
in signalling62, 157, 159. To our knowledge, Met endocytosis / trafficking has not 
been reported in breast cancer cells. My next step was therefore to 
characterise the trafficking of Met in the two breast cancer cell lines studied 
here62, 157. 
 
In order to follow Met trafficking, our lab has fluorescently labelled HGF, 
HGF-alexa555 (HGF*)157. HGF* colocalises strongly with total Met staining 
and therefore allows us to follow the localisation of HGF-bound Met reliably 
(Figure 4A). In both cell lines, I observed HGF* uptake indicating an 
internalisation of Met triggered by HGF. At 30 minutes of HGF, Met appears 
fully internalised and partially colocalises with the early endosomal marker, 
EEA1.  
Interestingly, HGF* also colocalises with phospho-tyrosine (4G10) and some 
triple colocalisations HGF*/EEA1/4G10 were observed  (Figure 4B). This 
indicates that Met remains bound to its ligand and activated within 
endosomal compartments in the breast cancer cell lines. I therefore 
wondered if the presence of an activated form of Met on endosomes was a 
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Figure 1: Met is activated by HGF in two basal-like breast cancer cell 
lines
A-D) Western blots on cell lysates of MCF10ADCIS.com and MDA-MB-468 
cells. A) Left: Western blot for Met and tubulin. Right: Quantification of 
Western blots showing Met expression levels normalised on tubulin using 
ImageJ software (n=3). B) Western blots of phospho-Met (Y1349), Met and 
tubulin upon HGF stimulation (50ng/ml) for 0, 15 and 120 minutes in the 
presence of DMSO or the Met inhibitor SU11274 (2μM). Bottom panel shows 
quantification (using ImageJ software) of Met phosphorylation (Y1349) (ratio 
of phospho-Met/tubulin) (n=3). C) Quantification of Met phosphorylation as a 
ratio of total Met (n=3). D) Western blots of phospho-ERK1/2, phospho-AKT 
and tubulin following stimulation with HGF for 0, 15, 120 minutes (n=3). 
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Figure 2: Met activation increases wound healing in two basal-like 
breast cancer cell lines
Wound healing assays. Wounds were made in confluent layers of 
MCF10ADCIS.com and MDA-MB-468 cells which were then incubated with/
without HGF (50ng/ml) and treated with DMSO or the Met inhibitor SU11274 
(2μm). Pictures of the same wound were taken immediately after the wounds 
were made (0hr) and 22 hours later. Graphs in the bottom panel are 
quantifications of mean wound closure expressed as a fold increase upon 






































Figure 3: Met activation increases cell migration in two basal-like breast 
cancer cell lines
Transwell migration assays in which cells were allowed to migrate through a 
Transwell membrane (pore size = 8μm) for 4 hours. The graph shows the fold 
increase in cell migration upon HGF in the two breast cancer cell lines. Data 

















Figure 4: Met is internalised upon HGF stimulation and traffics to early 
endosomes where it remains activated
A) Immunofluorescence showing colocalisation between HGF (labelled with 
Alexa 555, “HGF*”) and Met in MDA-MB-468 cells. B) Immunofluorescence 
on MCF10ADCIS.com and MDA-MB-468. Cells were stimulated with HGF* 
(red) for 0 and 30 minutes and then stained with EEA1(blue) and phospho-








4) The inhibition of endocytosis impairs Met activation in the 
aggressive MDA-MB-468 cells only 
In order to inhibit Met internalisation, I used Dynasore, a cell permeable 
inhibitor of the activity of the GTPase dynamin269. Preincubation of the cells 
with Dynasore prevented HGF* uptake such that, at 30 minutes, more than 
90% of HGF* cellular uptake (thus Met endocytosis) was inhibited in both cell 
lines (Figure 5A and B).  
 
I then investigated the potential influence of the inhibition of endocytosis on 
Met activation in MCF10ADCIS.com and MDA-MB-468 cells stimulated with 
HGF (Figure 6A). Interestingly the result was very different in the two cell 
lines. While Met phosphorylation (Y1349) decreased significantly by over 
70% at 15 and 120 minutes of HGF stimulation in the MDA-MB-468 cells 
(p<0.05), it remained unchanged in the MCF10ADCIS.com cells (Figure 6A).  
 
The effect of Dynasore on HGF stimulated ERK1/2 and AKT activation was 
then monitored in the MDA-MB-468 cells alone (as it could not be observed 
in MCF10ADCIS.com cells). Treatment with Dynasore greatly reduced the 
activation of these signalling molecules, which underwent a 49.5% and a 
61% reduction in ERK1/2 phosphorylation (p<0.05) and a 48% and a 37% 
reduction in AKT phosphorylation (p<0.05) at 15 and 120 minutes of HGF 



















































Figure 5: Dynasore blocks Met internalisation
A) MCF10ADCIS.com and MDA-MB-468 cells were treated with HGF* for 30 
minutes +/- treatment with Dynasore. Quantification of HGF* uptake was 
performed by counting 100 cells per experiment, Data are mean (arbitrary 
units) ± SEM (n=3). B) Immunofluorescence showing uptake of HGF* in 
MDA-MB-468 cells. Cells were also stained with DAPI (blue) and EEA1 
(green).
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Figure 6: Endocytosis is required for the full activation of Met as well as 
ERK and AKT in the aggressive MDA-MB-468 cells
AB) Western blots on indicated cell lysates following stimulation with HGF for 
15 and 120 minutes +/- Dynasore. Bottom panels are quantification of 
Western blots using ImageJ software. A) Western blot on MCF10ADCIS.com 
and MDA-MB-468 cell lysates of phospho-Met (Y1349) and the loading 
control tubulin. Data are mean (arbitrary units) ± SEM (n=3).  B) Western blot 
on MDA-MB-468 cells of phospho-ERK 1/2, phospho-AKT and the loading 
control tubulin. Data are mean (arbitrary units) ± SEM (n=3). *=p<0.05; 








These results suggest that there could be a correlation between the 
aggressiveness of breast cancer cells and the dependence on an endosomal 
location of Met for its optimal activation.  
 
5) The inhibition of endocytosis impairs the HGF dependent migration 
of the aggressive MDA-MB-468 cells only  
I then repeated the Transwell migration assays in the presence of Dynasore 
or DMSO. A significant reduction of nearly 60% (p<0.001) of HGF dependent 
migration was observed for MDA-MB-468, while only a small, but non-
significant, reduction occurred for the MCF10ADCIS.com cells (Figure 7), 
even though they have similar levels of cell migration upon HGF stimulation 
(Figure 2 and 3). Importantly, no reduction in the basal migration was 
observed following treatment with Dynasore alone (Figure 7).  
 
Thus, Met endosomal signalling appears to be required for the full migration 
of the more aggressive cells, but not for similar behaviour of the pre-invasive 
MCF10ADCIS.com cells. However Met appears to internalise and be 
activated on endosomes in both cell lines (Figure 4B). We wondered 
whether a potential difference in the rate of Met internalisation between the 
two cell lines could occur and explain this result. 
 
6) Met internalises faster in the more aggressive cell line MDA-MB-468  
I performed a flow cytometry internalisation assay (see Methods) to quantify 
Met reduction at the plasma membrane (and thus internalisation) upon time 
of HGF stimulation. This assay confirmed the immunofluorescence results 
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(Figure 4B) that Met gets internalised in both cell lines (Figure 8A). 
Interestingly however, the internalisation rate differed between the two cell 
lines, with significantly more Met internalised in the MDA-MB-468 (49%) cells 
as compared to MCF10ADCIS.com cells (34%, p<0.05) following 15 minutes 
of HGF stimulation. Nevertheless, after 60 minutes of HGF an equal amount 
(50%) of total Met had been internalised in both cell lines (Figure 8A). This 
suggests that Met internalises faster initially in the MDA-MB-468 cells, while 
it does so at a steadier rate in the MCF10ADCIS.com cells such that the total 
amount internalised is similar after 60 minutes of HGF. These results were 
confirmed by immunofluorescence, performed by Dr. Ludovic Menard, a 
post-doc in the lab. Thus, at 15 minutes, although HGF* was detected in 
EEA1 positive endosomes in the MDA-MB-468 cells, it mostly was observed 
at the plasma membrane in the MCF10ADCIS.com cells. It was detected on 
















































































Figure 7: Inhibition of endocytosis reduces Met dependent cell 
migration of the aggressive MDA-MB-468 cells
The graph shows the fold increase in the number of MCF10ADCIS.com and 
MDA-MB-468 cells that migrated through Transwell membranes over a period 
of 4 hours following treatment with DMSO or Dynasore (80μM) and, where 
mentioned, stimulated with HGF (50ng/ml). Data are mean (arbitrary units) ± 
SEM (n=3). Percentage decrease in migration is stated. *=p<0.05; 





























































Figure 8: Met traffics faster in the more aggressive MDA-MB-468 cells
A) FACS internalisation assay measuring the amount of Met at the cell
surface over 0, 15 and 60 minutes of HGF stimulation (100ng/ml) using FACS 
Calibur in MCF10ADCIS.com and MDA-MB-468 cells. Data are mean 
(arbitrary units) ± SEM (MCF10ADCIS.com (n=7) and MDA-MB-468 (n=9)). 
B) Immunofluorescence on MCF10ADCIS.com and MDA-MB-468 cells. Cells 
were stimulated with HGF* (red) for 0, 15, 30 and 120 minutes. The cells 
were then stained with EEA1(green) and DAPI (blue). 
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These data, showing a difference in the rate of Met internalisation between 
the two breast cancer cell lines, suggest that the MCF10ADCIS.com cells are 
less sensitive to Dynasore, in terms of Met activation and Met dependent cell 
migration, due to the slower internalisation rate of Met. As a consequence, in 
these cells, a higher proportion of Met may signal from the plasma 
membrane than in the MDA-MB-468 cells. This is evident at 15 minutes 
when more Met remains at the plasma membrane in MCF10ADCIS.com 
cells. However, at 120 minutes this may also be the case, since by FACS I 
have observed that 47% of Met is still at the plasma membrane in both cell 
lines (data not shown), so it is possible that the majority of Met signalling is  
occurring at the plasma membrane in MCF10ADCIS.com cells and on 
endosomes in MDA-MB-468 cells at this time. 
 
7) Only the more aggressive MDA-MB-468 cells invade upon Met 
activation and Met is observed on endosomes in aggressive cells. 
HGF triggers a similar migration of the MCF10ADCIS.com and MDA-MB-468 
cells (Figure 2 and 3). We therefore hypothesised that possibly Met 
endosomal signalling is important for cell invasion. I investigated the invasive 
ability of the two cell lines upon Met activation. In order to imitate 
physiological conditions, the cancer cells were added to a 3D organotypic 
invasion assay270 containing an extracellular matrix embedded with 
fibroblasts264, in this case MRC-5 fibroblasts that are known to secrete 
HGF271. It was first confirmed that MRC5 conditioned medium activates Met 
in both cell lines. Indeed MRC5 conditioned medium led to a strong 
phosphorylation of Met that was inhibited by treatment with SU11274 (Figure 
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9A). It was further verified that cells would migrate across Transwell 
membranes towards MRC5 cells, cultured in the lower well (Figure 9BC). 
Importantly, SU11274 strongly inhibited the migration (Figure 9C) while 
inhibitors against other RTKs, such as EGFR, VEGFR and FGFR, had no 
effect (Figure 9D), indicating that an important part of the cell migration 
towards MRC-5 conditioned media is due to Met activity. 
 
Organotypic cultures were then set up consisting of a synthetic extracellular 
matrix containing MRC-5 fibroblasts (Figure 9E). After 10 days of incubation 
the gels were analysed and an invasive index, as developed by Nystrom et 
al., was calculated264. In organotypic gels with no fibroblasts there was no 
invasion of the MCF10ADCIS.com cells and a very small, barely discernible, 
amount of invasion of the MDA-MB-468 cells (Figure 10AB). The gels 
containing MRC-5 cells showed a substantial increase in invasion of the 
MDA-MB-468 cells (invasive index of 7.73), which was reduced significantly 
by treatment with SU11274 (invasive index of 1.96, p<0.05). 
MCF10ADCIS.com cells only had a very small non-significant amount of 
invasion into the gels as compared to the MDA-MB-468 (invasive index of 
0.37) cells when MRC-5 cells were present. 
 
Thus, upon HGF/MRC5 stimulation, MCF10ADCIS.com cells are poorly 
invasive while MDA-MB-468 cells are highly invasive. Initially these results 
do not seem surprising since MCF10ADCIS.com cells are a model for the 
pre-invasive ductal carcinoma in situ (DCIS) stage of breast cancer, while 
MDA-MB-468 cells have a more aggressive phenotype. Conversely though, 
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Met is activated in both cell lines to a similar degree upon exposure to HGF 
(Figure 1A). In fact, the major differences I have observed between the two 
cell lines is the sensitivity to Dynasore for Met phosphorylation, Met 
dependent migration and the rate of Met internalisation. 
 
Interestingly, using immunofluorescence analysis, I observed in the 3D 
organotypic sections, that Met was present in early endosomes in the 
individual invading MDA-MB-468 cells (Figure 11). Perhaps the difference in 
their ability to invade ECM could be due to the localisation of activated Met 
on endosomes for a longer period of time in the MDA-MB-468 cells. Thus 
there might be a correlation between Met signalling from the endosome and 
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Figure 9: MRC-5 fiboblasts activate Met and breast cancer cell 
migration
A) Western blot for phospho-Met and tubulin on MCF10ADCIS.com and 
MDA-MB-468 cell lysates stimulated with MRC-5 conditioned media following 
treatment with DMSO or SU11274 (2μM). B) Diagram of the Transwell 
migration assay used in CD). C) Transwell migration assay with 
MCF10ADCIS.com cells +/- HGF (50ng/ml) or MRC-5 fibroblasts and treated 
with DMSO or SU11274 (2μM) (n =1, in triplicate). D) Transwell migration 
assay with MCF10ADCIS.com cells +/- MRC-5 fibroblasts following treatment 
with DMSO; SU11274 (2μM); EGFR inhibitor, AG490 (50μM); VEGFR 
antibody, DC101 (1.25μg/ml) and FGFR inhibitor, PD17074 (80mM) (n=1 in 





















































































































Figure 10: Met activation induces cell invasion of the MDA-MB-468 cells
A) Representative pictures of organotypic cultures without MRC-5 or with 
MRC-5 fibroblasts in the presence of DMSO or the Met inhibitor SU11274 
(2uM). B) Quantification of the level of invasion into organotypic cultures using 
the invasive index as developed by Nystrom et al. Ten fields analysed per gel 
(n=3 gels/condition). Data are mean (arbitrary units) ± SEM.
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Figure 11: Met is present in endosomes in invading MDA-MB-468 cells
Immunofluorescence on an organotypic section with MDA-MB-468 cells 
invading into a gel containing MRC-5 fibroblasts. Section was stained with 
Met (red), EEA1 (green) and DAPI (blue). Image (left) taken using a 20x 
objective, the insert image (right) of the indicated invading cell was taken 
using a 63x objective.
DAPI   MET  EEA1
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8) Aggressive phenotypes correlate with variations in Met trafficking 
and degradation that suggest an increased endosomal location 
The results obtained so far suggested the possible importance for Met to 
prolong its location on endosomes in aggressive cells. To further investigate 
this, we extended the study to a wider panel of basal breast cells. Two 
additional breast cell lines were selected that were also of basal origin267 and 
that extended the range of invasive phenotypes studied.  These were the 
MCF-10A cell line, a normal mammary gland cell line that has been 
immortalised, and the MDA-MB-231 cell line, the most aggressive cell line in 
the panel, which commonly forms lung, liver and brain mice metastasis 
following xenografting in immunoincompetent 272.   
 
In a similar fashion to what was observed in the previous cell lines 
investigated, Met was phosphorylated (Y1349 in the docking site) upon 
stimulation with recombinant HGF for 15 minutes and, although decreased 
somewhat, this phosphorylation was sustained over two hours (Figure 12A). 
Furthermore, the activation of Met was inhibited in the presence of 2µM 
SU11274, demonstrating the specificity of the activation (Figure 12A). 
 
Treatment with HGF led to the internalisation of Met from the plasma 
membrane in the two new cell lines and thus was observed in all 4 breast cell 
lines (Figure 12B). However, while I previously found that the more 
aggressive MDA-MB-468 cells internalised significantly faster than the 
MCF10ADCIS.com cells, here I found that the aggressive MDA-MB-231 cells 
internalised the slowest (25.4%) and the normal MCF10A cells internalised 
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the fastest (52.4%) after 15 minutes of HGF stimulation (Figure 12B). In fact 
there were significant differences between the two cell lines at 15, 30 and 60 
minutes, showing that, contrary to MCF10ADCIS.com versus MDA-MB-468, 
the difference is maintained over a long period of time and the MDA-MB-231 
cells never manage to “catch up”.  
 
In fact the FACS internalisation assay reveals the Met levels at the plasma 
membrane over time of HGF stimulation and thus does not reveal a potential 
recycling of Met. In order to investigate whether Met is recycled upon HGF 
stimulation in the breast cell lines, I pre-treated the cells with 60µM 
Primaquine, an inhibitor of recycling from endosomes273. Interestingly, there 
was a tendency for a greater amount of Met to internalise in the aggressive 
MDA-MB-468 and MDA-MB-231 cells following treatment with Primaquine, 
while no difference was observed between DMSO or Primaquine treatment 
for MCF10A and MCF10ADCIS.com cells (Figure 13A). At 15 minutes, 
74.5% of Met was present at the plasma membrane in MDA-MB-231 cells, 
which was reduced to 62.5% following treatment with Primaquine. While Met 
internalised much quicker in the MDA-MB-468 cells, such that only 51% Met 
remained at the cell surface upon 15 minutes of HGF stimulation, this 
however was reduced to 37.6% with Primaquine treatment (Figure 13A). 
This suggests that in these two aggressive breast cancer cell lines, upon 
HGF stimulation, a small percentage of internalised Met recycles back to the 
plasma membrane and possibly re-internalises following restimulation with 
HGF. The significant difference in Met level at the plasma membrane 
between the most aggressive cells MDA-MB-231 and the normal cells 
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MCF10A was lost at 15 minutes following MDA-MB-231 cells treatment with 
Primaquine (Figure 13B). Therefore, there is a trend for the more aggressive 
breast cancer cell lines to recycle, perhaps increasing the amount of time 
spent on endosomes. Thus we hypothesise that in aggressive breast cancer 
cell lines, a shuttling between the plasma membrane and endosomes may 
occur for a proportion of Met, resulting in an enhanced endosomal signalling. 
 
 
These differences in Met internalisation rates and in recycling between the 
cell lines could possibly be coupled to differences in Met degradation. I 
therefore checked Met total levels by Western blots in the four cell lines. 
Met underwent significant degradation after 2 hours of HGF stimulation in all 
cell lines (p<0.01) except the most aggressive MDA-MB-231 cells (Figure 
14). Moreover, the % of Met degradation correlated inversely with the cells’ 
aggressiveness. Thus, it was 24% (but non significant) in MDA-MB-231 cells, 
32% in MDA-MB-468 cells, 39% in MCF10ADCIS.com and 49% in MCF10A 
cells (Figure 14). Thus while the most aggressive MDA-MB-231 cells did not 
significantly degrade Met at 2 hours, the normal MCF10A cells degraded the 
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Figure 12: Met is activated upon HGF stimulation in a wide panel of 
human breast cells
A) Western blots for phospho-Met (Y1349), Met and tubulin upon HGF 
stimulation (50ng/ml) for 0, 15 and 120 minutes in the presence of DMSO or 
the Met inhibitor SU11274 (2μM) on lysates from MCF10A and MDA-MB-231 
cells. B) FACS internalisation assay measuring Met internalisation upon HGF 
(100ng/ml) in MCF10A, MCF10ADCIS.com, MDA-MB-468 and MDA-MB-231 
cells. Data are mean (arbitrary units) ± SEM. (MCF10A (n=4), 
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Figure 13: Met tends to recycle more in the more aggressive breast 
cancer cells
A) FACS internalisation assays measuring Met internalisation upon HGF
(50ng/ml) for 0, 15 and 60 minutes in MCF10A (n=3), MCF10ADCIS.com (n=3), 
MDA-MB-468 (n=4) and MDA-MB-231 (n=4) cells following treatment with 
DMSO or Primaquine (60μM). B) FACS internalisation assays comparing Met 
internalisation upon HGF(50ng/ml) for 0, 15, 30 and 60 minutes between 
MCF10A (n=3) and MDA-MB-231 (n=4) cells following treatment with DMSO 
or Primaquine (60μM). Data are mean (arbitrary units) ± SEM. Significance 





















































































Figure 14: Met is degraded slower in the more aggressive breast cancer 
cell lines
Quantification of Western blots of Met normalised on tubulin in MCF10A, 
MCF10ADCIS.com, MDA-MB-468 and MDA-MB-231 cells stimulated with 
HGF (50ng/ml) for 0, 15 and 120 minutes (n=3). Quantification was 
performed by densitometry using ImageJ software. Data are mean (arbitrary 
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Therefore, there is a difference in Met degradation between the cell lines 
which correlates with the internalisation rate which occurs and the amount of 
Met recycling and which, furthermore, correlates with an aggressive 
phenotype. The normal MCF10A mammary cells exhibit a rapid degradation 
of Met, which is faster than all the tested cancer cell lines, correlating with its 
rapid internalisation. Interestingly, the most aggressive breast cancer cell 
line, MDA-MB-231, has the slowest Met degradation, correlating with its slow 
internalisation and recycling of Met. These results are summarised in Table 2 
and, taken together, they suggest quite strongly that Met may spend more 
time on endosomes in aggressive versus normal/pre-invasive cells. 

























Table 2: Summary of trafficking behaviour of Met in the four breast 





9) Met expression increases with breast cancer progression 
Dr. Colan Ho-Yen looked at the level of Met expression by classical 
himmunohistochemistry in on human breast cancer samples. Although Met 
has been shown to be over-expressed in 20-30% of breast cancer172-174, a 
comparison between DCIS and IDC has not been reported as far as I can 
ascertain. We therefore investigated whether Met expression correlated with 
disease progression. Met expression levels were compared in 47 cases of 
Ductal Carcinoma In Situ (DCIS) and 153 cases of Invasive Ductal 
Carcinoma (IDC) containing a mixture of subtypes, including basal-like. It 
was found that Met expression (both cytoplasmic and plasma membrane) 
was significantly increased in IDC versus DCIS (Appendix Figure 1AB and 
E), with a greater number of IDC cases having a strong Met staining (17% of 
DCIS versus 65% of IDC), while more DCIS cases were found to have 
intermediate (66% of DCIS versus 28% of IDC) or weak (17% of DCIS 
versus 7% of IDC) Met staining.  
 
10) The levels of Met endosomal localisation in patients’ samples 
correlates with the tumour progression  
I next wanted to see if the importance of Met localisation that I have 
observed in vitro on cell lines is also occurring in breast cancer tissues. 
Therefore, Dr James Hulit, a post-doc in the lab, used immunofluorescence 
and confocal microscopy analyses to investigate Met endosomal localisation 
in normal, DCIS and IDC human breast tissue samples. Indeed, Met 
localisation on endosomes could be visualised on these patients samples 
(Appendix Figure 2A). Although these analyses have so far been performed 
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on a small number of samples, our results so far are consistent with the ones 
obtained on the cell lines. Thus a correlation between Met - EEA1 
colocalisation and disease progression was found. 25% of Met was present 
in EEA1 positive compartments in IDC, which was significantly higher than 
the 15.5% of Met in DCIS, which was also, in turn, significantly higher than 
the 8.9% in normal breast tissue (p<0.05; Appendix Figure 2B). Together 
with the results obtained on the cell lines, our study suggests that there 
indeed is a correlation between Met endosomal signalling and breast cancer 




DISCUSSION CHAPTER 1  
Met endosomal signalling correlates with breast cancer 
progression  
 
The results presented here on cell lines and breast tissue are consistent with 
the concept that Met is involved in the promotion and progression of breast 
cancer to metastasis 174-176.  While both of the cell lines investigated in detail 
respond to HGF similarly in terms of Met activation and cell migration, there 
is a correlation between aggressiveness and their ability to invade 
extracellular matrix in response to HGF.  
Moreover, I have shown in this study, that, in breast cell lines, Met gets 
internalised upon HGF stimulation and signals from endosomes. This 
endosomal signalling plays a significant role in the activation of Met, ERK1/2 
and AKT as well as cell migration in the aggressive MDA-MB-468 breast 
cancer cell line (Figure 15). I further found that Met presents differences in 
rates of internalisation, recycling and degradation between four breast lines, 
of normal, DCIS or invasive phenotype. Our hypothesis is that these 
differences result in a longer Met localisation on endosomes in aggressive 
cells versus the normal / DCIS cells. Supporting this, we have demonstrated 
in human breast cancer tissues, that the endosomal location of activated Met 
within cancer cells indeed correlates with cancer progression. These results 
therefore indicate that the trafficking and the endosomal signalling of Met 




Figure 15: Met endosomal signalling correlates with breast cancer 
progression 
Met can be activated to a similar level and stimulate cell migration similarly in 
a model of DCIS and IDC. However, Met trafficking is altered in IDC such 
that Met spends longer on endosomes, where it can activate ERK1/2 and 
AKT and stimulate cell migration. As a result IDC cells are sensitive to 
inhibition of endocytosis, using Dynasore, which inhibits Met, ERK1/2 and 




1) Met expression in breast cancer 
Met is expressed in human breast cancer cases  
Staining of 47 cases of Ductal Carcinoma In Situ (DCIS) and 153 cases of 
Invasive Ductal Carcinoma (IDC) revealed that Met expression was 
significantly higher in IDC compared to DCIS cases. To my knowledge no 
studies have thus far directly compared Met expression between DCIS and 
IDC cases. The results obtained in this study strongly suggest that Met may 
be involved in breast cancer progression, as has been proposed in previous 
studies through investigating IDC and lymph node metastasis174-176, 178.  
 
While most studies investigating Met expression in breast cancer have found 
it to be expressed in 20-30% of cases172-174, we have found that Met is 
strongly expressed in 17% of DCIS and 65% of IDC cases, which is much 
higher than the previously described figures. The set of IDC cases 
investigated here, contained 17% triple-negative cases, with only 2% basal-
like. Thus, the high level of Met expression observed is not due to a higher 
level of basal breast cancer cases, for which Met has been suggested to be a 
marker. Nevertheless, it would be interesting to extend this analysis of 
human breast cancer tissue to look more specifically at whether Met 
expression is altered in basal-like breast cancer compared to other breast 
cancer sub-types. Alternatively, it is possible that the set of cases 
investigated here had an unusually low patient survival, due to the fact that 
Met expression has been associated with a poor prognosis175. Therefore it 
would be interesting to obtain the patient survival data for the cases we have 
investigated in this study and compare them to Met expression levels. 
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Furthermore, we have taken into account both membrane and cytoplasmic 
Met staining in this analysis, while many other studies may have solely 
investigated plasma membrane staining (or when both plasma membrane 
and cytoplasmic staining were present together176), perhaps believing that 
cytosplasmic staining was in some way unspecific. 
 
Met is expressed in a panel of breast cancer cell lines that represent the 
basal breast cancer phenotype 
The normal MCF10A as well as the three breast cancer cell lines used 
throughout this study have basal-like gene expression267, they are 
ER/PR/Her2 negative267 and express EGFR268, 274.  
Each of the cell lines express endogenous Met, in accordance with previous 
studies on these cell lines180, 274-276 as well as studies showing Met is a 
possible marker for basal breast cancer175, 182, 277.  
This use of these basal-like cells makes this study therapeutically relevant 
since patients with basal breast cancer currently have a poor prognosis due 
to both the aggressiveness of the disease and to a lack of effective treatment 









2) Met signalling and its influence on the behaviour of breast cancer 
cells  
Met is specifically activated to comparable levels upon HGF stimulation 
in the pre-invasive MCF-10ADCIS.com cells and the more aggressive 
MDA-MB-468 cells. 
We have shown that HGF stimulates Met phosphorylation in each of the four 
cell lines. I have investigated the Y1349 Met docking site and, while this is 
the site that is most representative of the activity of Met functionally, it also 
would be interesting to look at the Y1234/5 site to investigate the intrinsic 
kinase activity of Met. 
 
Met phosphorylation was calculated in the MCF10ADCIS and MDA-MB-468 
lines and interestingly, cells from both have a similar level of Met 
phosphorylation (around 6 fold) following stimulation with HGF. The two 
major downstream signalling pathways, ERK 1/2 and AKT, were then 
investigated. We detected that HGF significantly activates ERK1/2 and AKT 
in MDA-MB-468 cells (Figure 3) despite the fact there is a basal activation of 
AKT, possibly resulting from the lack of PTEN expression278 in these cells. 
In MCF10ADCIS.com cells, we could not detect the activation of ERK1/2 and 
AKT following HGF stimulation, probably due to the fact they already were 
highly activated under basal conditions, despite serum starvation (Figure 1). 
This may be due to the expression of the h-Ras oncogene265. Since HGF 
stimulates these cells’ wound healing and migration, the activation of a more 
extensive range of signalling molecules could be looked at by Western blot 
analysis, for instance JNK, FAK, PLC- γ and SHC.  
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HGF stimulates the migration of MCF10ADCIS.com cells and of MDA-
MB-468 cells to a similar level but affects their invasion differentially. 
HGF increased the healing of wounded monolayers of both the MCF-
10ADCIS.com and MDA-MB-468 cells to a similar degree. However, since 
wound-healing assays are measuring a result of a mixture of cell function, 
including cell migration and proliferation, I also performed Transwell 
migration assays, which offer a more accurate study of migration alone as 
they were performed over a much shorter time frame (4 hours versus 
overnight). In this assay, both of the cell lines responded to HGF by 
increasing their migration. Perhaps surprisingly, the more aggressive MDA-
MB-468 cells had the same level of migration upon HGF stimulation as the 
MCF-10ADCIS.com cells. However, this was also not completely unexpected 
as both MCF10ADCIS.com cells and MDA-MB-468 cells have similar levels 
of Met expression and activation upon HGF stimulation.  
 
Nevertheless, a difference between the two cell lines was observed in their 
ability to invade in response to HGF secreting MRC-5 fibroblasts embedded 
in an extracellular matrix of an organotypic 3D model. The MCF-
10ADCIS.com cell line only showed a small amount of invasion. This is not 
surprising as it is a model for DCIS, which is the pre-invasive stage of breast 
cancer. Nevertheless, HGF recently has been shown to induce invasion of 
MCF-10ADCIS.com cells in a 2D co-culture system with fibroblasts180. By 
contrast, the MDA-MB-468 cells, which represent an aggressive stage of 
breast cancer, showed substantial invasive activity, which was largely due to 
Met activity as SU11274 significantly and strongly reduced the invasion. 
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Obviously MRC5 may secrete growth factors or cytokines other than HGF 
and despite the fact that optimisation experiments showed that EGFR, 
VEGFR and FGFR were not involved in the increased Transwell migration 
towards MRC-5 cells, these receptors may still be involved in the invasion of 
these cells. To fully establish this, it would be necessary to check the 
phosphorylation status of a variety of RTKs by Western blot. Nevertheless, 
again, the strong reduction of cell invasion in the presence of the Met 
inhibitor allows us to use this model to follow Met-dependent invasion. 
 
In summary, these studies indicate that while there is a similar level of Met 
activation and cell migration upon HGF stimulation in both the 
MCF10ADCIS.com and MDA-MB-468 cells, the MDA-MB-468 cells have a 
significantly higher level of HGF-induced invasion.  
 
3) Endosomal signalling of Met 
Met internalisation is dependent on dynamin and can be impaired to a 
similar level in MCF-10ADCIS.com cells and in MDA-MB-468 cells  
I have shown that HGF stimulates HGF bound Met internalisation in the four 
cell lines studied. Previously, Met has been shown to be internalised by 
clathrin and dynamin dependent mechanisms63, 82. Pre-treatment of 
MCF10ADCIS.com and MDA-MB-468 cells with dynasore, a pharmacological 
inhibitor of the GTPase dynamin, prevented internalisation of approximately 
95% of Met in both cell lines. Thus, this method was used to compare the 
effect of endocytosis inhibition on Met signalling and stimulation of cell 
migration in both cell lines. 
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Because a pharmacological compound may trigger side effects, it would be 
interesting to confirm these results comparing the influence of a dominant 
negative dynamin mutant versus a wild type dynamin construct159.  
 
Due to the fact that dynamin is involved in the endocytosis of many cargos 
through controlling clathrin-dependent and -independent internalisation 
mechanisms279, blocking dynamin likely leads to much broader inhibition than 
just Met. However, since in my studies I have always compared the effect of 
dynamin inhibition on HGF stimulated events (as compared to no stimulation) 
and since I could verify that Met endocytosis was efficiently impaired, it is 
reasonable to think that the results observed are the consequence of Met 
endocytosis inhibition. It would be interesting however to inhibit Met 
endocytosis with other methods, if possible more specific approaches than 
the pharmacological inhibition used here, in order to confirm these results.  
 
I attempted to knock down clathrin heavy chain (CHC) by RNAi using Amaxa 
technology. However, I was not able to achieve an appropriate level of CHC 
diminution in these breast cancer cells for a functional effect to be observed. 
One possibility would be to impair the function of specific regulator(s) of Met 
endocytosis but so far, very little is known regarding which regulators are 
likely to be the significant ones. A few clathrin adaptors have been reported 
to control Met endocytosis. For example, overexpression of AP180 could be 
used82. Knocking down the adaptor and ubiquitin ligase c-Cbl could also be 
used, as I have successfully shown this to inhibit Met endocytosis (see 
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Chapter II). Given more time, this would improve the specificity over dynamin 
inhibition since c-Cbl specifically controls the endocytosis of RTKs65.  
 
Met remains activated post-endocytosis in breast cancer cells 
In the two breast cancer cell lines investigated in detail (MCF10ADCIS.com 
and MDA-MB-468), Met was found to be recruited in early endosomes, 
where it colocalised with a phospho-tyrosine staining. These results are 
consistent with previous studies in HeLa cells82 and suggest that Met is 
activated on endosomes in both breast cancer cell lines. Similar results have 
been obtained with a phospho-Met antibody, however the quality of the 
staining is not very good. This is the reason I used a general phospho-
tyrosine antibody (clone 4G10). To obtain a more specific result, I could use 
the Proximity Ligation Assay (PLA), which allows the detection of two 
associated proteins by immunofluorescence, with a high level of sensitivity 
and specificity. This technique utilises specially designed secondary 
antibodies with a probe, containing a small fragment of DNA, attached. 
Closely associated probes ligate and following an amplification step, highly 
visible colocalisations between two desired molecules can be observed by 
fluorescence microscopy280. This could be used to more specifically observe 
the location of phosphorylated Met with a higher degree of sensitivity using 






The aggressive MDA-MB-468 cells require endocytosis for full Met 
activation and signalling 
In MCF10ADCIS.com and MDA-MB-468 cells, where Met is activated 
following HGF stimulation to the same fold increase (around 6, see Figure 1) 
Blocking endocytosis strongly reduced this phosphorylation in MDA-MB-468 
cells, while there was no decrease in Met phosphorylation in the 
MCF10ADCIS.com cells. These results suggest that, although in both cells 
Met appears to be activated on endosomes (Figure 4), the less aggressive 
cell line has a lower requirement for this spatial restriction for the activation of 
Met. This is quite a remarkable finding, as to our knowledge, a requirement 
for endocytosis for the phosphorylation of an RTK itself upon stimulation with 
its ligand has not been reported. It would be very interesting to see if 
endocytosis is also required for the phosphorylation of the Y1234/5 site in the 
kinase domain of Met, or whether it is only required for the Y1349 site in the 
MDA-MB-468 cells. 
 
The comparison could not be made between the 2 cell lines regarding 
ERK1/2 and AKT as they were not stimulated by HGF in the MCF-
10ADCIS.com cells. In order to fully examine the requirement for endocytosis 
for Met signalling in the MCF-10ADCIS.com cells, it would be necessary to 
investigate more signalling pathways. Meanwhile, In MDA-MB-468 cells, 
levels of Met, ERK1/2 and AKT phosphorylation were reduced significantly 
upon endocytosis inhibition, indicating that these cells require endocytosis to 
fully activate Met and downstream signalling pathways.  
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These results suggest that, while the endocytosis of Met may not be very 
important for its activation of Met in the less aggressive MCF-10ADCIS.com 
cells, endosomal signalling plays a large role in the activation of downstream 
signalling pathways in the more aggressive MDA-MB-468 cell line.  
 
Signalling from the endosome versus from the plasma membrane 
Vieira et al. showed that while ERK1/2 and PI3K signalling is 
hypophosphorylated in endocytosis defective cells upon EGF stimulation, 
PLC- γ and SHC are hyperphosphorylated, suggesting that these molecules 
do not require EGFR endosomal signalling for their full activation145. It would 
therefore be interesting to investigate the signalling of both PLC- γ and SHC 
in our cell models to see if there is also a subset of molecules that signal 
from the plasma membrane, while other molecules signal from endosomes. 
Perhaps, the MCF-10ADCIS.com cells have a larger requirement for PLC- γ 
and SHC signalling. ERK1/2 activation through the endosomal signalling of 
the EGFR and Insulin receptors has been previously demonstrated145, 147, 
while studies on HeLa cells have shown that the endosomal signalling of Met 
leads to ERK1/2 activation62. However, in contrast to EGF activated cells not 
relying on endocytosis for activation of SHC, activation of SHC by the insulin 
receptor does depend on intact endocytosis machinery147. This suggests that 
different RTKs may activate molecules at different localisations within cells. It 
would be interesting to investigate in the breast cancer cell lines whether 
there are any molecules activated by Met whose signalling does not take 
place from endosomes as previously shown for the EGF receptor145.  
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4) Met endosomal signalling and influence on breast cancer cell 
migration 
Interestingly, my results have demonstrated that upon endocytosis inhibition, 
while the HGF dependent migration was not modified significantly in the 
MCF-10ADCIS.com cells, it was significantly reduced by almost 60% in the 
more aggressive MDA-MB-468 cells (Figure 7). These results are consistent 
with the ones obtained on Met activation and signalling and demonstrate that 
the endosomal signalling of Met is required for the migration of the 
aggressive MDA-MB-468 breast cancer cells. The fact that Dynasore did not 
affect the basal cell migration suggests that at least over the time-frame of 
the experiment, Dynasore does not lead to non-specific effects or toxicity.  
 
A few studies have investigated the role of RTK endocytosis in cell migration. 
Jékely et al. demonstrated that RTK endocytosis is important for directional 
cell migration towards ligands during Drosophila development149. This finding 
was further developed by Assaker et al., who found that fully functional 
trafficking between the plasma membrane and endosomes, involving both 
Rab5 and Rab11, was required to keep RTKs active at the leading edge of 
migrating border cells and consequently for directional cell migration150.  
Importantly, a few studies have demonstrated a requirement for endocytosis 
in cell migration upon Met activation. Palamidessi et al. showed in HeLa cells 
that Rac activation upon HGF requires clathrin- and rab5-dependent 
endocytosis, which is consequently required for mesenchymal cell 
migration158. Work from our lab, in which I was involved, has showed that 
prevention of the internalisation and accumulation on endosomes of a 
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constitutively active Met receptor, reduces Rac activation, cell migration and 
experimental metastasis 159 (see Chapter II-2). However, so far, no studies 
have demonstrated a requirement for RTK endocytosis in breast cancer cell 
migration. 
 
Interestingly, in this study I have observed Met on endosomes in invading 
MDA-MB-468 cells in a 3D organotypic invasion assay, suggesting that the 
endosomal signalling of Met may also provide an advantage for invading 
cancer cells. In addition, the 3D organotypic cultures used could provide a 
valuable preclinical model to test endocytic inhibitors as a potential future 
cancer therapy and it would be very interesting to test Dynasore on a panel 
of breast cancer cell lines in this assay. 
 
Studies by Wang et al. have shown that the endosomal signalling of EGFR is 
sufficient to promote cell proliferation and survival in BT20 breast cancer 
cells144. Cancer cells often have increased survival, compared to non-
transformed cells, providing them with the ability to survive in the 
bloodstream and then at the site of metastasis. Therefore, both proliferation 
assays and further survival assays could be performed on the cell lines with 
and without Dynasore, in order to assess the role of Met endosomal 






5) Correlation between Met endosomal signalling and breast cancer 
progression 
 
Differences in RTK trafficking and degradation in four breast cell lines. 
Interestingly, I observed differences in trafficking in the four breast cell lines 
studied, which are summarised in Figure 16. Although it is not possible to 
make definite conclusions on only four cell lines, especially as the differences 
are not “clear cut”, nevertheless our results suggest that the consequences 
of the observed differences in Met trafficking/degradation in the four cell lines 
result in Met being more accumulated on endosomes in aggressive versus 
DCIS and even more versus normal cells.  
 
In the normal mammary cells, MCF10A, Met is internalised rapidly but was 
also rapidly degraded following HGF stimulation, suggesting that, in such 
cells, Met does not remain long on endosomes.  
In the MCF10ADCIS.com cells, Met is internalised more slowly upon HGF 
stimulation but degrades rather quickly, although slower than in the normal 
MCF10A cells. In addition, Met activation and Met dependent cell migration 
were not affected by Dynasore treatment, suggesting that these cells do not 
depend on endosomal location for Met signalling, perhaps because the 
majority of Met signalling takes place from the plasma membrane. All 
together, these results suggest that, in MCF10A.DCIS cells, Met does not 
stay too long on endosomes.  
In the aggressive MDA-MB-468 cells, Met has a significantly faster 
internalisation upon HGF addition than in the MCF10ADCIS.com cells, but it 
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degrades more slowly and, moreover, a proportion of internalised Met 
recycles and probably undergoes cycles of internalisation / recycling (as long 
as the ligand is present). In addition, Met activation and Met dependent cell 
migration were impaired by Dynasore treatment. These results suggest that 
Met remains for a longer period of time on endosomes in these cells.  
Finally, in the aggressive MDA-MB-231 cells, upon HGF stimulation, Met 
internalises and degrades the slowest. Additionally a small percentage of Met 
seems to recycle in these cells. I have not yet obtained any data on the 
requirement for endocytosis for Met signalling and Met dependent cell 
functions in these cells, but it will be very interesting to see if Met endosomal 
signalling is important in these cells.  
 
Thus, again, although the differences between the cells are not all obvious, 
our results suggest that Met trafficking is modified with the aggressiveness of 
the breast cancer cells. The differences are quite clear if looking at opposite 
ends of the spectrum. Thus the normal MCF10A cells have the fastest 
internalisation and subsequent degradation of Met upon HGF stimulation, 
while the aggressive MDA-MB-231 cells have the slowest internalisation and 
the slowest degradation of Met, which also appears to undergo recycling 
upon HGF stimulation. Additionally, we find that only the two cell lines 
representative of IDC seem to have some Met recycling occurring upon HGF 
stimulation and that the level of Met degradation decreases with the cells’ 
aggressiveness.   
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We therefore hypothesise that through modification in its internalisation 
and/or recycling characteristics, together with modification of its degradation 
kinetics, Met accumulation on endosomes increases with the progression of 
breast cancer. We could imagine that cancer cells modify Met trafficking in 
order to maintain it longer on endosomes, from where it could sustain 
transforming signals. 
 
This work is ongoing however and, in order to verify our hypothesis, I am 
planning to quantify Met endosomal localisation in the four cell lines following 
HGF stimulation through analysing confocal pictures. As a control, the 
transferrin receptor will be investigated using fluorescently labelled 
transferrin. This would indicate if the differences we observe are specific to 
Met or are due to a general difference in receptor trafficking between the cell 
lines, which could, for example, occur as a result of some overexpression of 
Rab proteins involved in vesicle trafficking. I also will analyse the influence of 
Dynasore on Met activation, signalling and Met dependent migration in 
MCF10A and MDA-MB-231 cells. Furthermore, in the future this work will be 
extended to investigate a larger panel of breast cancer cell lines. 
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Figure 16:  Changes in Met trafficking during breast cancer progression 
In normal mammary cells; MCF10A, Met is internalised and degraded rapidly 
following HGF stimulation, suggesting that Met does not stay long on 
endosomes. In the MCF10ADCIS.com cells, Met is internalised more slowly 
but degrades rather quickly, although slower than the normal MCF10A cells, 
suggesting that Met has an increased life-span but does not stay too long on 
endosomes. Finally, there are the models of IDC: the MDA-MB-468 cells, 
where Met has a significantly faster internalisation but a slower rate of 
degradation compared to MCF10ADCIS.com cells; the MDA-MB-231 cells, in 
which Met internalises the slowest but also degrades the slowest. Moreover 
a proportion of internalised Met recycles in both of these cell types. 
Altogether these data are suggesting that Met spends a longer time on 




In the experiments investigating recycling, I have only observed a tendency 
for Met to recycle in the MDA-MB-468 and MDA-MB-231 cells using the drug 
primaquine. I am planning to use other tools to impair recycling such as a 
Rab11 dominant negative construct as we did in NIH3T3 cells expressing 
mutant Met159. Given more time, I could perform Biotinylation Recycling 
Assays, which would provide a clear indication of any Met recycling that is 
occurring in these cells. It is also worth noting, that the investigation of Met 
degradation in the breast cancer cell lines was not performed in the presence 
of cycloheximide. Thus, it may be possible that over a two hour time period, 
new Met has been synthesised and processed by the cells and any future 
experiments, particularly over longer periods of time, should be performed in 
the presence of cycloheximide to prevent protein synthesis. 
Correlation between Met endosomal localisation and breast cancer 
progression on tissue samples 
A few studies have investigated Met localisation in breast cancer using 
immunohistochemistry, with conflicting results; one correlating cytoplasmic 
staining with a significantly shortened survival172, and the other correlating 
plasma membrane staining with tumour aggressiveness176.  
Our observation by immunofuorescence and confocal microscopy of Met on 
endosomes in human breast tissue was very exciting; as this has not been 
reported as far as I am aware.  
Moreover, we observed an increase in the amount of Met present on 
endosomes in breast cancer as compared to normal breast tissue, with the 
greatest amount observed in invasive breast cancer. This supports my 
observations on the cell lines and is consistent with our hypothesis that an 
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endosomal localisation of Met correlates and thus may be involved in tumour 
progression. We need however to extend this study on a larger number of 
cases to increase its clinical relevance. 
 
“Addiction” to endosomal signalling 
The idea that cancer cells alter Met trafficking in order to increase the 
amount of time Met spends on endosomes suggests that cancer cells are 
“addicted” to “endosomal signalling”. The concept of “oncogene addiction” 
has been around for many years. Originally described by Weinstein in 
2002281, “oncogene addiction” illustrates the high dependence of cancer cells 
on one particular oncogene and how suppression of this oncogene is 
detrimental for cancer cells282. This forms the basis of many types of novel 
cancer therapy approaches today. However, perhaps it is also possible for 
cancer cells to be “addicted” to endosomal signalling, due to the multitude of 
possible advantages this location may provide to a signalling RTK. 
 
A few studies have demonstrated a deregulation in trafficking of RTKs in 
breast cancer cell models, leading to decreased degradation and/or 
increased recycling of RTKs. The EGFRvIII mutant, found in many cancers 
including breast cancer191, 192, has a defect in ubiquitination, internalisation 
and degradation of the receptor, as it is unable to undergo correct 
phosphorylation of its c-Cbl binding site193.  
 
In fact, of particular interest to the cancer research community are the 
studies by Caswell et al.252 and Muller et al.262 on EGFR and Met recycling 
  176 
respectively. They demonstrated that H1299 cells (non-small cell lung cancer 
cells) containing mutant p53 have increased recycling of EGFR or Met 
together with α5β1 integrin in an RCP dependent manner255, 262. In Chapter 
3, I investigate the role of β1 integrin in Met signalling, the results obtained 
here suggest that this may also be worth investigating in breast cancer cells. 
Interestingly, the MDA-MB-231 and MDA-MB-468 cells used in my study 
both have a mutant p53283, which may explain why I may have observed a 
small amount of Met recycling. It would therefore be interesting to investigate 
the potential role of RCP in Met recycling and signalling in MDA-MB-231 and 
MDA-MB-468 cells.  
Interestingly, RCP has been associated with breast cancer progression, with 
its overexpression leading to normal MCF10A cells acquiring tumourigenic 
properties with increased activation of Ras and ERK1/2187.  
Other endocytic regulators have also been found to be deregulated in breast 
cancer. For example, Rab11a has been shown to be overexpressed in DCIS 
and induce proliferation and increased MAPK signalling in MCF10A cells 
upon EGF stimulation, through recycling of EGFR194. Whilst an increased 
expression of Rab25 in breast cancer patients is an indicator of poor 
prognosis190.  
RCP, Rab11a and Rab25 are all involved in vesicle recycling and therefore it 
is not clear whether their overexpression would play a part in tumourigenesis 
through a decrease in RTK degradation or the increased presence of 
activated RTKs on endosomes. Most of these studies demonstrate persistent 
signalling due to a prolonged lifespan of activated receptors through 
decreased degradation or increased recycling. So far, to my knowledge, 
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nothing has been shown demonstrating a difference in RTK internalisation 
and trafficking towards endosomes or a role for endosomal signalling in 
breast cancer progression.  
 
Thus, our study, performed both on cell lines and in human breast cancer 
tissues, suggest a correlation between breast cancer progression and the 
amount of time spent on endosomes by Met. Further investigation on a wider 
panel of breast cancer cell lines as well as a larger set of breast cancer 
tissue samples, will reveal whether this is indeed the case. 
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RESULTS CHAPTER II 
Understanding Met oncogenic Mutants’  signalling and 
targeting this in tumourigenesis. 
 
Under normal conditions, Wt Met is activated by its ligand HGF, after which it 
is internalised and traffics to early endosomes. Met continues to signal from 
early endosomal compartments, and in fact, this location is required for Met 
signalling to ERK 1/262. However, Met usually is degraded efficiently, thereby 
putting a stop to continuous Met signalling.  
 
Recent work from our lab has investigated the trafficking of the D1246N and 
M1268T constitutively active Met mutants that have previously been 
identified in papillary renal cell carcinoma202. Carine Joffre showed that 
M1268T Met mutants have increased internalisation and decreased 
degradation compared to Wt Met159. The mutants constitutively internalise 
and traffic to endosomal compartments from where they signal, and then 
recycle back to the plasma membrane. It is proposed from these studies that 
the accumulation of the M1268T and D1246N mutant Met on endosomes 
leads to a persistent endosomal signalling, cell transformation and in vivo 
tumourigenesis. 
 
The aim of my work was to understand mechanisms regulating the increased 
endocytosis on the one hand (Part 2) and the decreased degradation on the 
other hand (Part 3), of Met mutants, and impair these mechanisms in the 
view of reducing their oncogenicity. I describe my contribution to the recent 
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publication (Joffre, Barrow et al, NCB 2011) and I present my original 
unpublished work. Initially, I have studied the sensitivity of both mutants to 
three Met TKIs, presented in part 1.  
 
1) Sensitivity of Met mutants D1246N and M1268T to Met 
specific inhibitors in vitro and in vivo. 
 
a) Met mutants are highly and constitutively phosphorylated. 
It has previously been shown that the three Met mutants are highly 
constitutively activated as compared to Wt Met 284. I performed Western blot 
analyses from NIH3T3 cells expressing murine Met Wt, D1246N or M1268T, 
which confirmed that both the D1246N and M1268T Met mutants are highly 
activated in both the kinase domain (Y1234/5) (Figure 1A) and the docking 
site (Y1349) (data not shown). This is to a much higher degree than in the Wt 
cells, either non-stimulated or stimulated with 5, 50 or 200ng/ml HGF for 5, 
10 or 20 minutes (Figure 1B). 
In the clinic, the response to RTK inhibitors of patients bearing cancers 
expressing RTK oncogenic mutations can be highly modified toward 
increased sensitivity or resistance. Therefore, I aimed to investigate the 







b) M1268T mutant Met is sensitive to Met inhibitors while the D1246N 
mutant is resistant. 
I tested various different pharmacological small molecule inhibitors of Met: 
PHA-665752 (PHA), SU11274 (SU) and PF-2341066 (PF) (which is orally 
available) on WT, M1268T and D1246N Met expressing cells.  
All three inhibitors were found to greatly reduce the phosphorylation of the 
M1268T mutant in a dose dependent manner (Figure 2ABC). Met 
phosphorylation was completely inhibited in these cells with PF at 0.025μM, 
PHA at 0.1μM and SU at 1μM (Figure 2ABC).  
 
The D1246N mutant, however, was found to be resistant to the three 
inhibitors, although it did appear to be slightly sensitive to higher doses of 
PF, though these differences were not significant (Figure 2ABC). To 
investigate this further, I tested higher doses of PF on the D1246N cells. At 
the very high dose of 5µM, D1246N Met phosphorylation (Y1234/5) was 
completely inhibited (Figure 3A). At a dose of 1µM, phosphorylation of 
D1246N Met was reduced by 62%, while an investigation into lower doses of 
PF on M1268T cells revealed that M1268T phosphorylation was reduced by 
65% at 0.01µM. Therefore the M1268T mutant is 100 fold more sensitive to 
PF than the D1246N mutant. Moreover, it is likely that the drug has lost its 
specificity towards Met at doses higher than 1μM225 and it can be concluded 
that the D1246N mutant is resistant or, at least, poorly sensitive to PF. It is 
worth noting here that all three inhibitors also reduced the phosphorylation of 
the Wt Met treated with HGF as shown for treatment with PF (Figure 3B). 
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Figure 1: M1268T mutant is phosphorylated to a higher degree than Wt 
cells + HGF
A) Western blot for phospho-Met (Y1234/35), Met  and HSC70 on Wt, 
D1246N and M1268T cell lysates. B) Western blot for phospho-Met 
(Y1234/5) and Met on Wt cells stimulated with either 5, 50 or 200 ng/ml HGF 
for 5, 10 or 20 minutes and the unstimulated M1268T cells.
































































Figure 2: M1268T cells are sensitive to various small molecule Met 
inhibitors, while the D1246N cells are resistant 
A) Western blots for phospho-Met (Y1234/35 and Y1349), Met and tubulin in 
D1246N and M1268T cells treated with stated doses of SU-11274. Bottom 
panel is quantification of the blots of D1246N and M1268T cells.  
BC) Quantification of Western blots of D1246N and M1268T cell lysates 
treated with stated doses of B) PHA-665752 and C) PF-2341066. Data are 





























































































Figure 3: M1268T cells are 100 fold more sensitive to PF-2311066 than 
the D1246N cells. 
A) Western blot for phospho-Met (Y1234/35) in D1246N and M1268T cells 
treated with low or high dose of PF-2341066 respectively (n=1). B) Western 
blot for phospho-Met (Y1234/35 and Y1349), Met and tubulin in Wt cells 
stimulated with HGF or not (-) and treated with the stated doses of 
PF-2341066. 
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Figure 4: Met inhibitors alter the morphology of the M1268T cells but 
not of the D1246N cells 
 
Wt, D1246N and M1268T cells were treated with either DMSO, PHA-665752 
(0.1μM), PF-2341066 (0.2μM) or SU-11274 (2μM) overnight, after which pictures 
were taken and morphological changes observed.
184
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The M1268T and D1246N mutant expressing cells have a distinct 
morphology, being more rounded and loosely adherent as compared to the 
Wt cells (Figure 4). The effect of treatment of the M1268T cells with the 
various inhibitors over 24 hours could be seen in a change in cell 
morphology, such that they came to resemble more closely the Wt 
morphology with a flattened and more spread appearance, while no effect on 
the morphology of the D1246N cells was observed. No change was observed 
in Wt cells either, consistent with the fact that the poorly phosphorylated Wt 
Met requires HGF to reach a threshold of phosphorylation necessary for cell 
transformation (Figure 4). I then investigated further the potential differences 
in the actin cytoskeleton organisation by staining the cells with phalloidin-
555. While only around 30% of Wt cells lacked stress fibres, around 70% of 
D1246N and M1268T cells lacked stress fibres (Figure 5AB). Treatment with 
PHA significantly reduced the number of M1268T cells lacking stress fibres 
but had no effect on the D1246N cells, while silencing of Met with Met RNAi 
(Figure 5C) reduced the number of both D1246N and M1268T cells lacking 
stress fibres (Figure 5AB). Furthermore, treatment with either PHA-665752 
or transfection with Met RNAi had no effect on the stress fibres of the Wt 
expressing cells (Figure 5AB).  
These results indicate that Wt Met is not transforming, that the lack of stress 
fibres observed in D1246N and M1268T cells is due to the expression of the 
Met mutants, and that the D1246N cells are resistant to the small molecule 
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Figure 5: Treatment with Met inhibitors restores stress fibres of M1268T 
but not D1246N cells  
A) Confocal sections of Wt, D1246N, M1268T cells stained with Cy3-
phalloidin (red) and DAPI (blue), following treatment with DMSO or 
PHA-665752 for 90 minutes or transfected with control or Met RNAi. Scale 
bars: 10 μm. B) Graph shows the mean percentage of cells lacking stress 
fibres ± SEM (n=3). Cont is the average of DMSO (n=3) and RNAi control 




The M1268T and D1246N mutants have previously been shown to be more 
tumourigenic both in vitro and in vivo 203, 285. I performed several biological 
assays to assess the influence of the Met inhibitors on cellular migration, 
growth in anchorage independent conditions and in vivo tumorigenesis.  
In Transwell migration assays, the M1268T mutant expressing cells migrate 
7-fold more than the Wt cells (p<0.05) (Figure 6A). The D1246N mutant cells 
are less migratory than the M1268T mutant cells but both of these Met 
mutant expressing cells still migrate more than the Wt cells stimulated with 
HGF in Transwell migration assays (Figure 6A). Moreover, HGF can 
increase further the migration of the D1246N and M1268T cells159.  
Treatment with the Met inhibitors PHA and PF significantly reduced the 
migration of the M1268T cells by over 50% (p<0.05), however the D1246N 
cells remained resistant to the Met inhibitors with no decrease in cell 
migration (Figure 6B). Nevertheless both mutant cells have a significantly 
reduced migration following Met knockdown (Figure 6C), while, neither 
treatment with Met inhibitors nor transfection with Met RNAi had an effect on 
the migration of Wt Met expressing cells.  
These results show that the increased migratory ability of the cells 
expressing Met mutants is dependent on the Met mutations and that the cells 
expressing Met mutant D1246N are insensitive to Met inhibitors fwith regard 
to affecting their increased cell migration. 
 
The growth in soft agar of the Met mutant cells was also investigated, as this 
measures the capability of cells to undertake anchorage independent growth; 
a prerequisite for cancer development and a necessary prelude to 
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metastasis. Colonies were allowed to form in soft agar after which they were 
treated daily with fresh media for 4 days. As compared to Wt cells, the 
M1268T and D1246N mutant expressing cells formed a significantly larger 
number of colonies (p<0.01) (Figure 7A). Following treatment with media 
containing DMSO or PF (0.1μM), PHA (0.1μM) or SU (2μM) for the last 4 
days the number of M1268T colonies was greatly reduced as well as the 
colony area (data not shown) by at least 50% (Figure 7BC), reaching a 
similar number and colony area (data not shown) to that formed with Wt cells 
(Figure 7C). Furthermore, none of the inhibitors had an effect on the number 
of colonies or colony area (data not shown) formed by the WT or D1246N 
cells (Figure 7BC). Meanwhile, transfection with Met RNAi significantly 
reduced the number of colonies grown in soft agar of both D1246N and 
M1268T cells, while there was no effect on Wt cells (Figure 7D). 
 
Both the soft agar and Transwell migration assays demonstrate that the 
D1246N cells are resistant to the Met inhibitors in terms of their biological 


































Figure 6: Treatment with Met inhibitors reduces cell migration of M1268T, 
but not of D1246N, cells  ABC) Transwell migration assays monitoring Wt, D1246N and M1268T cells 
migration towards a chemoattractant (complete media). A) Without or with 
HGF (50ng/ml). After 2 hours the number of cells migrated through Transwell 
pores were counted. B) Cells were treated with DMSO, PF-2341066 (0.2μM) 
or PHA-665752 (0.1μM). C) Cells were transfected with Control or Met RNAi 










































































































































































































































Figure 7: Treatment with Met inhibitors prevents anchorage 
independent growth of M1268T but not D1246N cells
A-D) Wt, D1246N and M1268T cells were cultured in soft agar. Experiments
were performed in triplicate. A) The graph shows the number of colonies 
compared to Wt cells. B) From day 5, DMSO or PF-2341066 (0.2μM) was 
added daily to the medium. Pictures taken at day 9. C) The graph shows the 
percentage decrease in the average number of colonies ± SEM following 
treatment with PHA-665752 (0.1μM) (n=1), SU-11274 (2μM) (n=2 for M1268T, 
n=3 for D1246N) or PF-2341066 (0.2μM) (n=3) compared to DMSO control. 
Each condition is in duplicate. D) The graph shows the percentage decrease 
in the number of colonies following transfection with Control or Met RNAi 
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In vivo, Wt, D1246N and M1268T mutant cells form tumours in nude mice 
when grafted subcutaneously. The M1268T and D1246N mutant cells form 
tumours very quickly and are palpable within 3 days, while the Wt cells are 
slower to form tumours (data not shown). Once tumours reached 50mm3, I 
applied either DMSO or PF in DMSO topically to the skin over the surface of 
each tumour. The M1268T grafted cells underwent a significant decrease in 
tumour growth while the D1246N cells did not respond to the treatment 
(Figure 8). Due to the fact that PF is orally available, Carine Joffre also 
treated mice with subcutaneous Wt, D1246N, M1268T tumours by oral 
gavage and a similar decrease in tumour growth was observed in M1268T 
tumours, while there was no effect on Wt or D1246N tumours (data not 
shown). This confirms that the in vitro results we have obtained where the 
M1268T cells are sensitive and the D1246N cells are resistant to Met 


































Figure 8: Treatment with Met inhibitors reduces tumourigenesis in vivo 
of M1268T, but not of D1246N, cells
The D1246N and M1268T cells were injected subcutaneously into nude mice 
(minimum of 5 mice per group). The graphs show the tumour growth curves 
of the different cell lines over time (mean tumour volume ± SEM). Tumours 
were measured daily and treated by topical application of either DMSO or 
PF-2341066 (0.2μM) daily over the surface of the tumour, once tumours 





2) Endocytosis inhibition reduces oncogenicity of Met 
mutants D1246N and M1268T in vitro and in vivo. 
 
As previously mentioned, the D1246N and M1268T Met mutants have 
increased levels of endocytosis. The resulting increased accumulation of 
these constitutively active Met mutants on endosomes leads to persistent 
endosomal signalling and cell transformation. I present here the experiments 
I performed during the study published (Joffre, Barrow et al, Nat Cell Biol 
2011), unless otherwise specified, which aimed at understanding the 
mechanism of increased endocytosis of these mutants. The purpose of this 
was that through inhibiting endocytosis, we were hoping to reduce the 
accumulation of mutant Met on endosomes and, consequently, reduce cell 
transformation in vitro and in vivo tumourigenesis.  
 
a) M1268T Met internalisation is not dependent on Met phosphorylation 
One obvious possible reason for the increased endocytosis of the Met 
mutants is due to their increased level of phosphorylation. Usually an RTK 
becomes phosphorylated upon ligand binding and this is then followed by 
receptor internalisation. Together with Carine Joffre we performed a 
biotinylation internalisation assay to follow Met internalisation from the 
plasma membrane over 15 minutes in the absence or presence of the Met 
inhibitor PHA-665752. We observed that the M1268T mutant is constitutively 
internalised without the need for ligand binding (Figure 9). Surprisingly, 
however, a decrease in the activation status of the M1268T mutant, through 
treatment with PHA-665752, did not affect the levels of Met endocytosis 
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(Figure 9). This demonstrates that the increased endocytosis is not a 
consequence of the increased phosphorylation of the M1268T mutant. 
 
b) Met internalisation is clathrin, Grb2 and c-Cbl dependent 
We then tried to determine some of the mechanisms involved in the 
increased endocytosis of the Met mutants. As clathrin dependent 
endocytosis has been shown to be a major route of Met internalisation, I 
investigated this pathway. I performed knockdown of clathrin heavy chain 
(CHC) by siRNA and Dr. Carine Joffre developed cells with a stable 
knockdown using shRNA. I have performed Western blots to check the levels 
of CHC in cells knocked-down by si- or shRNAs and observed that a good 
knockdown of CHC was achieved in both cases (Figure 10A). 
 
Subsequently the ability of clathrin knockdown to prevent Met internalisation 
was investigated. I should mention here that both siCHC and chCHC were 
shown to prevent both constitutive and HGF-bound Met internalisation very 
effectively and here I present only the data that I personally obtained. Initially, 
I confirmed that the knockdown of CHC prevented the internalisation of 
M1268T Met through performing a biotinylation internalisation assay over 15 
minutes of incubation at 37ºC. The quantification of this biochemical assay 
showed Met endocytosis was reduced by 98% upon CHC knockdown by 
siRNA over control siRNA (Figure 10B). This inhibition of Met internalisation 
following clathrin knockdown was also observed by immunofluorescence, 
when cells were stimulated with HGF* 157 (Figure 10C). After 15 minutes, 
HGF* was observed in the cytoplasm of cells transduced with control shRNA, 
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while the majority of HGF-alexa555 remained at or near the plasma 
membrane in cells transduced with CHC shRNA, confirming that clathrin 
knockdown prevents Met internalisation (Figure 10C). Importantly, I 
observed by Western blot that clathrin knockdown did not affect Met 
phosphorylation, indicating that the Met mutants’ activation is not dependent 
on their internalisation, or Met expression levels (Figure 10D). 
 
c-Cbl is an E3 ubiquitin ligase and adaptor protein which plays a role in RTK 
and, in particular, Met internalisation65. Grb2 is an adaptor protein that binds 
directly to Met and has been shown to be involved in regulating clathrin 
dependent endocytosis of receptor tyrosine kinase receptors through acting 
as a scaffold for c-Cbl binding 65. Furthermore, it has been proposed that 
both the D1246N and M1268T mutants are associated with Grb2286, 287. We 
therefore hypothesised that c-Cbl and Grb2 are involved in the increased 
endocytosis of the Met mutants.  
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P-Met (Y1234/35)
Figure 9: M1268T Met undergoes constitutive internalisation 
independent of its phosphorylation status. 
Biotin internalisation assay. Cells expressing M1268T Met mutant were 
pretreated (+),or not (-), with PHA-665752 for 30 minutes, surface 
biotinylatedand then incubated at 37°C for 15 minutes with or without 
PHA-665752. The biotin was then cleaved, and the remaining biotinylated 
Met was analysed by Western blotting with anti-Met or anti-phospho-Met 
(Y1349) antibodies.TS = total surface Met. Int = internalised Met. The graph 
shows the percentage of Met internalisation following treatment with DMSO 
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Figure 10: Clathrin knockdown inhibits Met mutant internalisation 
without affecting the activation status of Met  
 
(A-D) M1268T cells were knocked down for clathrin heavy chain (CHC) or 
non-silencing control by siRNA transfection or shRNA transduction as 
indicated. A) Western blots for CHC and the loading control tubulin. 
B) Biotinylation internalisation assay. Cells were surface biotinylated and 
then incubated for 15 minutes to allow internalisation of surface proteins. The 
biotin was then cleaved from the surface. The remaining biotinylated proteins 
were pulled down using Strepdavidin beads and analysed by Western blot for 
Met expression. The graph shows the quantification of Met internalisation by 
densitometry normalised to the siControl. Data are mean (arbitrary units) ± 
SEM. C) Confocal sections of cells transduced with control or CHC shRNA. 
The cells were stimulated with HGFAlexa555 (red), fixed and stained for 
DAPI (blue). Scale bars: 10μm. D) Western blots for CHC, phospho-Met, 


































I achieved a good knockdown of both c-Cbl and Grb2 by siRNA using a 
nucleofactor transfection method (Figure 11AB). Furthermore, as observed 
with CHC knockdown, Grb2 or c-Cbl knockdown did not affect Met 
phosphorylation or Met expression levels (Figure 11AB).  Together with Dr. 
Carine Joffre we showed, however, that the endocytosis of the M1268T 
mutant was greatly reduced, using biotinylation internalisation assays 
(Figure 11C). In order to verify the specificity of these mechanisms of 
internalisation as regards to Met, Transferrin-546 uptake (the ligand of the 
constitutively recycling non-RTK Transferrin receptor) was monitored as a 
control. Both Dynamin inhibition (using Dynasore) and CHC knockdown 
inhibited Transferrin-546 internalisation, however upon c-Cbl or Grb2 
knockdown Transferrin-546 uptake could still be observed (Figure 11D), 
consistent with the fact that c-Cbl and Grb2 are required for RTK 
internalisation only. Furthermore, I did not detect EGFR expression in these 
cells, removing the possibility of any effect of inhibition of EGFR 
internalisation, which also can be regulated by Grb2 and c-Cbl288 (Figure 
11E).  
 
Finally, in order to be more specific, we sought to impair Grb2 binding to the 
Met mutant. To do this, the M1268T Met mutant was additionally mutated on 
N1358H, in the +2 position of Y1356 in the Met docking site, in order to 
abolish the Grb2 consensus sequence without obstructing other molecules 
binding to Met289. For this, a human Met Wt cDNA (hWt) was mutated on 
M1268T (hM1268T) or on both M1268T and N1358H (hM1268T/N1358H), by 
Dr. Veronique Calleja; these constructs were subsequently sequenced by Dr. 
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Ludovic Menard. I then transfected these respective constructs into NIH3T3 
cells and made stable cell lines using G418 (800µg/ml) for selection. Western 
blots of the lysates from the stable cell lines demonstrated that the hM1268T 
mutation triggered an enhanced Met phosphorylation (Figure 12A). 
Furthermore, together with Dr Ludovic Menard, we observed a significantly 
increased colocalisation of hM1268T with EEA1 (Figure 12B), and thus 
internalisation, versus hWt; confirming results obtained with murine Met 
forms. Moreover, while Met phosphorylation was maintained in the double 
mutant (Figure 12A), its colocalisation with EEA1 was significantly reduced 
as compared to the single mutant (p<0.05) and was similar to Wt Met (Figure 
12B), demonstrating its reduced endocytosis.  
 
Thus, these results show that clathrin, c-Cbl or Grb2 expression, as well as 
the Grb2 consensus sequence on Met mutants, are required for the 
endocytosis of the Met mutants, such that their knockdown (or mutation in 
the case of the Grb2 consensus sequence) provide appropriate methods to 
block Met internalisation. 
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Figure 11: Met mutant internalisation is inhibited more specifically by 
Grb2 or c-Cbl knockdown
AB) M1268T Met expressing cells were transfected with control, c-Cbl or 
Grb2 RNAis. Western blots for A) c-Cbl, B) Grb2, phospho-Met (Y1234/35), 
Met and HSC70 or tubulin are shown. C) Biotin internalisation assay on 
M1268T Met mutant expressing cells following transfection with control and 
c-Cbl or Grb2 RNAis. D) Representative confocal sections of M1268T 
expressing cells transfected with RNAi control (Cont), treated with Dynasore 
or transfected with CHC, c-Cbl or Grb2 RNAi. Cells were incubated with 
transferrin-546, fixed and stained for DAPI (blue). Arrows indicate transferrin 
retained at the plasma membrane. Scale bars: 10μm. E) Western blots for 
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Figure 12:  A mutation in the Grb2 binding site of hM1268T (hM1268T/
N1358H) decreases the accumulation of Met on endosomes 
A) Met and tubulin Western blots from cells expressing human Met forms, 
hWt, hM1268T and hM1268T/N1358H, stimulated (+) or not (-) with HGF or 
PHA-665752. Numbers below are the densitometric values for phospho-Met/
Met. B) Confocal sections of cells expressing human Met constructs, hWt, 
hM1268T and hM1268T/N1358H, pre-treated with cycloheximide for 4 hours 
and stained for Met (green), EEA1 (Early Endosome Antigen 1, red) and 
DAPI (blue). Scale bars: 10μm. The graph (below) represents the percentage 
of colocalisation. Data are mean (arbitrary units) ± SEM (n=3). *p<0.05.
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c) Inhibition of Met endocytosis reduces in vitro and in vivo 
tumourigenicity of the oncogenic Met mutants. 
 
Having found ways to inhibit the endocytosis of the Met mutants, we 
investigated whether the endosomal localisation of active Met mutants was 
required for their in vitro and in vivo tumourigenicity. 
 
First, I looked at the effect of endocytosis inhibition on the organisation of the 
Met mutants’ actin cytoskeleton. Reducing Met mutant accumulation on 
endosomes using c-Cbl or Grb2 knock-down led to a significant restoration of 
actin stress fibres to a similar degree as Met knockdown in both the D1246N 
and M1268T cells (p<0.05), while there was no effect on Wt cells (Figure 
13AB).  
This suggested that there would consequently also be a reduction in the 
migration of Met mutant cells. Indeed, in Transwell migration assays, c-Cbl or 
Grb2 knockdown greatly reduced the high level of cell migration observed in 
both mutant expressing cells, again to a level similar to that observed with 
Met knockdown (Figure 13C), while there was no effect on Wt cell migration. 
The M1268T mutant expressing cells transduced with shCHC also had a 
great reduction in cell migration. Furthermore, cells expressing Met 
hM1268T/N1358H were significantly less migratory as compared to the 


















































































































































































































Figure 13: Inhibition of Met mutant internalisation reduces cell migration
A) Confocal sections of M1268T Met expressing cells transfected with control, 
c-Cbl or Grb2 RNAi, then stained with Cy3-phalloidin (red) and DAPI (blue). 
Scale bars: 10μm. B) Percentage of Wt, D1246N or M1268T Met expressing 
cells lacking stress fibres when transfected with Met (n=3), Grb2 (n=3) or 
c-Cbl (n=3) RNAi. Data are normalised to cells transfected with control RNAi. 
Data are mean (arbitrary units) ± SEM. C) Percentage of Wt, D1246N or 
M1268T Met expressing cells that have migrated through Transwells when 
transfected with Met (n=3), c-Cbl (n=3) or Grb2 RNAi (M1268T: n=3, D1246N: 
n=1), or transduced with CHC shRNA (n=2). The last column represents the 
percentage of migration of cells expressing hM1268T/N1358H human Met 
(n=3). Data are normalised to appropriate controls (DMSO, RNAi control, 
shRNA control, and cells expressing hM1268T Met respectively). Data are 
mean (arbitrary units) ± SEM, each experiment was performed in triplicate. 
*p<0.05.
Wt                 D1246N          M1268T
Wt            D1246N              M1268T
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Carine Joffre previously showed that the loss of actin stress fibres observed 
in the Met mutants was a consequence of Rac1 activity, as knockdown of 
Rac1 (Appendix Figure 3A) or treatment with the Rac1 inhibitor NSC23766 
(data not shown)159, restored the stress fibres and also consequently 
reduced M1268T cell migration. She also showed that Rac1 was highly 
activated in the D1246N and M1268T mutant Met containing cells, through 
doing a GST pull down assay (Appendix Figure 3B), and furthermore Rac1 
activation could be decreased by treating M1268T cells with PHA-665752 
(100nM) (Appendix Figure 3C). This effect of PHA-665752 could also be 
observed as a decrease of Rac1 staining at the plasma membrane159. Rac1 
has been shown to be activated on endosomes from where active Rac1 
relocates to the plasma membrane to carry out its role in actin remodelling158. 
Interestingly, Dr. Ludovic Menard observed Rac1-GTP colocalisation with 
M1268T Met on endosomes. 
All together these results strongly indicated that Met mutants activate Rac1 
from endosomal compartments, leading to the loss in stress fibres and 
enhanced cell motility.  
Thus we went on to investigate this pathway, using the presence of strong 
Rac1 staining (by immunofluorescence) at the plasma membrane as a read 
out of Rac1 activity, as shown by the fact that treatment with PHA-665752 
reduces plasma membrane staining of Rac1. In Met mutant expressing cells, 
there was an increased percentage of cells with Rac1 present at membrane 
protrusions in D1246N and M1268T cells (64 and 66% respectively) 
compared to Wt cells (40%, p< 0.05) (Figure 14AB). Blocking Met 
internalisation using c-Cbl or Grb2 knock down led to a significant reduction 
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in the percentage of both D1246N and M1268T mutant expressing cells that 
had Rac1 present at membrane protrusions (p<0.05), to the same level as 
Met knock down. Furthermore, the reduction observed resulted in the 
percentage of cells with Rac1 at membrane protrusions reaching the same 
level as Wt expressing cells, in which no effect of Met, c-Cbl or Grb2 
knockdown was detected. 
 
The hM1268T Met mutant expressing cells were found to behave in the 
same way as the mouse M1268T Met expressing cells. Cells expressing 
hM268T Met had a significantly higher percentage of cells with Rac1 at 
membrane protrusions compared to the hWt cells, as quantified by Dr. 
Ludovic Menard (Figure 14C). This observed increase in Rac1 at membrane 
protrusions in hM1268T cells was significantly reduced by treatment with 
PHA-665752 (p<0.01), confirming that this phenotype is dependent on the 
Met mutation. Moreover, hM1268T/N1358H Met expressing cells had a 
significantly reduced percentage of cells with Rac1 localisation at membrane 
protrusions, to a similar level as that observed in hWt cells (p<0.01) (Figure 
14C), confirming that Met mutant endocytosis is required for the full 
activation of the Rac1 pathway. 
 
These results indicate that the Rac1 activation, induced by the accumulation 
of the active Met mutants on endosomes, and consequent loss of actin stress 
fibres, can be greatly reduced by blocking Met endocytosis, using a panel of 
endocytic blocking tools. 
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Figure 14: Inhibition of mutant Met internalisation reduces Rac1 
localisation at membrane protrusions
A) Confocal sections of M1268T Met expressing cells transfected with control, 
Met, c-Cbl or Grb2 RNAi, fixed and stained for Rac1 (green) and DAPI (blue). 
B) The graph represents the percentage of Wt, D1246N or M1268T cells with 
marked Rac1 staining present at membrane protrusions when transfected 
with control RNAi, Met RNAi, c-Cbl RNAi or Grb2 RNAi. Data are mean ± 
SEM (n=3). C) Percentage of cells expressing human Met forms, hWt, 
hM1268T and hM1268T / N1358H, that display Rac1 at membrane 
protrusions. hM1268T were untreated or treated with PHA for 90 minutes. 
Data are mean ± SEM (n=3). *p<0.05; **p<0.01; NS=not significant.
Wt           D1246N       M1268T
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Using the same endocytic blockers, I then carried out soft agar assays to 
assess the ability of the cells to undergo anchorage independent growth 
following inhibition of Met internalisation. After transfection with c-Cbl or Grb2 
RNAi, the cells were grown in soft agar for 6 days. The use of these methods 
to block Met endocytosis led to huge reduction in total area of soft agar 
colonies of both D1246N (p<0.05) and M1268T (p<0.01) Met mutant 
expressing cells to a similar level as measured in Wt cells (Figure 15A). 
Importantly, no effect was observed on Wt cells (Figure 15A). The number of 
colonies was also significantly reduced (Figure 15B). Furthermore, 
hM1268T/N1358H Met expressing cells had a significant reduction (60%) in 
colony number compared to hM1268T cells (Figure 15B). 
These results indicate that blocking endocytosis can reduce the 
transformation of Met mutant expressing cells and may consequently reduce 
tumour growth in vivo. 
 
I then went on to block Met endocytosis, using these newly acquired 
methods, and investigate whether the endosomal accumulation of the Met 
mutants is required for tumour growth. To achieve this, the M1268T cells 
transduced with shControl and shCHC were injected subcutaneously (by 
Professor Ian Hart) into nude mice and I measured the tumour sizes daily. 
Interestingly, the tumours formed by the clathrin-depleted (shCHC) cells had 
a significant (50%) reduction in size (p<0.05) compared to the shControl 
tumours (Figure 16A). Surprisingly, but consistent with in vitro results 
(Figure 10D), the tumours derived from the shCHC cells had no decrease in 
Met phosphorylation as compared to shControl tumours (Figure 16B). This 
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suggests very strongly that the decrease in tumour growth was due purely to 
the change in Met mutant localisation rather than due to any effect on the 
activation status of Met. 
 
In order to confirm the results obtained by clathrin knockdown, I treated Wt 
and M1268T expressing tumours with dynole 34-2, a novel, highly-specific, 
inhibitor of dynamin, which inhibits both clathrin-dependent and clathrin-
independent mechanisms of internalisation290. Wt and M1268T mutant cells 
were allowed to form tumours in athymic nude mice (Injected by Professor 
Ian Hart). I measured the tumour sizes daily and once tumours reached 
50mm3, I topically applied on the tumours either DMSO or dynole 34-2. 
Treatment with dynole 34-2 led to a significant decrease in tumour growth, 
the tumour sizes being 450mm3 in the control and 320mm3 in the treated 
tumours respectively at day 7 of treatment (p<0.01) (Figure 16C).  
In a similar experiment, tumours formed from M1268T mutant cells were 
treated topically with Dynasore (80µM) leading to a large, significant 

































































Figure 15: Inhibition of mutant Met internalisation inhibits anchorage 
independent growth 
AB) Cells were cultured in soft agar. Each experiment was done in triplicate. 
A) Wt, D1246N and M1268T cells were transfected with control, Met, c-Cbl or 
Grb2 RNAis. The graph represents the average colony area. Data are mean 
(arbitrary units) ± SEM (n=3). B) The graph represents the percentage of 
reduction in colony number formed by cells expressing M1268T Met when 
treated with Dynasore or transfected with Met, c-Cbl or Grb2 RNAi versus 
their appropriate controls (DMSO, RNAi cont) (n=3). The last column shows 
the colony number of cells expressing hM1268T/N1358H Met versus cells 
expressing hM1268T Met (n=3). Data are mean (arbitrary units) ± SEM. 
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Figure 16: Inhibition of mutant Met internalisation decreases tumour 
growth in vivo
A-D) Cells (5x10 ) were injected subcutaneously into the right flank of nude 
mice (minimum 5 mice per group). When tumours had reached 30-50mm , 
DMSO or inhibitors were applied topically over the surface of each tumour 
daily. A) The graph represents tumour growth curves of M1268T cells 
transduced with control or CHC shRNA over indicated time. B) Western blots 
for phospho-Met (Y1234/35), total Met and tubulin were performed on 
tumour samples from 3 different mice per condition (from A). The numbers 
are the fold increases of phospho-Met/Met for shRNA CHC cells versus 
shRNA control cells. C) Wt and M1268T Met expressing tumours were 
treated with DMSO or dynole 34-2 (30 μM). The results are represented as 
box and whisker plots, representing the tumour volume after seven days of 
treatment. D) M1268T Met expressing tumours were treated with DMSO or 
Dynasore (80 μM) for five days. The graph represents tumor growth curves 
of the different treatments over the indicated time. Data are mean ± SEM. 
*p<0.05; **p<0.01.
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My results presented here (together with additional results obtained by 
Carine Joffre, not presented here159) confirm that it is the accumulation of the 
activate Met mutants on endosomes that is the cause of their high 
tumourigenicity. Indeed, through blocking their endocytosis by different 
means (clathrin, c-Cbl or Grb2 knock-down, hM1268T/N1358H mutation as 
well as the dynole 34-2 and Dynasore inhibitors), I was able to reduce Met 
mutant dependent cell migration, anchorage independent growth and in vivo 
tumourigenicity, without affecting their activation status. Therefore, it is the 
altered trafficking together with the constitutive activation of the Met mutants 
that leads to their increased tumourigenicity. 
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3) Restoration of Met degradation reduces oncogenicity of 
Met mutants D1246N and M1268T in vitro and in vivo. 
 
Previous results from our lab by Carine Joffre have demonstrated that Met is 
degraded in the WT cells over a period of 8 hours, while Met is not 
significantly degraded in the D1246N and M1268T cells with 86% still 
remaining after 8 hours159. I have managed to replicate these results, 
confirming that the Wt cells have normal Met degradation over 8 hours HGF, 
while the D1246N and M1268T cells have little Met degradation (Figure 
17A).  
My aim was to investigate the mechanisms regulating the stability of the 
mutants in view of restoring their degradation and consequently cell 
transformation. 
We tested several hypotheses. Firstly, the Met mutants could have a defect 
in phosphorylation of the Y1003 site, which is necessary for direct binding of 
c-Cbl, subsequent Met ubiquitination and degradation88, 89. Dr. Carine Joffre 
has investigated this and found that the mutants are in fact constitutively 
phosphorylated on this site, excluding this hypothesis (supporting data not 
shown). 
Secondly, the Met mutants may alternatively have a defect in their ability to 
be ubiquitinated. Dr. Carine Joffre and I performed ubiquitination assays and 
found that the M1268T mutant is, if anything, more ubiquitinated than its Wt 
counterpart (not shown). Finally, the chaperone protein HSP90, which has 
been shown to protect various oncogenic RTKs from degradation291, 
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including Met91, 134, 135, could be involved in preventing the degradation of Met 
mutants. I investigated this possibility.   
 
a) Both Met oncogenic mutants are sensitive to inhibition of HSP90, 
which restores the degradation of Met mutants. 
I first investigated the potential role of HSP90 in maintaining the stability of 
M1268T and D1246N mutants using a pharmacological inhibitor or RNAi 
knock down. I monitored Met degradation following time of HGF stimulation 
by Western blot. Treatment of the M1268T mutant with 100nM 17-AAG (17-
allylamino-17-demethoxygeldanamycin), a pharmacological inhibitor of 
HSP90, significantly restored the degradation of the M1268T mutant Met to 
that seen in WT Met, such that after 4 hours 63% Met had been degraded 
(p<0.01) (Figure 17AB). I confirmed this by depleting HSP90 expression 
from M1268T cells. Both HSP90α and HSP90β isoforms were knocked down 
simultaneously by siRNA using nucleofactor transfection, achieving a good 
knockdown (Figure 17D). 
In a similar way to the results obtained following treatment with 17-AAG, 
HSP90 knockdown restored Met degradation of the M1268T mutant to that of 
the WT (Figure 17AB).  
Importantly Met degradation was also restored in the D1246N mutant after 4 
hours of HGF stimulation following treatment with 100nM 17-AAG, an 
interesting result knowing that this mutant is resistant to the small molecule 
Met inhibitors (p<0.05) (Figure 17AB). Importantly, there was a significant 
decrease in basal Met expression of both of the oncogenic Met mutants 
following treatment with 17-AAG for 24 hours (p<0.01)  (Figure 17C), 
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showing that HSP90 inhibition can restore Met degradation of the Met 
mutants both upon HGF stimulation and in their ligand-independent activated 
state. 
 
b) Inhibition of HSP90 reduces D1246N and M1268T dependent 
anchorage independent growth, however the D1246N mutant requires a 
higher dose of the HSP90 inhibitor 17-AAG. 
I then asked whether the restoration of Met degradation would lead to a 
reduction in tumourigenicity of the Met mutants. A comparison of the ability of 
the Wt and M1268T to undergo anchorage independent growth, following 
either treatment with 17-AAG or transfection with HSP90 RNAi, showed that 
while HSP90 inhibition had very little effect on Wt cells, it significantly 
reduced the number and area of M1268T colonies by more than 46% 
(p<0.05), to a level similar to that observed in Wt cells (Figure 18AB).  
As the D1246N mutant is resistant to small molecule Met inhibitors it seemed 
particularly interesting to test HSP90 inhibition on these cells as a potential 
means for possible therapeutic intervention. However, in soft agar assays, 
the D1246N cells had only a 29% significant reduction in colony number 
(p=0.01) and a non-significant reduction in colony area following treatment 
with 100nM 17-AAG (Figure 18CD). Nevertheless, transfection with HSP90 
RNAi led to a greater decrease both in colony number and area of the 
D1246N cells (Figure 18CD). This led to the idea that perhaps 100nM 17-
AAG was not sufficient to efficiently reduce cell transformation triggered by 
the D1246N mutant and hence I tried higher doses of 150nM and 200nM. 
Treatment of D1246N cells with 200nM 17-AAG in soft agar assays led to a 
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small, but significant, 27% decrease in colony number (p<0.01) (data not 
shown) and a larger 50% decrease significant in colony area (p<0.05), which 
was a similar decrease observed following HSP90 knockdown, suggesting 
that 17-AAG is still specific to HSP90 at this concentration (Figure 19A). 
Furthermore, a larger degradation of D1246N Met was observed with the 
doses of 150 and 200nM versus 100nM 17-AAG, both upon HGF stimulation 
(Figure 19B) and under basal conditions (Figure 19C), both of which 
occurred in a dose dependent manner with 200nM being the most effective. 
Meanwhile, we also hypothesised that maybe the D1246N mutant is resistant 
to Met inhibitor due to a particular conformation, which could prevent binding 
of Met inhibitor to the ATP binding site and this conformation could be 
maintained by the activity of HSP90. Thus, I tested whether HSP90 inhibition 
would restore the sensitivity of the D1246N cells to small molecule Met 
inhibitors. However, a Western blot of D1246N cell lysates showed that Met 
phosphorylation was maintained in the D1246N cells in the presence of 
SU11274 together with 17-AAG for 1 hour. Nevertheless, when the treatment 
with 17-AAG was for 6 hours, an inhibition of Met phophorylation was 
observed. But this result was also obtained even in presence of 17-AAG 
alone (Figure 19D).  This suggests that the activation of the mutant could 
result from a specific conformation, maintained by the chaperone, though this 
possibility needs to be examined further in future experiments.  
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Figure 17: HSP90 Inhibition restores D1246N and M1268T Met 
degradation
A) Western blots for Met and tubulin on the indicated cells pretreated either 
with DMSO or 17-AAG (100nM) for 16 hours and treated with HGF (50ng/ml) 
for indicated times. B) Quantification of Western blots using the ImageJ 
software (M1268T DMSO/RNAi Control n=4; M1268T 17AAG n=3; M1268T 
HSP90 RNAi n=1; D1246N DMSO and 17AAG n=3). C) Quantification of Met 
levels at 0 minutes HGF following treatment with DMSO or 17AAG for 24 
hours. Data are mean (arbitrary units) ± SEM (n=3). D) Western blots for 
HSP90 ά, HSP90 β and tubulin in M1268T cell lysates 72 hours following 
transfection with control, HSP90 ά and HSP90 β RNAi. *p<0.05; **p<0.01; 






























































































































































































































Figure 18: HSP90 inhibition reduces anchorage independent growth of 
both D1246N and M1268T cells  
AB) Results of soft agar assays monitoring the anchorage independent 
growth of Wt and M1268T cells following treatment with 17AAG (100nM) or 
transfection with HSP90 RNAi compared to DMSO or Control RNAi controls 
and normalised to M1268T control. A) Number of colonies (n=3). B) Colony 
area (n=3). CD) Soft agar assays monitoring anchorage independent growth 
of  D1246N cells following treatment with 17AAG (100nM) or transfection with 
HSP90 RNAi compared to DMSO or Control RNAi controls. C) Number of 
colonies (n=3). D) Colony area (n=3). Data are mean (arbitrary units) ± SEM. 













Figure 19: Higher concentrations of 17-AAG restore D1246N 
degradation more efficiently but specificity is maintained. 
A) D1246N cells were cultured in soft agar. The graph shows the average 
area of colonies measured using ImageJ software. Data are mean (arbitrary 
units) ± SEM (100nM, 200nM n=3; 150nM and HSP90 RNAi n=2). 
B) Western blots for Met and tubulin in D1246N cells stimulated with HGF 
following treatment with 100, 150 or 200nM 17-AAG and the corresponding 
DMSO concentration. Bottom panel is the quantification of the western blots. 
Data are mean (arbitrary units) ± SEM (DMSO n=6; 17AAG 100nM n=4; 
17AAG 150nM and 200nM n=1). C) Quantification of the percentage 
decrease in basal Met expression in D1246N cells following 24 hours of 
treatment with indicated doses of 17AAG. Data are mean (arbitrary units) ± 
SEM (DMSO/17-AAG (100nM) n=3; 17-AAG (150, 200nM) n=1). D) Western 
blots of phospho-Met, Met and tubulin in D1246N  cells treated with DMSO, 
SU-11274 (2μM) for 1 hour, 17AAG (100nM) for 1 or 6 hours and SU-11274 





















































































































































c) Inhibition of HSP90 reduces M1268T cell migration and in vivo 
tumourigenesis. 
While I was establishing the most efficient, yet specific, dose of 17-AAG for 
the D1246N cells, I continued with the studies on the M1268T mutant. First I 
asked whether the restoration of M1268T Met mutant degradation would 
reduce the migratory potential of these cells.  
A restoration of stress fibres was observed in M1268T cells following 
treatment with 17-AAG (100nM) for 1 hour (Figure 20A). Subsequently, 
M1268T cells transfected with HSP90 RNAi had a significant decrease in 
migration in Transwell migration assays of 41% compared to Control RNAi 
(p<0.05), while there was no effect on cell migration in the Wt cells, 
confirming that the observed effect is Met mutation dependent (Figure 20B).  
 
Following these results, M1268T cells were injected sub-cutaneously into 
athymic nude mice (by Professor Ian Hart). Once the M1268T tumours 
reached 50mm3, I treated them topically with DMSO (control) or 17-AAG 
(100nM).  Treatment with 17-AAG led to a significant decrease in tumour size 
(p<0.05) (Figure 20C). In fact, the same reduction in tumour growth was 
obtained by blocking endocytosis with Dynasore in an experiment performed 
at the same time (Figure 20C). This demonstrates that either inhibition of 
Met internalisation or restoration of Met degradation, both of which reduce 
the accumulation of the oncogenic Met mutant on endosomes, can inhibit 
Met mutant tumourigenesis to the same degree. 
I am currently investigating mechanisms further using the M1268T mutant as 
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Figure 20: HSP90 inhibition reduces M1268T cell migration and in vivo 
tumourigenesis
A) Confocal sections of M1268T cells treated with DMSO or 17-AAG (0.1μM) 
for 1 hour and then stained  with Cy3-phalloidin (red) and DAPI (blue). Scale 
bars: 10μM. B) Transwell migration assay with Wt and M1268T cells 72 
hours following transfection with control or HSP90 RNAi. Data are mean 
(arbitrary units) ± SEM (n=3). C) Growth of tumours in vivo using M1268T 
cells. Cells were injected subcutaneously into nude mice. Tumours were 
measured daily and treated by topical application of either DMSO, 17-AAG 
(0.1μM) or Dynasore (80 μM) daily over the surface of the tumour, once they 
reached 30-50mm . Data are mean ± SEM.
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d) The HSP90 α isoform is increased in M1268T cells but is not 
specifically required for cell transformation 
 
Several studies have shown that HSP90 α is the HSP90 isoform that is 
associated with oncogenic proteins94, 98. As I had so far combined RNAis of 
HSP90 α and β, it seemed interesting to investigate whether a single isoform 
is required for maintaining mutated Met tumourigenicity. To test this I initially 
looked at the expression levels of both isoforms in the Wt and M1268T cells 
by Western blot. While there was no change in HSP90 β expression there 
was a small, but significant, increase in HSP90 α expression in the M1268T 
cells compared to Wt cells (Figure 21A). Furthermore, work carried out by 
Dr. Carine Joffre showed that M1268T Met associates with HSP90 α in Co-IP 
experiments (Appendix Figure 4).  
In order to determine the role of each HSP90 isoform in Met degradation and 
Met dependent tumourigenesis, I transfected cells with HSP90 RNAi against 
each isoform individually. Surprisingly, decreased expression of either 
isoforms (Figure 17D) appeared to restore M1268T Met degradation (Figure 
21B).  
Accordingly, M1268T cell migration was inhibited by decreased expression of 
either isoform or both together (Figure 21C). There was no change in Wt cell 
migration following HSP90 α knockdown, however decreased expression of 
both isoforms together led to a significant increase in cell migration of the Wt 
cells and this correlated with a small increase in cell migration following 
knock-down of HSP90 β in the Wt cells (Figure 21C). Thus perhaps 
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decreased expression of the HSP90 β isoform may have a greater adverse 
effect on normal non-oncogenic cells than the HSP90 α isoform.  
However, only decreased expression of both isoforms together decreased 
the number of M1268T colonies that grew in soft agar. There was no effect 
on the number of colonies or colony area (data not shown) when each 
isoform was knocked down individually (Figure 21D). This may have been 
due to the length of time (6 days) over which this experiment was performed. 
By the end-point the effect of knockdown of each isoform individually may 
have been lost, while the knockdown of both isoforms together may be more 
potent or synergistic such that the effect is maintained for longer. 
 
e) The HSP90 co-chaperone Hop does not appear to protect M1268T 
mutant Met from degradation 
I wanted to investigate which co-chaperone is involved in helping HSP90 
protect M1268T Met from degradation. Several co-chaperones have been 
associated with maintaining oncogenic proteins in a complex with HSP90. 
The co-chaperone Hop/Stip1 brings together HSP90 and HSP70, which 
brings the oncogenic client protein to HSP90104, 105. Hop seemed to be a 
promising target as a co-chaperone involved in the M1268T-HSP90 complex, 
both due to its increased expression in tumours292 and also due to the fact 
that its knockdown has previously been shown to decrease Wt Met 
expression293. 
 
I investigated the influence of Hop knockdown on M1268T Met degradation. I 
managed to achieve a good knock-down of Hop in M1268T cells using the 
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nucleofactor transfection method (Figure 22). However, when I looked at Met 
expression and degradation upon Hop knock-down I found conflicting results 
between the two experiments I was able to conduct in the time avaliable. 
Although in both experiments I saw no restoration of HGF-stimulated Met 
degradation following Hop knockdown, a large decrease in basal Met 
expression was detected in the first experiment, while a large increase was 
detected in the second experiment. The reasons for this are unclear, it may 
be due to environmental differences or differences in the percentage 
knockdown between the two experiments and, obviously, further experiments 
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Figure 21: The HSP90 ά isoform is increased in M1268T cells but is not 
specifically required for migration or anchorage independent growth
A) Western blot for HSP90 ά, HSP90 β and tubulin on Wt +/- HGF and 
M1268T +/- PHA-665752 (0.1μM) cell lysates. The graphs are quantification 
of HSP90 ά or β expression by densitometry (left: n=6, right: n=5). B) M1268T 
cells were transfected with Control, HSP90 ά or HSP90 β RNAi. Western 
blots for Met and tubulin from cell lysates treated with HGF (50ng/ml) for 0, 1 
and 4 hours, 72 hours following transfection. The graph shows the 
quantification by densitometry (n=1). CD) Transwell migration assay of Wt 
and M1268T cells 72 hours following transfection with Control (n=6), HSP90 
ά (n=3) or HSP90 β RNAi (n=3) or both HSP90 ά and HSP90 β RNAi (n=6). 
D) Soft agar assay of Wt and M1268T cells 72 hours following transfection 
with Control, HSP90 ά or HSP90 β RNAi or both HSP90 ά and HSP90 β 
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Figure 22: The HSP90 co-chaperone Hop does not appear to be involved 
in preventing M1268T Met degradation
Western blots for Met, Hop and tubulin in M1268T cells treated with HGF
(50ng/ml), 72 hours following transfection with Control or Hop RNAi. Two 
experiments are shown and the graphs on the right are the quantifications of 
the basal Met expression (no HGF) for each experiment measured using 
ImageJ software (arbitrary units). 
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Overall HSP90 inhibition seems to be a promising treatment option for Met 
driven cancers. Although the D1246N mutant requires a higher dose of the 
HSP90 inhibitor 17-AAG to achieve the same level of reduction in Met 
dependent transformation, I have showed that impairing HSP90 activity or 
expression re-establishes M1268T Met mutant degradation which reduces its 
impact on cell migration and in vivo tumourigenicity.  
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DISCUSSION PART II 
Understanding Met oncogenic Mutants’  signalling and 
targeting this in tumourigenesis. 
 
In this chapter, I have confirmed that two mutations located within the kinase 
domain of Met, lead to constitutive phosphorylation of the receptor, which 
induces cell transformation. I tested three small molecule Met inhibitors on 
these Met mutant expressing cells and found that while one Met mutant is 
sensitive to these forms of Met inhibition, another is resistant.  
Carine Joffre originally characterised the trafficking of these two naturally 
oncogenic Met mutants, in NIH3T3 cells. She previously described that they 
accumulate on endosomes due to constitutive internalisation via dynamin 
and clathrin dependent mechanisms, and constitutive recycling. Importantly, 
their location on endosomes is accompanied by their high activation status 
and she demonstrated that both are required for Rac1 activation, migration 
and for the in vivo tumourigenicity of the Met mutants.  
I have extended her work, to further understand the mechanisms of Met 
mutants’ endocytosis, and showed it also is dependent on c-Cbl and Grb2 
expression and on Grb2-Met binding. Blocking endocytosis through impairing 
these mechanisms reduces cell transformation in vitro and in vivo and 
importantly does not affect Met activation, confirming that Met localisation 
together with Met activation are both required for Met mutant dependent 
tumourigenicity (Figure 23). 
Furthermore, Carine showed that the mutants also have a defect in 
degradation. I found that this is due to the activity of the chaperone protein 
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HSP90. HSP90 inhibition and/or knock down can restore Met degradation 
and in doing so can reduce the transforming ability of Met mutant in vitro and 
in vivo (Figure 23).  
 
1) Met Oncogenic Mutants: Sensitivity to Met inhibitors 
Met mutants are constitutively active and are transforming 
I have confirmed that the M1268T and D1246N Met mutants are both more 
highly phosphorylated than the Wt Met, with the M1268T Met mutant more 
phosphorylated than Wt Met when stimulated with increasing doses of HGF. 
The NIH3T3 murine fibroblasts used were chosen as they produce very low 
levels of HGF203, suggesting that there is no autocrine loop. This does indeed 
appear to be the case as there is very little Wt Met phosphorylation, but this 
can be induced upon HGF treatment. This therefore, indicates that the Met 
mutant M1268T and D1246N expressing cells are intrinsically and 
constitutively active. This previously was established by Jeffers et al. where 
the extracellular domain of Met was replaced by the extracellular domain of 
the Nerve Growth Factor (NGF) receptor (Trk)285. Since NIH3T3 cells do not 
secrete NGF, the observed phosphorylation and tumourigenicity of the Met 
mutants was shown to be a result of their constitutive activation rather than 




Figure 23: Model of Met oncogenic mutant signalling mechanisms 
The D1246N and M1268T Met mutants have a defect in degradation and 
undergo constitutive internalisation and recycling, leading to transforming 
signals from endosomes. Met tyrosine kinase inhibitors (TKI) effectively block 
M1268T Met phosphorylation reducing cell transformation. Inhibition of 
D1246N and M1268T Met internalisation (using clathrin, c-Cbl, Grb2 RNAi or 
Dynasore) or restoration of Met degradation (with HSP90 inhibitors or HSP90 




As a result of their constitutive activity, I have also observed that these 
mutants are transforming without the need for ligand binding. They have a 
transformed morphology, are more migratory, more readily grow in soft agar 
and form tumours in nude mice more rapidly than cells expressing Wt Met.  
 
Individual Met mutants have different sensitivity to Met inhibitors 
Some mutations in EGFR, such as exon 19 deletions and the L858R point 
mutation, confer an increased sensitivity to TKIs, while others, including 
insertion mutations into exon 20 or the T790M mutation, confer resistance to 
tyrosine kinase inhibitors (TKI) 195. However, very little is known regarding the 
sensitivity of Met mutants to TKIs.  
 
In my study, three ATP-competitive small molecule inhibitors of Met, PHA-
665752 (PHA), SU11274 (SU) and PF-2341066 (PF), were tested on the 
D1246N and M1268T mutants. The M1268T mutant was highly sensitive to 
all three inhibitors. This mutant previously has been shown to be sensitive to 
PF by ELISA assay but no studies on the cell functions and in vivo 
tumourigenesis were done 225.  
We have shown that treatment with each inhibitor led to inhibition of M1268T 
Met mutants’ phosphorylation, which consequently reduced cell migration 
and anchorage independent growth in vitro, to the same level as Wt Met, as 
well as a reduction in tumourigenicity in vivo. Furthermore, the reduction in 
cell migration and anchorage independent growth observed with the three 
inhibitors was similar to that following Met knockdown using Met RNAi, which 
had no effect on the Wt Met expressing cells. This confirms that, firstly, the 
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inhibitors induce near complete inhibition of M1268T Met mutant dependent 
tumourigenesis and, secondly, there is not a significant autocrine loop 
occurring in these cells. 
 
The D1246N mutant was, however, resistant to all three inhibitors both in 
vitro and in vivo, although at very high doses of PF-2341066, the D1246N 
mutant exhibited decreased phosphorylation. However, at high doses of PF-
2341066, such as 1µM, the drug no longer specifically targets Met, but also 
inhibits Tie-2, TrkA, TrkB and Insulin receptor activation225. In fact, when 
compared to the M1268T mutant, the D1246N is 100 times less sensitive to 
PF-2341066 (Figure 3a). Despite the resistance of the D1246N mutant to the 
various small molecule Met inhibitors, the transforming capability of this 
mutant was definitely due to the constitutive activation of Met as depletion of 
Met expression with Met RNAi reduced the stress fibre formation, cell 
migration and the anchorage independent growth of the D1246N Met 
expressing cells.  
 
The D1246N and M1268T mutations are located in different regions of the 
kinase domain, suggesting that this could be the reason for their different 
sensitivities to TKIs, especially since each of the inhibitors act by binding to 
Met in a similar way. The M1268T mutation is found in the P+1 loop and 
destabilises the inhibitory position of the activation loop leading to an active 
conformation, while the D1246N mutation is located in the activation loop and 
leads to stabilisation of the active conformation294. These structural 
differences could affect the binding ability of the TKIs. Intriguingly, the 
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D816Y/V mutation found in the Kit receptor is analogous to D1246N and 
causes Kit to be resistant to imatinib, but this mutation is sensitive to an 
alternative and broader TKI, PKC412295. In a study by Timofeevski et al., 
comparing the small molecule inhibitors PF-02341066 and PF-0421709 on a 
range of oncogenic Met mutations (not including the M1268T and D1246N 
mutations), it was found that while PF-0421709 was more specific for the Met 
kinase than PF-02341066 (although they both exhibited high specificity), PF-
02341066 could act on a wider range of Met mutations due to a difference in 
conformation that altered the affinity for inhibitor binding226. However, I have 
shown that the D1246N Met is resistant even to PF-02341066,. But perhaps 
a broad spectrum TKI against a range of RTKs maybe be effective on the 
D1246N mutant. 
 
The Met inhibitors tested in this study were all ATP competitive small 
molecule inhibitors and therefore are likely to bind to Met in the same 
manner.  In fact, Amgen has recently produced the orally available AM7, 
which binds to a different area of the kinase domain than SU11274 and 
which has been shown to be effective against the Met mutations that are 
resistant to SU1124 (not including the D1246N)296. So, inhibitors with a 
different mode of binding may be effective against resistant RTKs. With more 
time it would certainly have been interesting to test other types of Met 
inhibitors on these two Met mutations. It is worth noting, however, that some 
inhibitors preferentially bind non-active or active forms of the receptor. For 
example, the non-ATP competitive small molecule inhibitor ARQ197, 
preferentially binds to the non-active form of Met212. This information is 
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valuable knowledge for a patients’ treatment strategy as, if the driving 
oncogene is a constitutively active receptor such as M1268T Met, it is 
possible that the inhibitor will not efficiently inhibit Met activation.  
 
2) Met Oncogenic Mutants: A role for endocytosis in their oncogenicity 
As I have already mentioned, the trafficking of these two Met mutants has 
previously been characterised by Dr. Carine Joffre, showing that they 
accumulate on endosomes through constitutive endocytosis and recycling. 
 
Met mutants constitutively internalise independently of Met 
phosphorylation 
Perhaps surprisingly, we have shown that the M1268T Met continues to 
undergo the same rate of constitutive internalisation when its activation is 
inhibited in the presence of PHA-665752. It is normally believed that RTKs 
are activated by their ligand and as a consequence undergo endocytosis. 
However here I have demonstrated that for the M1268T Met they are two 
separate events. This has been previously demonstrated for EGFR, where a 
kinase-dead EGFR (K721A) can internalise and in fact it has been reported 
that it may actually be receptor dimerisation not activation that induces 
internalisation297, 298. Thus, inhibition of phosphorylation using PHA-665752 
may not affect receptor dimerisation. However, to be certain that there is not 
a small amount of Met phosphorylation remaining following treatment with 
PHA-665752, another mutation in the kinase domain to establish a kinase 
dead M1268T Met mutant would be required. Nevertheless, we can conclude 
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that the increased internalisation of the mutants is not a consequence of their 
increased activation. 
 
Met mutants internalise via clathrin, Grb2 and c-Cbl dependent 
mechanisms. 
Firstly, I have confirmed that the internalisation of the M1268T Met occurs 
through clathrin dependent mechanisms, as previously shown for Wt Met 
stimulated with HGF82, 157. Secondly, Carine Joffre additionally found that the 
mechanism for the increased internalisation of the Met mutants was through 
a constitutive association with Grb2, which has previously been suggested to 
occur with the M1268T mutant286, 287. 
 
Thus, we have shown that the internalisation of the M1268T mutant is 
dependent on Grb2 binding, which may then bring c-Cbl to Met. In this 
scenario, c-Cbl will ubiquitinate Met and induce its subsequent 
internalisation, as has been shown previously to occur with Wt Met 
stimulated with HGF65 and indeed we have shown that M1268T Met also 
requires c-Cbl for internalisation.  
 
Blocking Met endocytosis specifically is a challenge, as it is not really known 
where there is a consensus sequence that controls Met internalisation. 
However, c-Cbl and Grb2 knockdown appeared at least to be specific for 
RTK internalisation and as Met was most probably the major oncogenic 
trafficking RTK in these cells (EGFR expression was not detected by 
Western blot), it seemed to be a good approach. More importantly, as we 
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have proved that the transformation of the Met mutant cells results from Met 
activity (as inhibited with Met knock down or inhibitor, with no change in the 
Wt untransformed cells), our functional studies on Met mutant expressing 
cells using the endocytic blockers were always compared to Wt Met 
expressing cells. 
 
However to increase specificity, and as we knew that Grb2 was required for 
M1268T Met internalisation, an additional Met mutant was created; 
hM1268T/N1358H, which was unable to bind to Grb2 as previously reported 
by Ponzetto et al.289. We were able to show that, in parallel to its reduced 
internalisation compared to hM1268T, although still highly phosphorylated, it 
also was less oncogenic, confirming the mutation M1268T triggers Met 
internalisation in addition to its activation and that mutant M1268T 
internalisation, together with its activation, drive its oncogenicity. The 
additional benefit of these human constructs, as opposed to the murine 
constructs expressed in the cell lines mostly used in our studies159, 203 is that 
they contain the human Wt Met both alone and with the mutations; M1268T 
and M1268T/N1358H. This provides us with the opportunity to study the 
M1268T mutation in a more physiological model for human cancer, for 
example by transfecting them into human cancer cells. The development of 
such cell lines currently is ongoing in our lab. Furthermore, in vivo studies 
using the human Met, either in mouse cells or human epithelial cells with low 
endogenous Met expression, will be free from HGF stimulation as murine 
HGF is unable to activate human Met206, 299. Therefore, grafting these cells 
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into nude mice would allow us to more clearly assess the intrinsic properties 
of these mutations. 
 
A study by Cho et al. was published at the end of my PhD suggesting a 
possible dileucine motif in the C-terminus of Met (amino acids 1378 to 1393) 
that is involved in its endocytosis through binding to adaptin β1/2 and 
caveolin300. They developed a specific peptide that competed with Met for the 
binding to the endocytic machinery300. However, we have shown that 
M1268T Met, as well as Wt Met stimulated with HGF62, 159, appears to 
internalise via different mechanisms i.e. using dynamin, clathrin, Grb2 and c-
Cbl. Furthermore, in this paper, it was not clearly demonstrated that Met 
internalisation was blocked and thus moreover was perhaps not specific to 
Met as it was compared to Glut4 and Transferrin receptors but to other 
RTKs. Therefore, although it forms an interesting idea that a peptide may be 
developed as a potential treatment, further work is required to investigate 
whether it could reduce the oncogenicty of Met mutants specifically. 
 
Endosomal signalling is required for Met mutant expressing cells’ 
migration and tumourigenesis 
Using our various methods to block Met mutants’ endocytosis, we observed 
that the internalisation of Met mutants is required for the transforming 
capacity in vitro and in vivo. Here I have shown that Met mutants M1268T 
and D1246N internalisation through Grb2 and c-Cbl dependent mechanisms 
is required for their stimulation of cell migration. As already discussed in 
Chapter 1, there are relatively few studies that demonstrate a role for 
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endosomal signalling in cell migration. Palamedessi et al. however recently 
demonstrated that Rac is activated by its GEF Tiam1 on endosomes upon 
HGF stimulation or Rab5 expression158. This is of particular interest to us, as 
the migration of cells expressing M1268T Met is dependent on Rac1 
activation and a requirement for the localisation of M1268T Met on 
endosomes. Thus perhaps in our model M1268T Met activates Rac on 
endosomes through the recruitment of Tiam1 and this would certainly be 
interesting to investigate.  
 
Importantly, I showed that blocking endocytosis, through either abolition of 
clathrin, Grb2 or c-Cbl expression, has no effect on Met mutants M1268T 
and D1246N activation in vitro but does reduce their ability to undergo 
anchorage independent growth. Furthermore, abolition of clathrin expression 
in vivo has no effect on Met M1268T activation but does bring about a 
significant size reduction of M1268T tumours (Figures 16). Together with the 
fact that Met mutants’ oncogenicity can be reduced to a similar level using 
Met inhibition, the reduction of tumourigenicity that occurs following 
endocytosis inhibition appears to be a consequence of the Met localisation in 
addition to its activation status. Thus, it is the constitutive internalisation 
together with the high activation status that makes the Met mutant highly 
tumourigenic. 
 
This shows that, despite the traditional view that it is RTK activation alone 
that drives tumourigenesis, in fact the localisation of this constitutively active 
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RTK on endosomes is absolutely necessary for it to fulfil its full oncogenic 
potential. 
 
Endosomal signalling of RTKs and Cancer 
It is recognised that RTKs can induce tumourigenesis through 
overexpression, activating mutations or excessive paracrine/autocrine 
signaling and normally the cellular location of an RTK is not investigated. 
Thus it has previously been thought that the high activation status of the 
D1246N and M1268T mutants causes them to drive tumourigenesis 286, 294. 
Nevertheless, a few studies have described constitutively active RTKs, that 
signal from intracellular compartments. These include KIT D814Y, which was 
found signalling from the Golgi301 as well as RET R918T, FGFR3 and Flt3-
ITD which were all found signalling from the endoplasmic reticulum302-304. 
However they were all signalling in their immature forms as they trafficked 
through the secretory pathway, but nevertheless the signalling from these 
locations was found to be able to promote tumourigenesis301, 305.  
Our observations, instead point towards “endosomal signalling” of a mature 
RTK following trafficking from the plasma membrane306-308. This form of 
signalling has been suggested to provide a way of enhancing signal 
specificity, which would seem to be especially important for the Met RTK, 
which transduces all of its downstream signalling from the Y1349 and Y1356 
tyrosines in the Met docking site309. Furthermore, endosomal signalling of 




3) Met Oncogenic Mutants: Sensitivity to HSP90 inhibitors 
Reduced degradation of RTKs has been shown to occur in cancer311. Here I 
have confirmed that both the M1268T and D1246N Met mutants suffer from a 
defect in degradation as compared to Wt Met as previously described by Dr. 
Carine Joffre.  
 
Met mutant degradation can be restored through inhibition of HSP90, 
resulting in reduction in cell migration and tumourigenesis 
Previously, Met mutations that induce a defect in degradation have been 
identified in lung cancer201. These mutations are somatic intronic deletions 
that lead to an alternatively spliced variant of Met lacking the juxtamembrane 
domain, and consequently the Y1003 c-Cbl binding site201. When a Y1003F 
Met mutant was generated that could not bind c-Cbl, Met still underwent 
endocytosis and trafficking with similar kinetics to WT Met, however it was 
not able to be degraded201.  However, our study is the first to report a defect 
in degradation of Met mutated in the kinase domain. Moreover, so far no Met 
mutants that have a defect in Met degradation and an increased Met 
internalisation have been described. 
 
Unpublished data from Dr. Carine Joffre have demonstrated that the M1268T 
mutant does not have a defect in Y1003 phosphorylation or Met 
ubiquitination and in fact if anything M1268T Met is more ubiquitinated than 
the Wt Met. Thus, the defect in degradation of the mutants observed is not 
due to a lack of ubiquitination. However, I showed that HSP90 activity is 
responsible for the mutants’ stability, consistent with Carine Joffre finding that 
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the Met mutant M1268T is constitutively associated with HSP90. This 
importantly suggests that HSP90 protects Met from degradation directly 
rather than via another protein. HSP90 is a molecular chaperone that is 
involved in the stabilisation of various proteins in their correct conformation 
and it has also been shown to be involved in protecting Wt Met from 
degradation91. In our study we have used the HSP90 inhibitor 17-AAG, which 
is a derivative of geldanamycins. In fact, geldanamycins have been shown to 
induce downregulation of the basal expression of the mutated Met 
L1213V/M1268T and revert the malignant associated phenotype of cells 
carrying this mutation134. This is the only study published so far that has 
investigated the effect of HSP90 inhibition on a Met mutation, however it did 
not notice a defect in Met degradation and did not investigate the effects on 
the Met induced tumourigenicity.  
 
I have shown that inhibition or knock down of HSP90 restores the 
degradation of the Met mutants M1268T and D1246N, both upon HGF and 
independently of HGF (Figure 17). Furthermore, I have shown that inhibition 
of HSP90 in the M1268T cells led to a reduction in anchorage independent 
growth and cell migration in vitro as well as a reduction of tumourigenesis in 
vivo (Figure 18AB and 20BC). Meanwhile, in vitro, there was no or very little 
effect on Wt Met expressing cells (which are not transformed). This, together 
with the fact that the transformation of the mutant cells is dependent on Met 
activity, suggests that this approach appears to impair Met mutants’ 
dependent cell transformation specifically. 
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D1246N mutant requires a higher dose of 17-AAG for efficient inhibition 
of Met dependent tumourigenesis 
Although inhibition of HSP90 also restored the degradation of the D1246N 
mutant, the same dose of 17-AAG did not seem to be as effective at 
inhibiting the anchorage independent growth of the cells expressing this 
mutant (24.4% decrease) compared to the M1268T cells (greater than 46% 
decrease). However, depletion of HSP90 using RNAi achieved a larger 
decrease in anchorage independent growth in the D1246N Met cells, similar 
to that obtained in the M1268T cells. While in M1268T Met expressing cells 
100nM 17-AAG and HSP90 RNAi reduced the anchorage independent 
growth to a similar level. This suggests that 17-AAG is not, over the time of 
the soft agar assays, as effective at restoring D1246N Met degradation 
through HSP90 inhibition as it is for M1268T Met. Consistent with this, the 
rate of D1246N Met degradation upon 4 hours of HGF stimulation following 
HSP90 inhibition appeared to be slower than that of the M1268T Met (Figure 
18B). The reason for the difference in sensitivity to 17-AAG between the two 
Met mutants could also be due to the conformational differences previously 
discussed294 between their mutations (Discussion Chapter II-1), which 
perhaps alter the way that they bind to HSP90 or to the inhibitors (Met TKI 
and 17-AAG). 
 
A dose dependent response to 17-AAG was however observed in D1246N 
Met degradation and the mutant expressing cells’ anchorage independent 
growth. Thus 200nM 17-AAG significantly decreased their anchorage 
independent growth to a similar level as following transfection with HSP90 
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RNAi, suggesting that specificity is still maintained at this dose. The IC50 of 
17-AAG varies depending on the cell type and especially whether the cells 
are normal or tumourigenic. For example, the IC50 of various cancer cell 
lines averages at 39nM. However, the IC50 is lower in Her2-positive breast 
cancer cell lines (oncogene driven), being 5nM, and much higher in normal 
primary cells, being 943nM124. Thus the dose of 200nM still remains within 
the range at which it should not affect normal cells at this dose.  
 
HSP90 Inhibition as cancer treatment for Met dependent cancers in the 
clinic 
HSP90 inhibitors are currently in phase I, II as well as a few phase III clinical 
trials for the treatment of various cancers (http://www.clinicaltrials.gov). Wang 
et al. showed that treatment of cancer cells harbouring Met amplification with 
17-AAG led to a durable decrease in the activation of Met and its 
downstream signalling molecules as well as inhibition of cell growth135. 
Furthermore, these effects were greater and more durable than those 
observed using the Met inhibitor SU11274135. These studies, together with 
the effective inhibition of Met M1268T dependent tumour growth that we 
observed in M1268T tumours using 17-AAG, suggest that treatment of 
patients bearing the M1268T mutation with HSP90 inhibitors may provide a 
very effective long-term therapy. 
 
This project is still ongoing and the next step will be to attempt treating 
D1246N tumours in vivo with 200nM 17-AAG. The in vitro data gathered so 
far provide promising results and suggest that 17-AAG may be effective at 
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reducing the growth of D1246N expressing tumours in vivo. If so, it will 
provide proof of principle that 17-AAG can be used to treat Met driven 
cancers, even in situations where Met is resistant to TKIs.  
 
One advantage of using HSP90 inhibitors where effective is that they have 
multiple indirect but cancer driving targets, as HSP90 has a very wide range 
of cancer-associated clients. They may therefore produce a more effective or 
durable response than Met TKIs. It is important to note however that 
acquired resistance to HSP90 inhibitors has been documented 
experimentally312. The current investigations on the use of HSP90 inhibitors 
in long-term cancer treatment will inform further on potential resistance to 
such inhibitors, which, otherwise appear very promising.  
 
HSP90 α expression is increased in M1268T expressing cells, however 
both isoforms α and β appear to play a role in cell functions 
In this study I have found that the M1268T Met oncogenic mutant expressing 
cells have increased expression of the HSP90 α isoform compared to Wt 
expressing cells. This is perhaps not surprising as the HSP90 α isoform has 
previously been shown to be upregulated in various tumours94.  
 
Investigation into the functional role of each HSP90 isoform in the M1268T 
expressing cells revealed that in fact either HSP90 α or HSP90 β isoform is 
required for M1268T Met dependent cell migration. Intriguingly, however, 
knockdown of both isoforms together significantly increased the migration of 
the Wt Met expressing cells, which correlated with increased Wt cell 
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migration observed following silencing of the HSP90 β isoform alone. Thus, 
although targeting either isoform can inhibit cell migration, possibly targeting 
the HSP90 α isoform alone has less effect on non-tumourigenic cells. This 
may be due to compensation by the HSP90 α isoform in the absence of 
HSP90 β, such that inhibition of HSP90 β knockdown may increase the 
expression of HSP90 α, which has a currently unknown role to play in 
general cell migration. This could be potentially interesting to investigate 
given the increased expression of HSP90 α in tumourigenic cells94, including 
the M1268T mutant.  
 
In a contrasting manner, only the depletion of both isoforms together had an 
effect on the anchorage independent growth of the M1268T expressing cells. 
However, this result could be due to difference in the time-span of the 
experiments, as soft agar assays last 6 days, at which point expression 
levels of the silenced proteins may have partially returned and perhaps when 
both proteins were silenced simultaneously the threshold of knockdown 
required to inhibit the cell growth in soft agar over 6 days might be achieved. 
In contrast, Transwell migration assays are performed 72 hours after 
transfection at the point of optimum protein depletion and last only 4 hours. 
Thus, another more comparable way to assess anchorage independent 
growth needs to be carried out. This could possibly be achieved by 
fluorescently labelling the cells, allowing the experiment to be stopped earlier 
(e.g. day 3) and then analysing by the more sensitive method of measuring 
fluorescence intensity produced by the colonies formed. 
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Inhibition of co-chaperone-HSP90 interactions 
Inhibition of the interaction between HSP90 and various co-chaperones has 
been proposed to provide an alternative way to target HSP90 client proteins 
more specifically. We have hypothesised that Hop may be involved in the 
stability of Met mutants. However, I generated inconclusive experiments with 
opposite results. The reasons for these discrepancies may be due to 
difference in knockdown efficiency. In the first experiment, Hop silencing led 
to a decrease in Met expression, which was not surprising as it is known that 
Hop is involved in delivering client proteins to HSP90. Thus Hop silencing is 
expected to lead to Met degradation. However, in the second experiment, I 
observed an increase in Met expression. As in this experiment, Hop silencing 
was more efficient; perhaps there is some compensation between other 
members of the HSP90 complex. Certainly further repetitions are required to 
establish what constitutes the real result. 
Another co-chaperone, CHIP, would be particularly interesting to investigate 
in M1268T expressing cells, as it has been found to associate with the 
constitutively active M1254T Ron mutant and is responsible for Ron 
degradation upon 17-AAG treatment130. This mutant is highly sensitive to 17-
AAG treatment and it could, therefore, be interesting to investigate whether 
there is a difference in the association between CHIP and the two Met 
oncogenic mutants studied here, as perhaps there is an increased 
association between CHIP and M1268T which could explain its increased 
sensitivity to HSP90 inhibition over the D1246N mutant. 
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Interestingly, Novobiacin, a coumarin antibiotic, binds to HSP90 in its C-
terminal domain and alters its interactions with co-chaperones94, 117. While 
Novobiocin itself has a low affinity for HSP90, several derivatives have been 
produced that have a higher affinity for HSP90 than 17-AAG and appear to 
have good anti-proliferative effects on several cancer cell lines93. Thus, it 
would be interesting to test this inhibitor on the D1246N and M1268T Met 
mutants to see if it is more effective than 17-AAG and if it alters interactions 
between Met, HSP90 and, as yet, unknown co-chaperones. 
 
Degradation versus Endocytosis 
One of the unanswered questions is whether the mutants recycle due to their 
defect in degradation? Or do they not degrade due to their increased 
recycling? Unpublished data from our lab have demonstrated that the Met 
mutants are not detected on late endosomes or on lysosomes. Thus, firstly, 
having restored Met degradation, it would be interesting to investigate if the 
trafficking of the Met mutants is restored to the late endosomes. Secondly, it 
would be interesting to block the proteosome/lysosomal degradation of both 
Wt cells and M1268T cells treated with 17-AAG and see if Met accumulates 
in late endosomes or if recycling is increased. Finally, it would also be 
interesting to do the inverse experiment and see if the impairment of Met 
mutants’ recycling restores their degradation.  
 
Interestingly, inhibition of M1268T tumourigenesis in vivo was inhibited to an 
equal degree by both 17-AAG and Dynasore, suggesting that inhibition of the 
accumulation of M1268T Met on endosomes, either by inhibition of 
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endocytosis or by restoration of Met degradation, is equally sufficient to 
reduce tumour growth. 
 
Many studies have reported RTKs that avoid degradation88, 193, 288, 313, and 
others have reported increased recycling of RTKs in cancer185, 187, 189, 194. 
However, these studies tend to assume that the resulting mechanism for 
increased tumourigenicity, is an increased life-span of the receptor in 
question. They do not question whether the location of the receptor is 
important. Whereas we have demonstrated that it indeed is the intracellular 
location of Met that is required for tumourigenesis. 
  248 
Results Part III: β1-integrin - Met Crosstalk: an endosomal 
inside-in signalling 
 
1) β1-integrin co-traffics with Met and is required for Met dependent cell 
migration and ERK 1/2 phosphorylation 
 
Crosstalk between various different integrins and RTKs has been shown to 
occur. In this study, I have investigated the relationship between Met and β1-
integrin, the ubiquitously expressed β1-subunit of most ECM binding 
integrins, including α5β1, the major receptor for fibronectin232, 248, 314. To 
investigate the crosstalk between these two major cell surface receptors, I 
used β1-integrin null GD25 cells generated from early β1-integrin null mouse 
embryos315 (“GD25 cells”) and the same cells re-expressing β1-integrin (“β1A 
cells”) (Figure 1A)263.  
 
I firstly wanted to investigate the role of β1-integrin in Met dependent cell 
migration. Interestingly, in scratched confluent monolayers, HGF increased 
the wound healing of β1A cells significantly (by more than 2 fold, p<0.01) but 
had no effect in GD25 cells (Figure 1BC). Dr Stephanie Kermorgant showed 
that PDGF, however, was able to increase the wound healing of GD25 cells 




















































Figure 1: β1-integrin is required for Met dependent cell migration 
A) Western blots for β1-integrin, HSC70 in β1A, GD25 and β1A-YYFF cells 
stimulated with HGF for 0, 15 and 120 minutes. B) Pictures of confluent 
β1A or GD25 cells just after wounding (0) or 24 hours after wounding. Cells 
were treated or not with HGF. Scale bar: 130μm. C) Quantitation of wound 
closure. Data are mean (arbitrary units)  ± SEM (n=5). D) Average number 
of the indicated cells that have migrated through Transwells over 2 hours of 
incubation with HGF. Data are mean ± SEM (n=3), each experiment done 
in triplicate. *p<0.05; **p<0.01.
HSC70






In order to confirm my observations in the wound healing assays, I used 
Transwell migration assays to investigate the Met dependent migration of 
these cells further. HGF significantly increased the number of β1A cells that 
migrated by more than 2 fold (p<0.05), while no significant increase in 
migration occurred in GD25 cells (Figure 1D). These results indicated that 
β1-integrin is required for HGF/Met dependent cell migration. Furthermore, 
β1-integrin could not be compensated for by fibronectin-binding β3-integrin 
heterodimers, as they are expressed in both of these cell types263.  
 
Since β1 trafficking (cycles of endocytosis and recycling) recently has been 
shown to play a substantial role in cell migration231, 248, 316, 317, I investigated 
whether the HGF / Met pathway influences the trafficking of β1-integrin.  
Flow cytometry experiments carried out in the laboratory of our collaborator 
Prof. Johanna Ivaska showed that cell surface expression of β1-integrin was 
reduced rapidly at the plasma membrane following short periods of HGF 
stimulation in β1A cells (Appendix Figure 5B), indicating integrin 
internalisation. They confirmed this through performing a biotin-based 
internalisation assay, where, upon 15 minutes of incubation, a higher 
proportion of surface biotinylated β1-integrin was internalised in the presence 
of HGF relative to in the absence of HGF (Appendix Figure 5C). I confirm 
these findings by immunofluorescence. Analysis by confocal microscopy 
showed that, at 30 minutes of HGF stimulation, there was an increased 
amount of β1-integrin in the intracellular pool compared to no stimulation 
(Figure 2A). I have used the fluorescently labelled HGF (HGF*) to follow the 
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localisation of HGF-bound Met13. As expected, punctate HGF* staining was 
observed at 30 minutes, indicating the internalisation of Met upon HGF 
stimulation82, which also was seen in GD25 cells (Figure 2B) showing that 
β1-integrin is not required for Met to be able to undergo endocytosis. 
Strikingly, colocalisations between β1−integrin and HGF* were observed in 
intracellular vesicles, indicating Met/HGF and β1-integrin co-traffic and 
suggesting that they might co-internalise (Figure 2A).  
 
Due to the fact that HGF dependent cell migration requires Met signalling 
from endosomes62, 157, 159, I tested whether β1-integrin could have a role in 
Met endosomal signalling. In β1A cells, HGF triggered a robust (x 5 fold 
increase at 15 minutes, p<0.01) and sustained (x 2.6 fold increase at 120 
minutes, p<0.05) ERK1/2 phosphorylation. Surprisingly, by contrast, in cells 
lacking β1-integrin (GD25), the intensity of the ERK1/2 signal was reduced 
by over 40 % at 15 minutes (p<0.05), and was not sustained over time (NS) 
(Figure 3A). However, Met expression levels (Figure 3B) and, moreover, 
Met phosphorylation were not affected (Figure 3B), indicating β1-integrin 
may influence downstream signalling of Met rather than affecting Met 
directly. Taken together, these results suggest that β1-integrin influences the 
Met-dependent ERK1/2 pathway on endosomes. 
 






















Figure 2: β1-integrin  co-traffics with Met
A) Confocal sections of β1A cells, stimulated, or not, with HGF-Alexa555 
(red) for 30 minutes, and stained for β1-integrin (green) and DAPI (blue). 
Co-localisations appear in yellow. Scale bars: 10 μm. Plots of the intensity 
profiles, at different emission wavelengths corresponding to the signals of 
β1-integrin and HGF-Alexa555, of a set of pixels distributed on a line drawn 
across a vesicle (shown in the top panel magnification) are shown. 
B) Confocal section of GD25 cells stimulated with HGF-Alexa555 (red) and 
stained for DAPI (blue). Scale bar: 10μm.
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Figure 3: β1-integrin plays a role in Met dependent ERK1/2 
phosphorylation
A) Western blots for tubulin and phospho-ERK1/2 in β1A and GD25 cells, 
stimulated with HGF for 0, 15 and 120 minutes. Numbers represent fold 
increases ± SEM (n=6) of phospho-ERK1/2 / tubulin ratios at 15 and 120 
minutes over 0 minutes. B) Western blots for phospho-Met (Y1234/35), total 
Met (p170, precursor, p145: mature β chain) and tubulin. Numbers represent 
mean ± SEM (arbitrary units, n=4) of phospho-Met / Met p-145 ratios. 
C) Quantitation of Western Blots. Numbers represent relative levels (arbitrary 
data) ± SEM (n=3) of Met / tubulin ratios in β1A versus GD25 cells.  *p<0.05; 














































The cytoplasmic domains of β-integrins contain two conserved NXXY motifs, 
which have been implicated in integrin function. Both motifs have been 
shown to regulate integrin activation231, to play a role in the signalling of β3-
integrin to Shc318 and to be critical for β1-integrin mediated activation of 
FAK319 . I therefore analysed the influence of the double mutation, 
Y783F/Y795F, in the NXXY motifs of β1-integrin. In cells expressing the β1-
integrin “YYFF mutant” (“β1A-YYFF cells”), ERK1/2 activation upon HGF 
stimulation was similar to that observed in GD25 cells (fold increases were 
not significantly different at 15 and 120 minutes) (Figure 4A). Although 
ERK1/2 phosphorylation was stimulated at 15 minutes (p<0.05), the intensity 
was reduced by nearly 50% compared to β1A cells at the same time 
(p<0.05). Furthermore, correlating with what was found in GD25 cells, the 
ERK1/2 signal was not sustained (Figure 4A). Meanwhile, Met 
phosphorylation and expression levels were unchanged (Figure 4B). The 
reduction in HGF-dependent ERK1/2 phosphorylation was not the result of a 
decrease in total ERK1/2 expression levels in GD25/β1A-YYFF cells 
compared to β1A, which were checked by Western blot (Figure 4C). The 
kinetics of Met degradation in all three cell lines were also unchanged 
(Figure 4D). Interestingly, in wound healing assays β1A-YYFF cells did not 
respond to HGF significantly (Figure 5A) thereby resembling GD25 cells 
(Figure 1BC). It is also important to note that the lack of β1-integrin (GD25 
cells) or the presence of β1A-YYFF in cells does not seem to alter the growth 
rate of the cell lines, such that in fact the GD25 cells grow slightly faster (non 
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significant) than the β1A and β1A-YYFF cells (Figure 5B).  
Thus, it can be concluded that the participation of β1-integrin in Met 
endosomal signalling, required to stimulate cell migration, is dependent on a 
signaling competent β1-integrin with intact cytoplasmic NXXY motifs.  
 
2) β1-integrin co-traffics with Met and is required for Met ERK1/2 
phosphorylation in cells existing in suspension 
 
All the results so far were obtained with cells cultured directly on plastic. Dr. 
Stephanie Kermorgant has performed some experiments to assess the 
influence of β1-integrin ligands on β1-integrin-Met dependent ERK1/2 
activation. β1A cells were trypsinised, the trypsin was neutralised with 
soybean trypsin inhibitor and cells plated on laminin or fibronectin or on the 
control substrate poly-L-lysine for different periods of time with or without 
HGF. Surprisingly, HGF activated ERK1/2 to a similar extent under each 
condition (Appendix 5D). This result suggested that the β1-integrin input in 
Met dependent ERK1/2 activation was unrelated to β1 substrate engagement 
and also that β3-integrin plays no role in this process, since fibronectin is 
also a ligand for β3-integrin whereas laminin binds specifically only β1-
integrins. To assess further whether Met dependent ERK1/2 activation was 
independent of β1 ligand, β1A cells, serum-starved for 24h, were trypsinised, 
the trypsin was neutralised with soybean trypsin inhibitor and cells were 
cultured in serum-free medium under non-adherent conditions for 1 hour 
followed by HGF stimulation for 15 and 120 minutes. At 15 minutes, HGF 
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was able to stimulate ERK1/2 phosphorylation to a level similar to that in 
adherent cells, confirming integrin ligand- and anchorage- independence 
(Appendix Figure 5E). Interestingly the ERK1/2 activation in these 
suspension cultures was more sustained than in adherent cultures 
(Appendix Figure 5E).  
 
These results on cells in suspension prompted us to extend this study to a 
different cell system that Dr Stephanie Kermorgant had previously generated, 
as a post-doc in Prof. Peter Parker’s laboratory, where cells lose adherence 
and grow in suspension in response to Met activity. This cell system, “Met-
GFP cells”, consists of HEK-293 cells with tetracycline-inducible Met-GFP 
expression (TET ON system). Met-GFP expression was detected after 3 
hours of incubation with 0.1 µg/ml tetracycline and the level increased with 
the time of induction (Figure 6A). Here I present experiments that I have 
performed (unless otherwise stated), however for  the majority of them, it was 
a repeat of experiments done by others in order to reach at least n=3.  
Interestingly, when expressed, Met-GFP was phosphorylated constitutively 
(Figure 6A) (most likely due to GFP-GFP oligomerisation and subsequent 
trans-phosphorylation of Met-GFP molecules), therefore also providing us 
with a model to investigate Met activity, which in this case occurs 
independently of HGF. Furthermore, cell rounding and detachment from the 
plate occurred, which temporally coincided with the induction of Met-GFP. 
The detached cells formed floating spherical colonies (Figure 6B) with 
retained Met-GFP activity after 16 hours (Figure 6C). Flow cytometry 
analysis (performed by Nick Luckens and Dr. Stephanie Kermorgant), for 
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propidium iodide staining of Met-GFP cells which were non-induced and 
induced for 48 hours with 0.1 µg/ml of tetracycline, showed that the Met-GFP 
expressing cells remained viable despite their detachment from the plastic 
(Appendix Figure 6A). Moreover, the Met-GFP expression, and consequent 
cellular phenotype, was reversible with tetracycline removal indicating that 
the loss of adhesion, occurring with Met-GFP expression, did not induce 
anoikis. Importantly, cells re-attached rapidly upon addition of the Met 
specific inhibitor SU11274 for just 1 hour (Figure 6B), while they did not 
upon addition of the unrelated VEGFR2 inhibitor SU1498. Thus cell 
detachment is dependent on Met activity. 
ERK1/2 was activated progressively following tetracycline induction (Figure 
6A), remaining activated after 16 hours when cells were fully detached 
(Figure 6C). Treatment with SU11274 inhibited ERK1/2 phosphorylation, 
indicating that ERK1/2 activation is the result of sustained Met action (Figure 
6C). 
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Figure 4: The conserved YYFF motif of β1-integrin plays a role in Met
dependent ERK1/2 phosphorylation
A) Western blots for tubulin and P-ERK1/2 in β1A-YYFF cells, stimulated 
with HGF for 0, 15 and 120 minutes. Numbers represent fold increases ± 
SEM (n=6) of P-ERK1/2 / tubulin ratios at 15 and 120 min over 0 minutes. 
B) Western blots for phospho-Met (Y1234/35), total Met and tubulin in YYFF 
cells, stimulated with HGF for 0, 15 and 120 min. C) Western blots for β1-
integrin, pan-ERK 1/2 and HSC70 in β1A, GD25 and β1A-YYFF cells 
stimulated with HGF for 0, 15 and 120 minutes. D) Quantitation of Western 
blots. Numbers represent levels of Met protein (p145-Met / tubulin ratios) 
upon time of HGF stimulation (arbitrary data) ± SEM (n=3). *p<0.05; 






























Figure 5: The YYFF motif of β1-integrin plays a role in Met dependent 
cell migration
A) Pictures of confluent β1A-YYFF cells just after wounding (0 hours) or 24 
hours after wounding. Cells were treated or not with HGF. Bar: 130μm. 
Graph shows the quantitation of wound closure for β1A-YYFF cells. Data 
are mean (arbitrary units)  ± SEM (n=3). *p<0.05; **p<0.01; ***p<0.001. 
B) Growth curve of GD25, β1A and β1A-YYFF cells incubated +/- HGF. 








































































Tet:       -       +        -       +
SU11274:       -        -        +       +  
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Figure 6: β1-integrin co-traffics with activated Met-GFP and plays a role 
in Met-GFP signalling to ERK1/2 in cells growing in suspension
A) Western blots for β1-integrin, GFP (Met-GFP: p195, precursor; p170, 
mature β chain), phospho-Met (Y1234/35), phospho-ERK1/2 and tubulin in 
Met-GFP cells, incubated in tetracycline (Tet, 0.1μg/ml) for the times 
indicated in hours (hrs). B) Low light images of Met-GFP cells, incubated or 
not (control) in tetracycline (Tet, 0.1 μg/ml) for 16 hours, further incubated for 
1 hour or not in the Met inhibitor SU11274 or the unrelated VEGFR2 inhibitor 
SU1498. Image 1: cells are attached; Images 2 and 4: cells have detached; 
Image 3: cells have re-attached. C) Western blots for phospho-Met (Y1234/
35), GFP (Met-GFP: p195, precursor; p170, mature β chain), P-ERK1/2, 
pan-ERK1/2 and tubulin in Met-GFP cells, incubated in tetracycline (Tet, 
0.1μg/ml) for 0 or 16 hours and treated for 1 hour or not with the Met inhibitor 
SU11274. D) Confocal projections of 7 Z-sections from the base to the apex 
of the cell. Arrows show examples of plasma membrane staining. Scale bar, 
10μm. Cells were cultured on Poly-L-lysine coated glass coverslips for 16 
hours in the presence of 0.1 μg/ml tetracycline. Cells were stained for anti-β1-
integrin in active conformation (9EG7) (red). Met-GFP is in green. Top panel: 
T-REx™-293 cells, non-transfected and stably transfected with Met-GFP 
(“Met-GFP cells”), at a 50/50 ratio. Bottom panel: T-REx™-293 cells stably 
transfected with Met-GFP (“Met-GFP cells”) and treated with SU11274 (2μM).
260
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We found that Met-GFP-induced cell rounding coincided with a decrease of 
β1-integrin from the cell surface. Flow cytometry analysis of pan β1-integrin 
expression on the cell surface, performed in Dr. Ivaska’s laboratory, 
demonstrated that the reduction reached 60% at 3 hours (p<0.05) (Appendix 
Figure 6B), whereas the total cellular β1 levels remained unaltered (Figure 
6A). Concomitantly, β1 internalisation was increased, as measured by a 
biotinylation-based endocytosis assay, over 1-5 hours of tetracycline 
induction (p<0.001 at 2 hours) (Appendix Figure 6C). Carine Joffre showed 
that, after 16 hours, when the cells were totally detached, there was still a 
significant reduction in pan β1-integrin expression at the cell surface, though 
only by 18% (p<0.01) (Appendix Figure 6D). Interestingly, a much more 
significant reduction (almost 60% p<0.001) was detected in cell surface 
levels of β1-integrin in the activated conformation (detected with anti-β1 
antibody clone 9EG7) (Appendix Figure 6E). The reduction of activated β1 
relative to pan β1 was 55 % (p<0.01) (Appendix Figure 7A) meaning that 
the internalised pool of β1- integrin is greatly enriched in activated β1-
integrin. Immunofluorescence studies were performed with cells seeded on 
coverslips coated with Poly-L-lysine, which allowed rounding of tetracycline 
treated cells but prevented their detachment. After 5 hours of tetracycline 
induction, Met and β1-integrin colocalised in intracellular vesicles (Appendix 
Figure 7B).  
 
To compare the localisation of the active β1-integrin in cells expressing or not 
Met-GFP, non-transfected cells and cells stably transfected with the Met-
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GFP construct were seeded together and induced with tetracycline for 16 
hours. In non-transfected cells, the active β1-integrin was distributed at the 
plasma membrane and in intracellular pools. In tetracycline-induced cells, the 
staining had decreased at the plasma membrane but had increased in 
intracellular pools, indicating again an increase in β1-integrin internalisation 
(Figure 6D). Treatment with the Met inhibitor SU11274 restored localisation 
of active β1-integrin at the plasma membrane (Figure 6D). Furthermore, 
triple colocalisation with EEA1 could be detected, indicating Met and β1 were 
recruited to EEA1 positive early endosomes (Appendix Figure 7C).  
 
Together, these results indicate that, in Met-GFP expressing cells existing in 
suspension, Met activity promotes endocytosis of active β1-integrins and that 
they co-traffic through early endosomes.  
The observed colocalisations between endosomal Met-GFP and active β1-
integrin suggested that, as in β1A cells, β1-integrin may have an input in 
activated Met-GFP endosomal signalling. Consistent with this notion, siRNA 
mediated silencing of β1−integrin led to a significant (44%) decrease in 
tetracycline-induced ERK1/2 phosphorylation (p<0.01) (Appendix Figure 
8AB), while Met activation and expression (Appendix Figure 8ACD) were 
not modified significantly. Thus, in both cell models, β1-integrin plays a role 
in the activation of Met dependent ERK1/2 phosphorylation on the 
endosome, under both adherent and non-adherent conditions. 
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3) β1− integrin is required for Met dependent anchorage independent 
growth, in vivo tumourigenesis and metastasis. 
 
Due to the fact that the influence of β1-integrin on Met endosomal signalling 
occurred in non-adherent cells, with the signal being maintained for longer 
periods under non-adherent conditions, I investigated whether β1-integrin 
could play a role in Met dependent anchorage-independent growth of the 
normally adherent GD25, β1A and β1A-YYFF cell lines. While GD25 and β1A 
cells formed colonies in soft agar, HGF increased the size of β1A colonies 
significantly but had no effect on colonies formed by GD25 or β1A-YYFF 
cells (Figure 7). These results show that β1-integrin, and the NXXY motifs in 
its cytoplasmic tail, play a role in anchorage independent growth stimulated 
by Met.  
 
I next wanted to test the role of β1-integrin in Met dependent tumourigenesis 
in nude mice using the model I have previously used; NIH3T3 cells 
expressing the Met oncogenic mutant M1268T (see Chapter II).  
First of all however, I investigated if β1-integrin is required for the Met 
dependent transformation of these cells in vitro. Confocal analysis of Wt and 
M1268T Met expressing cells revealed colocalisation between Met and β1-
integrin both at the plasma membrane and in EEA1-positive vesicles in 
M1268T Met expressing cells, while colocalisations mainly occur at the 
plasma membrane in Wt Met expressing cells (Figure 8A). This promising 
result led me to perform Transwell migration assays with the Wt and M1268T 
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expressing cells following β1-integrin knockdown. Abrogation of β1-integrin 
expression (Figure 8B) significantly reduced the migration of M1268T cells 
by 79% (p<0.01), while there was no effect on the Wt cells (Figure 8C). 
When these cells were grown in soft agar, there was also a significant 
decrease, of 44%, in the number of M1268T colonies that formed compared 
to cells transfected with control RNAi (p<0.05), whereas there was no effect 
on the anchorage independent growth of Wt cells (Figure 8D). 
As a consequence of these encouraging results, M1268T Met 
expressing cells were injected subcutaneously into nude mice (by Professor 
Ian Hart). Here I used mutant cells transfected with control- or β1-integrin- 
siRNA. Tumours formed rapidly in both conditions (at day 3 and 4) but 
tumour volumes were reduced significantly, by 50 to 60% (p<0.001 to 0.05), 
for β1-integrin silenced cells, as compared to control siRNA transfected cells, 
from day 5 to 11. By day 11, the tumour volumes of control silenced cells had 
reached 300mm3 and all mice were killed (Figure 9A). At the end of the 
experiment, I removed and weighed the tumours. Tumours formed by the β1-
integrin silenced cells were 2.5 x smaller than those formed by their control 
counterparts (p<0.05) (Figure 9B).  
To assess the influence of β1-integrin on Met dependent metastasis, I 
performed an experimental lung colonisation assay, developed with the same 
cells, as previously159. Control and β1-integrin knock down cells were 
injected (by Prof. Ian Hart) into the tail veins of nude mice.  At 21 days, the 
lungs of mice injected with control siRNA transfected cells presented an 
average of 8.5 macroscopic tumours per mouse while this number was only 
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2.8 in β1-integin knocked down cells (p<0.05) (Figure 9CD). Histological 
analysis confirmed that while most of the lung tissue of mice injected with 
control siRNA transfected cells was invaded by these cells, the lung tissue of 
mice injected with siRNA transfected cells was largely free of metastatic 
involvement (Figure 9E). These experiments indicated that β1-integrin plays 
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Figure 7: β1-integrin is required for Met dependent anchorage 
independent growth
Pictures of soft agar cultures for β1A and GD25 cells, at Day 13. From Day 8, 
HGF (14ng/ml) was added to the medium, or not, every other day. Data are 
the average colony areas ± SEM (a.u. arbitrary unit, n=3) for β1A, GD25 and 




































































Figure 8: β1-integrin is required for M1268T Met dependent in vitro 
tumourigenicity
A) Confocal sections of Wt and M1268T expressing cells stained for Met 
(red), β1-integrin (green) and EEA1 (blue). Colocalisations appear in yellow. 
B) Western blots for β1 integrin and tubulin on Wt and M1268T cell lysates 
72 hours following transfection with control or β1 RNAis. C) Fold change in 
Wt or M1268T Met expressing cells that have migrated through Transwells 
when transfected with Control or β1 RNAi (n=3), normalised to Wt control 
expressing cells. Each experiment was done in triplicate. D) Wt, and M1268T 
cells were grown in soft agar following transfection with control, Met or β1 
RNAis. The graph represents the average colony number on Day 6. Data 
are mean ± SEM (n=3), each experiment was done in duplicate). *p<0.05; 
**p<0.01; NS=not significant.













































































































Figure 9: β1-integrin is required for Met dependent in vivo 
tumourigenesis
A) Tumour growth curves, over time, of M1268T Met expressing cells, 
knocked down with control or β1-integrin siRNA. Data are mean ± SEM of 
n=5 mice per group. B) Weight (mg) of tumours derived from M1268T Met 
expressing cells transfected with control or β1-integrin siRNA, at day 11. Data 
are mean ± SEM (n=5 mice per group). C) Number of macroscopic tumours 
in lungs of mice, previously injected into the tail vein with M1268T Met 
expressing cells, transfected with control (n=4) or β1-integrin (n=5) siRNA. 
Data are mean ± SEM. D) Pictures of the lungs of mice injected in the tail 
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Figure 10: Development of stable cell lines lacking β1-integrin
A) Wt and M1268T cells were transduced with non-targeting control shRNA 
or 5 different sequences of β1-integrin shRNA  (43-47) at MOI 5 and MOI 10. 
Knock-down was tested by western blot for β1-integrin, HSC70 and tubulin. 
B) Western blot for β1-integrin and HSC70 in Wt and M1268T cells 
transduced with non-targeting control or sequence 47 of β1-integrin shRNA 
at MOI 10 -/+ HGF (50ng/ml) for 15 minutes. 
Wt              M1268T
HGF:   -    +    -   +    -   +    -   +
RNAi:  Cont     β1    Cont     β1
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Although we have previously shown (in Chapter II) that the tumorigenesis of 
the M1268T Met cells is dependent on Met activity, in vivo timourigenesis 
experiments with Wt Met expressing cells silenced for β1-integrin performed 
in parallel, would provide a good control. However, as Wt Met expressing 
tumours form much later, we can not use RNAi as β1-integrin knockdown 
would be too short-lived.  
To overcome this problem, I have developed Wt and M1268T Met expressing 
cell lines that have been transduced with either Control or β1-integrin shRNA 
to form cell lines that permanently contain or lack β1-integrin. Following 
transduction of the two cell lines with 5 different shRNA sequences, it was 
clear that one sequence (sequence 47) was much more efficient than the 
others at depleting β1-integrin expression (Figure 10A). I therefore 
expanded these cells, in which a very good knockdown was achieved 
(Figure 10B). These results are a promising indication for future work with 
these cells, in which I will investigate to a greater extent the requirement for 





DISCUSSION CHAPTER III 
β1-integrin - Met Crosstalk: an endosomal inside-in signalling 
 
This study demonstrates that Met activity (either constitutive or HGF induced) 
promotes Met and β1-integrin internalisation and co-recruitment on 
endosomes. From this location, β1-integrin plays a role in Met downstream 
signalling, leading to an optimal and sustained ERK1/2 activation. The intact 
NXXY signalling motifs in the β1-integrin cytoplasmic tail appear to be 
required since the Y to F mutations lead to a comparable reduction in HGF-
induced ERK1/2 phosphorylation to that observed in the absence of β1-
integrin. Interestingly, this influence of β1-integrin on Met signalling occurs in 
cells existing both under adherent and non-adherent conditions. Consistent 
with these results, we also show that, in addition to playing a role in Met 
dependent cell migration, β1-integrin signalling is required for Met stimulated 
anchorage-independent growth, in vivo tumorigenesis and experimental 
metastasis. 
 
1) Met activation triggers Met and β1-integrin co-internalisation 
β1-integrin trafficking is altered by Met activation 
β1 trafficking (cycles of endocytosis and recycling) recently has been shown 
to play a large role in cell migration231, 248, 316, 317. Interestingly, using three 
different cell models, we have found that upon Met activation, by both HGF 
dependent and independent mechanisms, β1-integrin is internalised and 
coincidently the presence of β1-integrin is required for Met dependent cell 
migration.  
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The fact that the GFP-Met cells detach upon tetracycline induced expression 
of the constitutively active GFP-Met may be due to internalisation of β1-
integrin induced by Met activation.  
 
β1-integrin was recently reported to internalise both in inactive and active 
conformations. Moreover, the net endocytosis rate of the active β1-integrin is 
higher, whereas the inactive β1-integrin recycles back to the plasma 
membrane241. Consistent with this, our data show that Met activity increases 
β1-integrin internalisation and that an important part of this internalised 
integrin is in the active conformation. 
Thus our hypothesis is that, to play a role in Met signalling on the endosome, 
β1 needs to be in an active conformation. 
. 
Met and β1-integrin co-internalise 
We have observed Met - β1-integrin colocalisation on endosomes upon Met 
activation. This, together with the observation that the two molecules already 
colocalise at the plasma membrane in cells with inactive Met, suggested to us 
that the two molecules co-internalise. Ludovic Menard in the lab has now 
confirmed this by real time confocal microscopy (not shown).  We are 
currently performing co-immunoprecipitation and PLA studies to assess 






2) β1-integrin is required for Met endosomal dependent signalling in 
anchored and unanchored cells 
β1-integrin is required for Met dependent signalling even in cells in 
suspension 
Here, we have shown that β1-integrin plays a role in Met signalling. 
Interestingly, β1-integrin expression recently was reported to also be required 
for full EGFR downstream signalling upon EGF stimulation in the lung cancer 
cells A549 320. It is worth noting however that β1-integrin silencing increased 
the expression of EGFR on the cell surface, something we have not observed 
for Met but we will look at this more carefully in future experiments. 
Interestingly, we are currently extending our study to human cancer cell lines 
including A549 cells, which will allow us to compare the mechanisms involved 
for these two RTKs (EGFR and Met), in the same experimental conditions. 
 
It may appear not so surprising to find that an RTK, such as Met, and an 
integrin, such as β1-integrin, cross-talk. This concept has been described for 
many RTKs, including Met258, 260, 261. However, most cases of these cross-
talks were reported to occur upon cell attachment, thus upon integrin ligand 
binding. What is most surprising about our study is that the cross-talk occurs 
in both attached cells and cells in suspension.  This suggests that, here, β1-
integrin has an unusual role, independent of its ligand binding functions. In 
fact, such a role for β4-integrin in Met signalling has been described by 
Trusolino et al.258. They showed, in attached cells, that β4-integrin acted as a 
signalling scaffold molecule to enhance Met signalling rather than as an 
adhesion receptor.  
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Thus our study is the first to demonstrate a requirement for β1-integrin in Met 
signalling, that moreover occurs in detached cells (Figure 11). 
 
Met signalling require a fully functional NXXY motif in the cytoplasmic 
domain of β1-integrin 
We have shown that optimum and sustained ERK1/2 signalling upon Met 
activation require the presence of the two tyrosine residues in the NXXY 
motif in the β1-integrin cytoplasmic tail, Y783 and Y795. This motif has been 
previously been implicated in integrin function, including regulation of integrin 
activation231 and to be critical for β1-integrin mediated activation of FAK319. 
Thus our results suggest that β1-integrin acts as a scaffold for Met signalling 
to the ERK1/2 pathway in a similar way to β4-integrin, which was reported to 
function as a scaffold between Met and ERK1/2 and Src, through binding Shc 
and Shp2 respectively258, 259. Thus, future experiments for this project will 
consist of investigating co-localisations and co-immunoprecipitations between 
Shc and Met as well as Shc phosphorylation upon Met activation in the 
presence and absence of β1-integrin with its functional or mutated NXXY 
motif.  
 
3) The cross talk appears to occur on endosomes: an “Inside-in 
signalling” 
One important hypothesis in our study is that we believe the cross-talk occurs 
on endosomes. The observation that, even in cells in suspension, Met and 
β1-integrin co-localise on endosomes and that β1-integrin is required for 
maximum and sustained ERK1/2 activation strongly suggests that β1-integrin 
impinges on Met signalling directly on endosomes, hence the term “inside-in 
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signalling”. Especially due to the fact that ERK1/2 activation upon Met 
activation has previously been shown to require Met endocytosis62. In the 
above reported Met-β4-integrin258 and EGFR-β1-integrin320 cross-talks, the 
location of the RTK and the integrin was not investigated.  
 
I will perform further studies to check our hypothesis. In particular, I will ask 
whether blocking β1-integrin internalisation, while maintaining Met 
endocytosis, leads to a significant reduction in Met dependent ERK1/2 
phosphorylation. We plan to achieve this using Rab21 knockdown by 
RNAi321-323. I already have checked that Rab21 knockdown does not affect 
Met internalisation (data not shown). 
Furthermore, blocking the internalisation of each molecule separately will 
determine whether it is the presence of both, or of only one, that is required 
on endosomes. As we saw in chapter II, Met internalisation could be blocked 
using c-Cbl or Grb2 inhibition or alternatively using Met mutated in the Grb2 
binding site 159. 
 
One could argue that rather than β1-integrin being important for Met 
endosomal signalling, the two molecules just need to be at the same place in 
order to interact. Thus we could imagine that when both are maintained at the 
plasma membrane, Met signalling would not be affected. This is however 
unlikely as we already know that blocking dynamin using for example 
Dynasore, which we have shown to block Met endocytosis in several cell 
systems (see Chapter I)157, 159 and should also block β1-integrin, does inhibit 
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Met dependent ERK1/2 signalling.  However, we will verify this in the cells 
studied here. 
 
Due to the fact that it is predominantly the active form of β1-integrin that 
appears to preferentially traffic upon Met activation and colocalise with Met 
on endosomes, future experiments will involve investigating cells lacking 
Sharpin, an endogenous inhibitor of β1-integrin activity324. These cells have a 
2-4 fold increase in the active form of β1-integrin, even when cells are in 
suspension324. Thus it will be very interesting to investigate Met-dependent 
β1-integrin localisation as well as the effects on Met signalling in these cells 
compared to cells expressing normal levels of Sharpin. 
 
The term “inside-in signalling” has been coined here, due to the fact that this 
novel mode of signalling appears to occur on endosomes and is cell 
anchorage independent, in marked contrast to the “outside-in” and “inside-
out” signalling mechanisms228, 231, 233.  “Outside-in signalling” occurs when 
integrin ligand binding, increases interactions with the cytoskeleton231, 232. 
While “inside-out signalling” occurs when changes in the cytoskeleton alter 
the ligand-binding affinity of integrins228, 231. 
 
Interestingly, the reduction in EGFR signalling upon β1-integrin knockdown 
observed in the recent study by Morello et al., could be partially rescued by 
over expression of Rab Coupling Protein (RCP)320, suggesting that integrin 
recycling may be important. It may be interesting to investigate the role of 
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RCP in Met- β1-integrin cross-talk in our models, especially given the recent 
evidence that RCP is involved in recycling of both Met and α5β1-integrin262.  
 
4) Biological outcome of Met-β1-integrin cross-talk 
Role for Met-β1-integrin cross-talk in cell anchorage independent 
growth 
Despite detachment from the plate upon tetracycline induction, GFP-Met cells 
do not undergo anoikis. In fact the expression of Met gives them a survival 
advantage versus HEK293 cells lacking Met expression in suspension as 
assessed by flow cytometry (not shown). We plan to determine whether β1-
integrin silencing reduces the survival of these cells.  
Moreover we find that β1-integrin expression increases the ability of both the 
GD25 and M1268T Met expressing cells to undergo anchorage independent 
growth upon Met activity. Similarly, the group of Comoglio has shown that, 
consistent with its role in Met signalling, β4-integrin was necessary to sustain 
Met dependent anchorage independent growth258, 259.  
 
Met dependent cell migration and anchorage independent growth 
require a fully functional NXXY motif in the cytoplasmic domain of β1-
integrin  
Met dependent cell migration as well as anchorage independent growth both 
were found to require the presence of the two tyrosine residues in the NXXY 
motif in β1-integrin cytoplasmic tail, Y783 and Y795. To investigate further 
the role of this β1-integrin motif in Met signalling and Met dependent 
biological outcome, I plan to stably express the human Wt or M1268T Met 
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constructs in Wt and β1-integrin-YYFF murine embryonic fibroblasts 
(MEFs)325, obtained from our collaborator in this study, Prof. Johanna Ivaska. 
In these cells, I will perform studies in vitro and in vivo as detailed in Results 
Chapter III-3. 
 
A role for the endosomal Met-β1-integrin cross-talk in cancer? 
The role of Met in tumour formation and progression has been demonstrated 
in many types of cancer, including bladder, breast, liver, lung, prostate, 
pancreas and colorectal cancer8. Meanwhile the lack of β1-integrin 
expression in a mouse model of breast cancer (MMTV/PyV MT) decreased 
tumour growth326. The same was observed in a mouse model of pancreatic 
cancer (Rip1Tag2), where additionally metastasis also was reduced327. Thus 
both of these transmembrane receptors have established roles in cancer 
formation and metastasis.  
 
As both Met and β1-integrin play important roles in tumourigenesis and 
tumour progression, it seemed logical that the two molecules would 
cooperate to enhance each other’s signalling. Thus, I have shown that lack of 
β1-integrin in the established M1268T Met driven in vivo tumourigenesis 
model 159 (see Chapter II) significantly reduces tumour growth and 
experimental metastasis. Importantly however, as I explained in the results 
part, I am planning to repeat these experiments using β1-integrin shRNA 
(instead of siRNAs). This will allow me to compare the influence of β1-integrin 
silencing between the mutant and the WT cells and thus, confirm that β1-
integrin plays a role in Met dependent tumorigenesis.  
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Figure 11: Model of Met- β1-integrin cross-talk in anchorage dependent 
and independent conditions. 
In anchored cells and unanchored cells, activation of cell surface Met leads to 
the internalisation of Met and β1-integrin. They are co-recruited on 
endosomes, and they cooperate to promote HGF dependent ERK1/2 
activation. In anchored cells, activated ERK1/2 plus the recycling of β1-integrin 
to the cell leading edge triggers cell migration. In unanchored cells, sustained 
activated ERK1/2 stimulates anchorage independent growth.     
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We currently are extending our study in human cancer cell lines including 
breast and lung. So far, our preliminary data suggest that the endosomal Met-
β1-integrin cross-talk also occurs in these cells. For example, in the MDA-
MB-468 cells, we have observed a co-internalisation of Met and β1-integrin 
and silencing β1-integrin reduces Met dependent ERK1/2 phosphorylation. 
 
Interference with RTK-Integrin cross-talk as a treatment option?  
β1-integrin is an ubiquitously expressed integrin and broad inhibition of β1-
integrin may therefore have severe consequences on cells. Although it is 
worth noting that, in our experiments, knockdown of β1-integrin, both 
transiently and stably, does not appear to affect cell growth or proliferation in 
culture. In fact, there are a few β1-integrin inhibitors available, that have 
already undergone clinical trial testing. ATN-161 and JSM6427 are both 
α5β1-integrin antagonists, which inhibit the interaction between α5β1-integrin 
and fibronectin. JSM6427 was first described in 2006, when it was 
demonstrated to decrease ERK1/2 phosphorylation that can occur upon 
fibronectin binding as well as induce apoptosis in endothelial cells328. 
Furthermore, it has been shown to reduce glioma growth in vivo329. JSM6427 
has recently completed a phase I clinical trial, although the results are as yet 
unknown (www.clinicaltrials.gov). ATN-161 is a small peptide consisting of 5 
amino acids and in animal models it has been shown to prevent tumour 
growth and metastasis both alone and in combination with chemotherapy or 
radiotherapy330. Importantly, a phase I clinical trial revealed low toxicity and 
prolonged stable disease in 1/3 of participants with advanced solid 
tumours330. Consequently, a phase II clinical trial is being set up in head and 
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neck cancer patients combining ATN-161 and chemotherapy or 
radiotherapy330. Volociximab, also known as M200, is a humanised 
monoclonal antibody against α5β1-integrin330. Phase I clinical trials have 
been successful with low levels of toxicity and stable disease occurring in a 
quarter of patients with advanced solid tumours330. There are currently 13 
phase I/II clinical trials of Volociximab that are recruiting, ongoing or have 
recently been completed in a variety of conditions including cancer 
(www.clinicaltrials.gov). The various inhibitors of β1-integrin therefore appear 
to be quite successful, perhaps because they target a single heterodimer, 
α5β1-integrin. They may indeed be valuable as a potential anti-cancer 
treatment and also it has been suggested that they may inhibit breast cancer 
recurrence330, 331. 
 
Taking our results into consideration, an interesting question would be 
whether such β1-integrin inhibitors could be used to treat Met dependent 
cancers? Our in vivo experiments suggest this (Figure 9). Moreover, our 
future planned experiments using Wt or M1268T Met expressing cells stably 
lacking β1-integrin expression may confirm this further and reveal whether 
there is any compensation by other integrins as well as the effects on Met 
dependent tumourigenesis in vivo.  
Alternatively, more knowledge of the way in which specific RTKs and 
integrins interact and traffic may provide us with a way to specifically inhibit 
the interaction or perhaps the localisation of specific RTK-integrin cross-talk 





“Endosomal signalling” of Met and cancer 
 
Traditionally, the concept was that receptors signal from the plasma 
membrane only and then get internalised to be “switched off” through 
degradation. However my results show that the RTK Met can still signal 
post-endocytosis in several different cell models. Moreover I have 
demonstrated that an endosomal location of Met plays a role in 
tumourigenesis.  
 
Firstly, I found that Met is expressed, activated and traffics in a panel of 
human breast cancer cell lines. Importantly, aggressive breast cancer cell 
lines appear to have altered Met trafficking and degradation, suggesting a 
longer time spent on endosomes. Furthermore, the aggressive MDA-MB-468 
cell line has a larger dependence on Met endocytosis for the Met dependent 
signalling and cell migration than a model of DCIS. Supporting these 
experimental observations I was able to show, in a pilot study on human 
breast cancer tissues, that Met was found to exist increasingly in an 
endosomal location as breast cancer progresses. This combination of cell 
line and clinicopathological data suggests that Met endosomal signalling 
might play an important role in breast cancer progression. 
 
Secondly, using a model of Met oncogenic mutants, I showed that Met 
endocytosis occurs via dynamin, clathrin, c-Cbl and Grb2 –dependent 
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mechanisms. In addition, I found that HSP90 protects the Met mutants from 
degradation. Importantly, either inhibition of endocytosis or restoration of 
degradation through targeting the newly discovered mechanisms, reduced 
the accumulation of mutant Met on endosomes. As a result, the transforming 
capacities of the mutants were greatly reduced in vitro and in vivo, including 
that of a Met mutant found to be resistant to Met inhibitors. Thus, the 
endocytosis of these Met mutants was found to be directly linked to their 
tumourigenicity. Such that it is its accumulation on endosomes coupled with 
constitutive activation that leads to tumour formation and metastasis. 
 
Finally, I have discovered that β1-integrin may act as a scaffold for Met 
endosomal signalling in several cell models. Met activity promotes Met and 
β1-integrin internalisation and co-recruitment on endosomes. Here, β1-
integrin, through its NXXY motif, is required for optimal ERK 1/2 activation in 
anchored but, more surprisingly, also in unanchored cells. Furthermore, I 
have also shown that, in addition to playing a role in Met dependent cell 
migration, β1-integrin signalling is required for Met stimulated anchorage-
independent growth and in vivo tumorigenesis. We propose that β1-integrin 
promotes Met signalling through a novel mechanism that we called 
“endosomal inside in signalling”.  
 
It is currently becoming clear from various recent studies that the trafficking 
of RTKs and their “endosomal signalling” play a major role in cellular 
outcomes. This, together with the emerging knowledge that many trafficking 
proteins, including Hip1 and Rab25332, 333, have altered expression in cancer, 
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strongly implies that trafficking and more specifically “endosomal signalling” 
could play an important role in cancer formation and metastasis.  
 
Various signalling pathways that are involved in cancer have been shown to 
be generated on endosomes. For instance, the endosomal signalling of 
EGFR is sufficient to activate ERK1/2144; Rac1 also is activated on 
endosomes upon HGF stimulation158 and both STAT3 and ERK1/2 require 
Met endocytosis for their full activation62, 157. The endocytosis of RTKs has 
also been shown to be important in cell functions including cell migration149, 
150, 158 and cell survival144, 162. However, until our study on Met mutants was 
published in 2011159 nothing had previously shown that the altered endocytic 
trafficking of RTKs can directly be involved with the development of cancer. 
 
A possible reason for the role of Met endocytic signalling in cell 
transformation is that the strength of Met and its downstream signalling may 
be maintained to a greater extent on endosomes. Endosomes may provide a 
better proximity of Met molecules with each other, which could be important 
for maintaining a better trans-autophosphorylation and/or a reduced access 
to phosphatases. Additionally, Met “endosomal signalling” may provide 
control over the specificity of Met dependent signals due to the fact that 
endosomes are able to act as signalling platforms bringing together various 
components for either the initiation or prolongation of signalling both spatially 
and temporally160, 162, 334. It is therefore possible to see how cancer cells may 
alter their trafficking in order to exploit specific signalling pathways.   
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The publication of studies demonstrating that mutant p53 not only leads to a 
loss of tumour suppressor function, but also has a gain of function effect by 
altering RTK and integrin trafficking255, 262, is of great interest to the cancer 
research community, as huge number of cancer patients (50%) have p53 
mutations255, 262 254. These studies showed that mutant p53 increases 
recycling of α5β1-integrin and EGFR255 or Met, in basal conditions, and 
increases signalling of these RTKs262. However, these studies did not 
investigate a potential co-trafficking of the RTK and α5β1-integrin upon HGF 
stimulation. In their model, whether the resulting tumourigenesis and 
metastasis is due to an increased life-span of the receptors, the recycling of 
individual receptors or the co-trafficking and interaction between these two 
classes of receptors is unknown. 
However, results of these studies and our study are not necessary exclusive, 
but more work is required to find out whether the two mechanisms co-exist in 
the same cancer cells. In our study we suggest that an accumulation of Met 
and β1-integrin on endosomes aids Met signalling and this may therefore 
also be the case for the studies performed on cells with mutant p53. 
Interestingly, the aggressive breast cancer cells studied in Chapter I; MDA-
MB-468 and MDA-MB-231, both have mutant p53283 and it is in these cells 
that I have observed a small amount of Met recycling. Thus the cross-talk on 
endosomes between β1-integrin and Met in these cells is something which 
would be very interesting to investigate. 
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Potential prognostic and therapeutic implications of my findings 
 
Met in cancer 
Several studies have reported an increased Met expression in various 
human cancers including breast cancer174, 175 and that Met is a marker of 
poor prognosis. Potentially, one of the reasons for this is that Met can 
activate many downstream signalling pathways leading to the initiation of 
many cellular functions. In fact Met can initiate many of the “Hallmarks of 
cancer” originally described by Hanahan and Weinberg in 200057, including 
cell survival, growth, invasion and angiogenesis8.  
In fact, the M1268T mutant, investigated in this thesis, has been shown to 
trigger the development of basal-like breast tumour in mice 182. This, together 
with the recent literature suggesting Met as a marker for basal breast 
cancer175, 277, suggest a role for Met activation in the development of basal 
breast cancer.  
Several studies indicate that Met could represent not only a prognostic factor 
but also possibly a target for therapy. As a consequence, Met is now 
established as an important target to consider for anti-cancer therapies, a 
fact that is demonstrated by the many Met inhibitors that are currently 
undergoing clinical trials  (see Chapter II-1). 
 
Considering the results obtained in my study, it also seems that Met 
“endosomal signalling” is important in the development and progression of 
cancer. Here we have provided a direct link between the endocytosis of a 
constitutively active Met mutant and tumourigenesis as well as a potential 
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role for endosomal β1-integrin in Met dependent tumourigenesis. We also 
present data that suggest that Met endosomal signalling correlates with 
breast cancer progression. Furthermore, this study suggests that the 
subcellular localisation of Met may also provide a prognostic marker, which 
may be important for pathologists to consider for cancer diagnosis, providing 
we confirm our results on a larger cohort of breast cancer tissues. Thus, the 
current models of oncogenic RTK driven tumorigenesis may require a rethink 
to also investigate the location of the RTK and the possibility of endosomal 
signalling.  
 
Inhibiting Met-dependent tumourigenesis 
The Met mutations studied in Chapter II are naturally occurring oncogenic 
mutations found in human cancers. My results suggest that patients with 
specific Met mutations may be resistant to small molecule Met inhibitors,  
highlighting the importance of knowing a patient’s genetic make-up prior to 
treatment. As we move closer to personalised cancer treatment, with more 
available and cost effective genetic screening, this might be feasible in the 
future. It further demonstrates the need for comprehensive in vitro and in vivo 
studies on mutated proteins as well as the appropriate classification of 
patients in clinical trials. It is worth noting however, that the Met mutations I 
have studied are quite rare and have not been found to occur in ‘major’ 
cancers, such as breast cancer. Thus, while our work on these Met mutants 
is relevant to patients bearing these mutations, they predominantly provide a 




Importantly, however, my results suggest potential alternative ways to target 
Met in cancer that appear to both effectively reduce Met dependent 
tumourigenesis and overcome resistance to TKIs, in my experimental model. 
 
My studies indicate that inhibition of endocytosis might be a potential 
therapeutic option for preventing the development and progression of Met 
driven cancers. While Met is an important target for various cancers, it is also 
involved in other normal biological functions such as homeostasis or wound 
healing51. Therefore, inhibiting Met endocytosis may impair the transforming 
signals only, according to our hypothesis that Met triggers its transforming 
signal from the endosome location. Thus, targeting the localisation of Met, 
rather than its activation, may have limited effects on the biological functions 
of the normal, non-transformed cells while at the same time reducing the 
Met-driven cell transformation. 
 
In addition to the inhibition of Met activation or Met endocytosis, the 
observation that HSP90 inhibitors can reduce Met dependent tumourigenesis 
by effectively inducing Met degradation is very interesting. HSP90 is 
ubiquitously expressed and has important functions in non-tumourigenic 
processes335. However, its expression is increased in many tumours and this 
therefore makes it a valuable target335. HSP90 inhibitors have been shown to 
provide a promising therapeutic approach to treat many cancers, including 
breast cancer336, and they are being tested in various clinical trials. They are 
known to target multiple oncogenic proteins that are protected by HSP90, 
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including various RTKs, downstream signalling molecules such as AKT and 
even mutant p53. In this study we have also demonstrated that HSP90 
inhibitors may be used to treat Met driven cancers. 
 
The observation that the ubiquitously expressed β1-integrin plays a role in 
Met endosomal signalling, suggests that β1-integrin antagonists or antibodies 
may be able to also target Met driven cancers. Furthermore, my studies have 
highlighted the need for further investigations on the mechanisms regulating 
RTK-integrin interactions and/or trafficking as their impairment could 
constitute the basis for the development of novel inhibitors against cancer 
development.  
 
Would RTK localisation be a plausible target for future therapy? 
 
A greater amount of research is required to fully understand the roles of RTK 
trafficking and endosomal signalling in tumourigenesis and cancer 
metastasis. Novel strategies are required to inhibit Met dependent 
tumourigenesis based on altering Met localisation or by devising “endosome-
specific targeting” approaches337, as broadly inhibiting endocytosis will have 
many unspecific targets and probably have high levels of toxicity, despite the 
fact that in our model there did not seem to be  a large amount of adverse 
effects on our control non transformed Wt Met expressing cells. Therefore, 
more in-depth knowledge is required of individual RTK internalisation 
mechanisms for drug-development to progress. 
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However, this ongoing research, together with a larger investment from 
pharmaceutical companies in the future, may make it possible to specifically 
inhibit the endocytosis of individual RTKs or interactions between RTKs and 
integrins that occur in certain cellular locations. 
 
It is hoped the suggested approach will represent a plausible alternative as a 
therapy for patients, particularly with advanced disease, in the future. It may 
target the dangerous signals while allowing normal cells to activate the 
signalling pathways that they require for normal cell functions and may also 
potentially target the ‘harmful signals’ of potentially multiple RTKs 
simultaneously. Interestingly, the use of agents to block Met endocytosis as 
well as HSP90 inhibitors to restore Met degradation, led to less accumulation 
of Met on endosomes and as a consequence reduced the tumourigenic 
properties of a Met mutant that I have shown to be resistant to conventional 
Met small molecule inhibitors. It is possible that control of signal location 
could provide an alternative therapy for those patients who are resistant to 

















Antibodies for flow cytometry: 
Rat monoclonal anti-mouse anti- β1-integrin, clone MB1.2 (MAB1997) from 
Millipore; rat monoclonal anti- β1-integrin in active conformation, clone 9EG7 
from BD Biosciences; mouse monoclonal anti-human anti- β1-integrin, clone 
DF7 from Biomol International. PE-conjugated donkey anti-rat (1/250) and 
APC-coupled donkey anti-mouse (1/250) from Jackson Immunoresearch 
were used as secondary antibodies. 
 
b) Plasmids 
Met GFP construct 
The human hepatocyte growth factor receptor (Met) open reading frame 
(ORF) was first introduced into pEGFP-N1 (BD Clontech) by Dr. Stephanie 
Kermorgant. Met ORF was amplified by PCR, using the flanking primers 5’ -
ccgctcgagatgaaggcccccgctgtgc-3’(Xho I site) and 5’ -
cccccaagcttcaatgatgtctcccagaaggaggc- 3’ (Hind III site) (the underlined 
sequence represents the mutated stop codon). Plasmid containing Met-EGFP 
construct was then digested with Eco RI and Not I restriction enzymes and 
was introduced into pcDNA™ 4/TO (Invitrogen Life Technologies) containing 
full length wild type Met digested with both restriction enzymes by Dr. 
Stephanie Kermorgant. Construct was then checked by full sequencing. 
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2) Flow Cytometry 
Expression analysis 
To determine the level of the desired protein at the plasma membrane, flow 
cytometry was performed by Dr. Carine Joffre. Cells were split and washed 2 
times in cold FACS buffer (PBS 2% serum). 1x106 cells were incubated with 
primary antibodies in 100µl cold FACS buffer on ice for 1 hour. After 
incubation, cells were washed three times in 1ml of cold FACS buffer 
(centrifuged at 400 g for 5 minutes between each wash) and incubated on ice 
with PE or APC conjugates for 30 minutes. After which, cells were washed 
three times and then resuspended in 300µl of cold FACS buffer. Flow 





Colocalisation analyses were performed by Dr. Ludovic Menard (cells on 
coverslips) and Dr. James Hulit (breast cancer tissue). Imaging parameters 
were set as follows; scan mode was set to frame; averaging set to 4 scans. 
Image dimensions at a 1.0 magnification were 134.82 microns along each of 
the x and y axes with images captured at a 1024x1024 resolution. Pinhole 
was set to 1 airy disk relative to the red emission, yielding a z axis slice of 0.9 
microns.  
The intensity threshold of the green and red channels were independently set 
to only include vesicle-like structures which were identified as areas of 
punctate staining. Only pixels identified as originating from a vesicle were 
included in the analysis, those not determined to be of vesicle origin were 
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excluded as noise. Imaging parameters allow us to confidently identify 
structures at a lower limit of roughly 200nm diameters. Data are displayed as 
the percent of green pixels (EEA1) with overlapping red pixels (Met). 
Co-localisation analysis of Met:EEA1 was performed on human breast tissue 
from 4 normal, 10-15 DCIS and IDC cases, from which a minimum of 2 fields 
were analysed per case. The total number of cells analysed from these 






Immunohistochemistry was performed by Dr. Colan Ho-Yen on DCIS and 
IDC TMAs. TMA sections were dewaxed in xylene and then re-hydrated 
through alcohol and placed in 3% hydrogen peroxide solution for 10 minutes 
to block endogenous peroxidase activity. Antigen retrieval was performed by 
microwave treating the sections in 0.1M citrate buffer at pH6 for 10 minutes. 
After washing in PBS, normal horse serum was deposited on the sections for 
15 minutes at a dilution of 1:75 in 1%BSA/PBS to block non-specific antibody 
binding. After draining the sections, met (mouse monoclonal antibody 8F11, 
Novocastra) was incubated for 1 hour at room temperature at a dilution of 
1:150. Following PBS washes, the secondary biotinylated horse anti-mouse 
antibody (Vectastain, Vector Laboratories) was applied to the sections at a 
dilution of 1:200 for 40 minutes. The sections were washed in PBS then 
incubated with avidin-biotinylated peroxidase complex (Vectastain ABC kit, 
Vector Laboratories) for 30 minutes. The reaction was developed using a 
DAB kit (Vectastain, Vector Laboratories), after which sections were 
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counterstained with haematoxylin, rinsed and dehydrated through alcohol to 
xylene and mounted with coverslips. A section of pancreas served as a 




For the semi-quantitative analysis, the cytoplasmic and membranous 
compartments of the tumour cells were scored individually. Intensity was 
scored on a scale of 0-3 (0 = no staining, 3 = strong) and area of reactivity 
was scored on a scale of 0-4 (0 = no staining, 1 = less than 25%, 2 = 25-
50%, 3 = 51-75% and 4 = more than 75%). The intensity and area were 
combined to give a score out of 7 and cytoplasmic and membranous scores 
were then added to give a total score out of 14. The total score was 
categorised as follows: 0-4 = weak, more than 4 but less than 10 = 
intermediate and greater than 10 = strong. 
 
 
5) Cell Transfection  
Oligofectamine transfection 
Met-GFP cells were transfected using Oligofectamine. Cells were plated at 
1x105/well in six-well plates. 24 hours later cells were transfected in 1ml 
serum-free Optimem (Invitrogen life technologies). 180ul optimem + 10 µl of 
20mM RNAi was mixed with 16ul + 4ul oligofectamine (Invitrogen Life 
Technologies) having been prepared separately and incubated for 7 minutes. 
200ul of the transfection mixture was added to each well. 1ml of complete 
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medium supplemented with 100µl FBS was added to each well after 5 hours. 































Appendix Figure 1: Met is involved in breast cancer progression. 
Staining and analysis performed by Dr. Colan Ho-Yen
A-D) Immunohistochemistry staining of Met on human tissue sections. 
Pictures taken on (x40 objective). A) Section of ductal carcinoma in situ 
(DCIS). B) Section of invasive ductal carcinoma (IDC). C) Negative control: 
section of human pancreas, where no primary antibody was included. 
D) Positive control:  section of human pancreas. E)  Percentage of DCIS cases 
(n=47) and invasive cancer cases (n=153) with strong, intermediate and weak 
total (cytoplasmic and membranous) Met expression; p<0.0001.
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Appendix Figure 2: Met is present in endosomes in human tissue and 
increases as breast cancer progresses. Staining and analysis 
performed by Dr. James Hulit.
A) Immunofluorescence on human tissue sections of normal breast (800 
cells)(top panel), DCIS (612 cells) (middle panel) and IDC (427 cells) 
(bottom panel) showing Met (red), EEA1 (green) and DAPI (blue). 
B) Quantification of the percentage of early endosomes positively 
colocalising with Met (using Image J software). A minimum of 10 fields 



































Appendix Figure 3: Carine Joffre showed that the D1246N and M1268T 
Met mutations induce Rac1 activation
A) Percentage of Wt and M1268T cells lacking stress fibres following 
transfection with control or Rac1 RNAi. Data are mean (arbitrary units) ± 
SEM (n=3). B) Levels of Rac1 GTP measured by GST-CRIB pull down and 
of total Rac1. C) Levels of Rac1 GTP measured by GST-CRIB pull down 
and of total Rac1 on Wt and M1268T expressing cells treated (+) or not (-) 
with PHA-665752. Numbers represent fold increases of Rac1 GTP between 





























Appendix Figure 4: Carine Joffre showed that M1268T Met constitutively 
associates with HSP90 ά  
Lysates from M1268T Met expressing cells were subjected to HSP90 ά IP 
(left panel) or Met IP (right panel). Cells were also subjected to an IgG control 
IP in each experiment.  Met, HSP90 ά and pan HSP90 Western blot from IP 


































































Appendix Figure 5: Met activation stimulates β1-integrin internalisation 
and is required for ERK1/2 phosphorylation in an anchorage 
independent manner. 
 A) Quantitation of wound closure from pictures (not shown) of GD25 cells 
non-stimulated, stimulated with HGF (50ng/ml) or PDGF (30ng/ml) for 19 
hours. Data are mean (arbitrary units) ± SEM (n=1 in triplicate). Performed by 
Dr. Stephanie Kermorgant. B) Surface levels of pan- β1-integrin in β1A cells 
upon time of HGF stimulation, obtained by flow cytometry. Average mean 
fluorescence intensity, in arbitrary unit, ± SEM (n=3). Performed by Prof. J. 
Ivaska’s laboratory. C) Biotinylation internalisation assay. In β1A cells, the 
levels of surface biotinylated β1-integrin internalised at 15 minutes, in 
absence or presence HGF, were measured and compared to total cell 
surface β1-integrin (mean ± range of error, n=2). Performed by Dr. Carine 
Joffre. DE) Performed by Dr. Stephanie Kermorgant. D) Western blots for 
tubulin and phospho-ERK1/2 in β1A cells non-plated (0) or plated on 
poly-L-lysine (PL). fibronectin (Fn) or laminin (Lam) for the indicated times 
without or with HGF. E) Western blots for tubulin and phospho-ERK1/2 in β1A 
cells, adherent or in suspension, and stimulated with HGF (50ng/ml) for 0, 15 
and 120 minutes. Numbers represent the percentages of increase ± range of 
error (n=1 in triplicate), in phospho-ERK1/2/tubulin ratios at 120 versus 15 
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Appendix Figure 6: Expression of constitutively activated GFP-Met 
leads to β1-integrin internalisation.  
A) GFP expression and viability analysed by flow cytometry. Met-GFP cells 
cultured in presence or absence of 0.1μg/ml of tetracycline (Tet) for 48hrs 
were stained with propidium iodide. Performed by Nick Luckens and Dr. 
Stephanie Kermorgant. BC) Performed by Prof. J. Ivaska’s laboratory. B) Cell 
surface integrins of Met-GFP cells, induced with tetracycline (Tet, 0.1 μg/ml) 
for the times indicated, were labelled with anti-β1-integrin-antibody and 
analysed by flow cytometry. Data are mean ± SEM (n=3). C) Biotinylation 
internalisation assay, in which the amount of internalised β1-integrin within 
30 minutes was evaluated in cells that have been induced with tetracycline 
(Tet) for the times indicated and compared to total cell surface β1-integrin 
(n=3). Data are means ± SEM. DE) Performed by Dr. Carine Joffre. Results 
of cell surface flow cytometry experiments performed with D) pan-β1 integrin 
(DF7) or E) activated conformation β1-integrin (9EG7) antibodies in cells 
non-treated (-Tet) and treated (+Tet) by tetracycline for 16 hours. Data are 
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Appendix Figure 7: Met colocalises with β1-integrin on endosomes 
A) Results of flow cytometry experiments performed with pan-β1-integrin 
(DF7) or activated conformation β1-integrin (9EG7) antibodies in Met-GFP 
cells non treated (-Tet) and treated (+Tet) by tetracycline for 16 hours. Data 
are cell surface active conformation β1-integrin expression reported on the 
cell surface pan-β1-integrin expression (arbitrary units) ± SEM (n=4). 
Performed by Dr. Carine Joffre. B) Confocal section of Met-GFP cells that 
have been induced with tetracycline for 5 hours and stained for β1-integrin 
(red). GFP-tagged Met is in green. Scale bar: 20μm. Performed by Prof. J. 
Ivaska’s laboratory. C) Confocal section of Met-GFP cells, grown on 
Poly-L-lysine coated coverslips, fixed and stained for active β1-integrin 
(9EG7, red) and EEA1 (blue), after incubation in tetracycline for 16 hours. 
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Appendix Figure 8: β1-integrin is required for Met dependent ERK1/2 
phosphoylation in an anchorage independent manner. 
Experiments performed by Carine Joffre and Naoki Kishi
A) Western blots for β1-integrin, P-ERK1/2, tubulin, P-Met (Y1234/35) and 
GFP (Met-GFP: p195, precursor; p170, mature β chain) on Met-GFP cells, 
transfected with control or β1-integrin siRNA for 72 hours and incubated in 
tetracycline (Tet, 0.1 μg/ml) for 0 or 16 hours. BC) Fold increases ± SEM 
(n=3) of B) P-ERK1/2 / tubulin and C) P-Met/Met-GFP ratios in cells knocked 
down for β1-integrin versus control knocked down. D) Quantitation of 
Western blots obtained from Met-GFP cells, transfected with control or β1-
integrin siRNA for 72 hours and incubated in tetracycline (Tet, 0.1 μg/ml) for 0 
or 16 hours. Numbers represent relative levels (arbitrary units) ± SEM (n=3) 
of p170 Met-GFP / tubulin ratios. *p<0,05, **p<0.01, ***p<0,001
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